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ABSTRACT
The use of antihistamines (AHs) has until recently heen associated with a number of 
undesirable side effects, the most troublesome of which is sedation. There are two 
aspects to sedation. The first, an objectively determined measure based on the results 
of psychometric tests from controlled trials, and the second, the subject’s response to the 
administration of a drug. Since AHs are largely used in ambulant patients, a complete 
evaluation of sedation should be performed thi'ough standardised objective tests, shown 
to be sensitive to the central effects of AHs and reliable ratings of subjective experiences. 
A critical review of the literature on the experimental studies with AHs revealed that the 
traditional AHs had a greater propensity to produce adverse central nervous system 
(CNS) effects, whereas the so called second generation AHs were generally less 
impairing when administered within their recommended ‘dose window’. A similar 
review of the clinical literature surveying subjective reports of sedation following the 
administration of AHs showed that the traditional AHs were perceived as more sedative 
than the second generation AHs.
On the basis of these findings, a series of controlled experiments in non-atopic volunteers 
investigated the effects of a number of second generation AHs on various aspects of 
cognitive functioning and psychomotor performance.
It is concluded that the second generation AHs have a lesser effect with respect to 
objective indices of sedation when compared to their predecessors, and that fexofenadine, 
has a claim to he the first truly non-sedating antihistamine as there is no objective 
evidence of CNS effects.
The identification of an antihistamine, devoid of adverse CNS activity regardless of the 
administered dose, highlights the need for the introduction of a ‘third generation’ of AHs.
In memory o f my father, who would have been very proud o f  this achievement.
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CHAPTER 1 : INTRODUCTION
1.0 Chapter Outline
This chapter discusses the context in which the present research was carried out. The 
term ‘sedation’ is defined and the importance of measuring sedation, which is commonly 
associated with the use of the traditional first generation antihistamines (AHs), is 
highlighted, A brief introduction to the history of AHs is given followed hy background 
information on the second generation AHs investigated in this thesis. Finally the 
contents of the thesis are outlined.
1.1 Introduction and Rationale
AHs have found their greatest therapeutic role in the treatment of various allergic 
disorders, particularly in the treatment of seasonal and perennial allergic rhinitis, 
conjunctivitis and acute urticaria, conditions where histamine mediated increase in 
capillary permeability and itch play a major role (Advenier & Queille-Roussel 1989, 
Flowers et al 1986, Tarnasky & Van Arsdel 1990, Wood 1988). The AHs are valuable 
in the treatment of allergic dermatoses, angio-oedema and chronic urticaria, providing 
symptomatic relief of pruritus (Monroe 1990). Some of the effectiveness of the anti­
pruritic effects may relate to the sedative effects of some of these compounds (Krause 
& Shuster 1983), although this has been questioned through the treatment of itching in 
atopic eczema using AHs with a low sedative profile (Doherty et al 1989). AHs are also 
effective in the control of ocular symptoms such as lacrimation and erythema, and they 
are sold over the counter either as sole entities or in combination preparations for the 
treatment of the ‘common cold’ (West et al 1975). Much research has been conducted in 
to the controversial role of the Hi receptor antagonists in the treatment of asthma and in
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this indication, the AHs seem to be of limited value (Holgate 1994, Van Ganse et al 
1997).
In addition, due to their non-specificity, the traditional AHs give rise to numerous side 
effects, some of which are often used therapeutically.
The anticholinergic action provides a drying effect on the nasal mucosa and the 
pulmonary system, as well as decreased gastric motility. This characteristic can be used 
beneficially to treat cholinergic excess associated with Parkinsonism and in 
drug-induced dyskinesia, by way of its central antagonism of acetylcholine actions 
(Peggs & Shimp 1995).
The anti-emetic effects, thought to be related to central muscarinic actions, decreased 
vestibular stimulation and labyrinthine function, or, by possibly affecting the 
chemoreceptor trigger zone, account for their use in motion sicloiess and vertigo 
(Norris 1988, Wood et al 1965). Some AHs directly suppress the cough reflex 
centre in the medulla, explaining their use as antitussives (Bryant & Lombardi 1993). 
Recently, AHs have been indicated in the treatment of anxiety disorders and success 
has been demonstrated with hydroxyzine in this indication (Fererri et al 1995,
Lader & Scotto, 1998, Shamsi & Hindmarch 1999).
Finally, it is worthy of note that antihistaminic properties are not limited to the APIs. 
There are other drugs such as tricyclic antidepressants (amitriptyline), and the calcium 
channel antagonists (cinnarizine) which possess antihistaminic effects as part of their 
pharmacological profile. However, this thesis is not concerned with other drug classes 
or indeed the use of these compounds for the treatment of various disorders in clinical 
practice, but is mainly concerned with the AHs and their potential to cause cognitive 
and psychomotor impairment.
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The use of AHs has until recently been associated with a number of undesirable side 
effects, the most troublesome of which is sedation (Goetz et al 1991, Hindmarch & 
Shamsi 1999, Matilla et al 1986). The somnolence produced by the first generation AHs 
may he welcomed by those who use them as sedatives or perhaps by individuals with 
allergic disorders who suffer from intolerable pruritus (Simons 1996). However, 
excessive daytime sedation can disrupt the abilities necessary for the safe performance 
of the cognitive and psychomotor tasks of everyday life and thus increase the risk of 
accidents (Brooldiuis et al 1993, Nicholson & Stone 1986, Rombaut et al 1989). In 
addition, excessive sedation is counter-therapeutic and reduces patient compliance and 
consequently the efficacy and utility of these AHs in clinical use (Pechadre et al 1991). 
In order to overcome the sedation, some physicians recommend giving these older Hi 
receptor antagonists at bedtime, because Hi blockade may be maintained the next 
morning and somnolence is of no concern during the night (Simons 1996).
Unfortunately, the morning after taking an Hi antagonist at bedtime, peripheral Hi 
blockade may not persist and the adverse CNS effects may not have always disappeared 
(Passalacqua et al 1996, Simons 1996).
As a result of their widespread OTC availability, there are large numbers of ambulant 
patients using AHs. Sedation and cognitive impairment induced by the first generation 
AHs is an important factor to consider, especially since most of the OTC AHs are of the 
first generation type. A survey of hay fever sufferers found that more than half (54%) 
self medicated with OTC drugs and a third of these patients experienced drowsiness 
because of their therapies (Richards et al 1992).
It would therefore seem essential that any treatment maintains the integrity of the 
cognitive system so as to protect the ambulant patient from drug-induced accidents, 
particularly in those who may be driving motor vehicles and those working in risk-prone
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domestic or industrial environments (Ramaekers et al 1992a, Sherwood & Hindmarch 
1993). Furthermore, it is imperative that appropriate methods and measures are 
identified to discriminate and differentiate between AHs which do not produce sedation 
from those with which there is no evidence of sedation when recommended daily doses 
are ingested and those which are inherently sedative regardless of the dose administered.
1.2 Sedation
The term ‘sedation’ is generally used to describe depressant effects on the CNS. An 
inspection of even the most recent research reports reveals that there is no general 
agreement on the meaning of ‘sedation’ as applied to AHs.
Matilla et al (1986) report ‘sedation of an unpleasant character’ referring to a subjectively 
assessed loss of alertness. Nicholson and Stone (1986) write that ‘impaired performance 
may be a non-specific effect of sedation’. Sedation was equated with drowsiness and 
was evaluated using subjective visual analogue scales (VAS) and EEG sleep latency 
tests. In fact, most investigators follow this approach and lump parameters of 
drowsiness together with measures of cognitive impairment, or alternatively the two 
kinds of CNS effects are included together on a continuum (Ahn & Barnett 1986, 
Hindmarch & Easton 1986, Nicholson & Stone 1986).
Within the context of this thesis however, the term ‘sedation’ is used to define a lowering 
of CNS activity which would be manifest as an impairment of superior cognitive 
functions such as attention, memory, sensorimotor co-ordination and psychomotor 
performance and which may or may not be associated with subjective feelings of 
tiredness, fatigue, drowsiness etc.
Until recent times, the history of pharmacotherapy has had a positive regard towards the 
term ‘sedation’. It was towards the end of the 1970s that the sedation produced by
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psychoactive drugs was recognised as a negative side effect. In 1972, the World Health 
Organisation (WHO) issued a caution against the use of psycho active drugs liable to 
induce sedation in ambulant patients. This effect was recognised as a threat to patient 
safety as well as the determinant factor in reducing patient compliance. Consequently it 
became especially unacceptable that drugs with primary peripheral effects caused 
secondary sedation.
It appears therefore that the general interpretation of the term sedation indicates an 
adverse event and represents a source of impairment of normal daytime Hinctioning, 
especially in the context of ambulant patients who may be driving cars or be involved in 
risk-prone industrial or domestic activities (Ramaekers et al 1992a). This concern 
becomes particularly important when it is considered that about 5% of drivers may use an 
antihistamine before driving (Starmer 1985). In an investigation examining the incidence 
of drug use among individuals killed in road traffic accidents (RTA) during a one year 
period, the adjusted culpability rate for AHs was 72% compared with 87% for alcohol, 
90% for cannabinoids and 97% for tranquillisers and antidepressants (Warren et al 1981). 
Similarly, the incidence of fatalities associated with the use of psychoactive drugs in 
RTAs was assessed in the UK (Everest 1989). An overall incidence of 7.4% of drugs 
likely to affect the CNS was found in all RTAs and in 6.7% of those suffering fatal 
RTAs. AHs either as single entities or as combination products with antihistaminic 
activity were present in 1.76% of the fatal accidents. AHs were also more frequently 
detected (1 2 %) in the bloods of accident involved drivers when compared to non­
accident involved drivers (Jick et al 1981). Such findings highlight the need for 
restricting the use of the AHs especially those of the first generation type, and the 
development of AHs which are free of detrimental effects on cognitive and psychomotor 
functioning.
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1.3 Histamine and Antihistamines - Historical Perspectives
Histamine was first identified as a potent vasoactive substance by Dale and Laidlaw in 
1910. Over a period of seventy years, the loiowledge of a much larger number of 
physiological activities has evolved. In 1931, in a series of experiments designed to 
demonstrate the actual release of histamine in association with the anaphylactic reaction, 
Watanabe (1931) noted differences in the histamine content of guinea-pig lung before 
and after shock. Dragstedt and Mead (1936) showed that the striking increase in the 
histamine content of the blood and lymph of dogs after anaphylaxis was sufficient to 
explain the shock and Code in 1937 noted that the amounts of histamine liberated in 
shocked guinea pigs were sufficient to produce anaphylactic symptoms. Blockade of 
many of the imdesirable effects of histamine was first achieved by Bo vet & Staub in 
1937, when protection of guinea pigs against lethal doses of histamine, by a diethylamine 
derivative, was observed. Due to toxicity, clinical use was prevented and the search 
began for more acceptable agents.
By 1942, progress was being made in the direction of a relatively non-toxic 
antihistamine, although the first to have acceptable clinical use was Antergan, another 
diethylamine derivative. Neo Antergan (Pyrilamine maleate) soon followed in 1944, 
with diphenhydramine and tripelennamine discovered in the late 1940s. Since then 
literally hundreds of compounds have been tested for histamine blocking activity.
Sixty years of intensive research was required to discover subclasses of the histamine 
receptor, through which, the wide-ranging activities of histamine are mediated. This 
discovery is attributed to Ash and Schild (1966), confirmed later by Black et al (1972) 
which led to a new therapeutic class of agents, the H2 receptor antagonists.
The next step in the development of AHs was the introduction of Hi blockers and the 
subsequent introduction of two distinct sub-classes of AHs, known as the older
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‘traditional’ or ‘classic’ histamine antagonists and the newer ‘non-sedating’ histamine 
antagonists.
1.4 The Role of Histamine in Physiology
Histamine is a naturally occurring amine, produced by the decarboxylation of the amino 
acid, histidine, found in most body tissues, primarily mast cells and basophils. The 
physiological fimctions of histamine are suggested by its distribution in the body. Its 
presence in the surface membranes of the alimentary canal, respiratory tract and skin is in 
line with its role as a defence mechanism against foreign substances. As a mediator of 
the secretory process, histamine is also found in the gastric, intestinal, lacrymal and 
salivary glands.
Histamine also plays a role in regulating the micro-circulation in accordance with its 
presence in cells, which line small blood vessels. Histamine is released from the tissue 
mast cell and blood basophil, by an energy dependent mechanism, in response to 
immunological and non-immimological stimuli. The former involves the IgE mediated 
antigen-antibody reaction, whilst trauma, drugs and other substances frequently 
constitute non-immunological stimuli. Localised release leads to itching, redness and 
oedema of the skin, or bronchoconstriction of the lung, whilst generalised release may 
induce anaphylactic shock.
The actions of histamine arise from its interaction with specific receptors on various 
histamine responsive target tissues. The effects of histamine at the Hi receptor include 
smooth muscle contraction, oedema which results from increased permeability of 
capillaries, flush and weal of the ‘triple response’ due to dilation of the capillaries, 
enhancement of respiratory mucus secretion and development of hypotension due to 
arterial dilation. The action of histamine at the H2 receptor involves the increase in
26
gastric pepsin and acid secretion. A third histamine receptor, H3 has recently been 
identified (Arrang et al 1983, Ishikawa & Sperelakis 1987), believed to have a role in the 
self-regulation of its own synthesis and release from nervous tissue, lung and skin.
1.5 Classification of the Hi-Receptor Antagonists
Unlike histamine, which has a primary amino group and a single aromatic ring, most Hi 
antagonists have a tertiary amino group linked by a two or three atom chain to two 
aromatic constituents (figure 1.1). The classical AHs are basically related at their central 
portion by a substituted ethylamine core, a moiety also present in histamine itself.
Figure 1.1 General formula of the classical AHs
ARw
 C  C  N-H2 \
The majority of these AHs are composed of one or two heterocyclic or aromatic rings 
(ARl & AR2) connected by nitrogen, carbon or oxygen (X) to the ethylamine group. 
The nitrogen of this ethylamine group is tertiary, having two substituents (R1 & R2). It 
is the presence of multiple aromatic or heterocyclic rings and alkyl substitutes in these 
AHs that results in their lipophilic characteristics, thus explaining their CNS effects 
(Woodward 1990).
The nature of the linlcage atom (X) has been used to categorise the classic AHs into six 
major classes. The various substitutions serve the purpose of modifying the 
characteristics of absorption and excretion as well as the side effect profile.
X = O, Ethanolamines e.g. Diphenhydramine, Clemastine
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X = N, Ethylenediamines e.g. Antazoline, Tripelennamine 
X = C, Alkylamines e.g. Chlorpheniramine, Triprolidine 
X = N in a piperazine ring. Piperazines e.g Hydroxyzine, Cyclizine 
X = N in a phenothiazine ring, Phenothiazines e.g. Promethazine, Trimeprazine 
X = N in a piperadine ring, Piperadines e.g. Azatadine, Cyproheptadine.
1.6 Postulated Mechanisms of Antihistamine-Induced Sedation
Numerous attempts to define the actual mechanism of antihistamine-induced sedation 
have been inconclusive. It is accepted hoAvever that histamine, like other biological 
amines, is a neurotransmitter in the brain Avith a role in the control of wakefulness and 
sedation (Nicholson et al 1985). Evidence to support this hypothesis lies in studies on 
the localisation of neuronal pathways and on the electrical responsiveness of the brain. 
Observations such as the desynchronisation of the EEG upon cerebrovascular injections 
of histamine (Wolff & Monnier, 1973), as well as the anatomical position of the 
ascending histaminergic pathway, projecting into the telecephalic regions suggest a role 
in arousal. This has been further confirmed by the circadian variation in the turnover of 
histamine in the brain, being in accordance with the maximum and minimum states of 
arousal (Nicholson et al 1985).
The underlying mechanisms by which CNS effects are caused by AHs is not precisely 
understood and is believed to be due to a number of factors. Penetration of the blood 
brain bamer to gain access to the CNS is a prerequisite before sedative side effects can 
occur (Meltzer 1990). The traditional AHs, due to their high lipophilicity, cross into the 
CNS without difficulty, and are therefore thought to be associated with sedative effects 
as a result of the interaction with the appropriate CNS receptor sites (Meltzer 1991, 
Simons 1989). Accordingly, the newer, second generation AHs with the hydrophilic
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characteristics and greater molecular size (>90Da) do not penetrate the CNS and within 
their recommended doses, appear to be free from adverse CNS effects (Kaliner 1992, 
Simons & Simons 1991).
A second theory suggests that greater central versus peripheral Hi affinity may account 
for the sedative activity of the traditional AHs (Le Fur et al 1981, Rose et al 1982, Uzan 
et al 1979). An alternative explanation for the sedation produced by the first generation 
is the slower association/dissociation of the Hi receptor antagonist to and from the Hi 
receptor (Wiech & Martin 1982, Timmerman 1999). Finally it has been proposed that 
the inhibition of N-methyl transferase may play a role in producing sedation with the 
traditional AHs (Netter & Bodenschatz 1967), through which increased concentration of 
histamine would become available to block central cholinergic, a-adrenergic or serotonin 
receptors, thereby producing effects which may be synergistic to the histaminic effects.
1.7 Second Generation Antihistamines
The development and introduction of the second generation of AHs has been a major step 
towards achieving the ideal qualities of an antihistamine, given that they should be non­
sedating, have a rapid onset of action, provide 24 hour relief of histamine mediated 
symptoms, employ a single daily dosage regimen and have high affinity for Hi receptors, 
but not so high as to preclude performance of sldn tests several weeks after 
discontinuation (Simons & Simons 1988).
Hi-receptor antagonists differ considerably from each other in their pharmacokinetics 
and pharmacodynamics, and an understanding of these differences is essential for 
optimal usage of these medications (Simons 1990). Maximum antihistaminic effects of 
the Hi-receptor antagonists continue for hours after peak concentrations have been 
achieved. Due to their reversible and competitive inhibition, they should be given before
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an anticipated exposure to allergen and subsequent allergic reaction, in order to enable 
the preferential binding to the Hi receptors in the tissue before the agonist does 
(Bernstein 1993). Even when serum concentrations of Hi-receptor antagonists have 
declined to the lowest limits detectable, significant antihistaminic effects persist, 
probably because of the presence of the Hi-antagonist and/or its active metabolite(s). 
They are generally well absorbed when administered orally. They have extremely 
variable serum elimination half-life values, ranging from hours to days (cetirizine, 7 
hours; astemizole, 9.5 days). Except for cetirizine, all of the currently available second 
generation AHs are metabolised extensively by the hepatic cytochrome P450 system. 
The maximum antihistaminic effect of these medications occurs several hours later than 
the peak serum concentrations and the duration of the antihistaminic effect is much 
longer than would be predicted from the serum elimination half-life values (Gonzalez & 
Estes 1998). The relative incidence of anticholinergic and CNS adverse effects caused 
by these medications is similar to that produced by placebo when they are administered 
at the manufacturer’s recommended dose (Haria et al 1994, Hindmarch et al 1999, 
Mctavish et al 1990, Richards et al 1984, Spencer et al 1993, Wiseman & Faulds 1996). 
The chemical structures of a number of these second generation AHs are presented in 
figure 1 .2 .
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Figure 1.2 The chemical structures of a number of second generation 
Hi receptor antagonists
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Ebastine
Ebastine is a selective and long acting Hi-receptor antagonist, chemically related to 
terfenadine. Ebastine is well absorbed and extensively converted to its active carboxylic 
acid metabolite, carebastine with peak plasma concentrations of the metabolite occiining 
3-4 hours following oral administration and lasting up to 24 hours (Wiseman & Faulds 
1996). In healthy human volunteers, ebastine significantly inhibited histamine-induced 
weal and flare compared with placebo (Buchmeier et al 1994, Vincent et al 1988a).
Onset of antihistaminic action was evident within 1 to 3 hours of administration, peaked 
between 3-12 hours and was sustained for at least 24 hours (Vincent et al 1988a). As 
regards the CNS depressant effects of ebastine, clinical studies have demonstrated the 
lack of impairments when administered at its recommended therapeutic dose of lOmg 
daily (Brookhuis et al 1993, Hopes et al 1992, Mattila et al 1992, Mattila et al 1993, 
Vincent et al 1988b). However, evidence exists to support the notion that ebastine may 
cause impairments in cognitive and psychomotor abilities when administered at doses 
above lOmg (Vincent et al 1988b, Barbanoj et al 1988).
Cetirizine
Cetirizine is the carboxylated derivative and principal metabolite of the potent first 
generation antihistamine hydroxyzine. Cetirizine is rapidly absorbed, reaching peak 
plasma concentration within one hour of administration, and has a terminal half-life of 7- 
11 hours. It possesses a potent and long lasting antihistaminic activity, peaking 4-8 hours 
after dosing and lasting up to 24 hours (Spencer et al 1993). Comparative studies 
indicate that cetirizine 1 Omg has a more rapid onset of antihistaminic action than 
terfenadine 60-120mg, loratadine lOmg, astemizole lOmg, chlorpheniramine 4mg and 
ebastine lOmg in healthy volunteers (Simons et al 1990). Clinical studies have clearly
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demonstrated the lack of CNS impairments when cetirizine is administered at its 
recommended therapeutic dose of lOmg daily (Schweitzer et al 1994, Simons et al 1995, 
Simons et al 1996, Tharion et al 1994). However, a number of studies have 
demonstrated significant impairments following the administration of higher doses of 
cetirizine (Gengo & Gabos 1987, Nicholson & Turner 1998, Riedel et al 1990a).
Fexofenadine
Fexofenadine is the active metabolite of terfenadine and has been shown to possess 
potent antihistaminic activity in studies with healthy volunteers and symptomatic patients 
(Bernstein et al 1997, Simons & Simons 1997). Following oral administration, 
fexofenadine is rapidly absorbed reaching maximum concentration within 1 - 2  hours. 
Pharmacological effects occur within 1-2 hours and are sustained over a period of 24 
hours (Simons & Simons 1997). Comparative studies indicate that fexofenadine has a 
much faster onset of action than loratadine (Simons & Simons 1997). As regards the 
CNS depressant effects of fexofenadine, clinical studies have clearly demonstrated the 
lack of impairments when fexofenadine is administered at doses up to 240mg 
(Hindmarch et al 1999, Nicholson & Turner 1999, Vermeeren & O'Hanlon 1998). In 
this respect, fexofenadine appears to be different from the other second generation AHs 
in that it is free of detrimental effects on aspects of performance and cognition even when 
administered at doses which are higher than the recommended clinically effective dose 
regimen. In addition, unlike its parent compound, fexofenadine is not associated with any 
cardiac side effects (Gonzalez & Estes 1998, Pratt et al 1997).
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Loratadine
Loratadine is also a selective Hi-receptor antagonist, which lacks the CNS depressant 
effects when administered at its recommended daily dose of lOmg (Bradley & Nicholson 
1987, Roth et al 1987). Loratadine is rapidly absorbed after single oral administration, 
with peak plasma concentrations occurring 1 to 1.5 hours after ingestion of 10-40mg 
doses (Haria et al 1994). Onset of antihistaminic action with loratadine occurs within the 
first hour and is sustained for 24 hours (Kassem et al 1988, Roman et al 1986). Direct 
comparison of single doses of various AHs in healthy volunteers revealed the following 
order of activity: cetirizine 1 0 mg> terfenadine 1 2 0 mg> terfenadine 60mg> loratadine 
10mg> astemizole 10mg> chlorpheniramine 4mg> placebo (Simons et al 1990).
Within the recommended therapeutic dose, loratadine is free from CNS adverse effects, 
however the administration of higher doses of loratadine has been reported to cause CNS 
impairments (Bradley & Nicholson 1987, O'Hanlon 1988, Riedel et al 1990b, Roth et al 
1987). While the doses which appear to be causing the sedation are higher than those 
recommended by the manufacturer, a powerful reduction in the histamine induced weal 
and flare response is only achieved with a 40mg dose of loratadine (Rihoux et al 1990), 
which is associated with significant CNS impairments.
Terfenadine
Terfenadine was the first second-generation antihistamine that became available 
clinically. It is well absorbed with peak plasma concentrations occurring one to two 
hours after drug administration (McTavish et al 1990). Terfenadine undergoes extensive 
first pass metabolism via the isoenzyme CYP3A of cytochrome P450 system to result in 
the formation of a major active metabolite, once referred to as the ‘acid-metabolite’ and 
now better known as fexofenadine (Gonzalez & Estes 1998, Simons 1990). Following a
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single 60mg dose of terfenadine, maximum suppression (approaching 1 0 0 %) of the weal 
response in healthy volunteers is evident after 4 hours and persists for 12 hours (Huther 
et al 1977). A single oral dose of 120mg has been shown to significantly inhibit the weal 
and flare response for up to 24 hours (Shall et al 1988). As regards CNS depressant 
activity, a large number of clinical studies has demonstrated the lack of either objectively 
measured or subjectively reported incidence of impairment with terfenadine (as assessed 
by a battery of valid, reliable and sensitive tests) at doses up to 600mg/day for up to 7 
days (Betts et al 1984, Gaillai'd et al 1988, Kulshrestha et al 1978, Moskowitz & Bums 
1988, Nicholson & Stone 1982).
The use of terfenadine has been restricted recently in the UK following the reports of 
potent cardiac side effects when terfenadine is administered concomitantly with 
cytochrome P450 system inhibitors such as the macrolide antibiotics (erythromycin) and 
antifungal drugs (ketoconazole) (Simons 1993).
1.8 Measuring Antihistamine-Induced Sedation
Having established that sedation produced as a result of antihistamine use is an unwanted 
(side) effect and that the accompanying sedation with a number of these AHs has serious 
implications in terms of safety for the patient, one needs to find ways to assess this 
sedation. There are two ways of assessing histamine-induced sedation.
Firstly, information about drug induced sedation can be gathered by asking the patient. 
This can be done either at regular time intervals during treatment as the patient visits 
their physician, or daily, by means of completing daily diary cards. Using this method, 
the questioning can be structured to varying degrees, from open, non-directive 
interviewing, to specific questioning using a set of potential effects. It is however clear 
that the response can be combined or verified by the opinion of the physician, as the
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reported experience is entirely subjective both with regard to its possible presence and 
severity. Another disadvantage of using subjective reports is that they lack objective 
measurement of the reported experience. Inter-subject variability also reduces the quality 
of the results obtained.
Secondly, the possible sedative potential of an antihistamine can be investigated in a 
standardised fashion, using a battery of validated and reliable, sensitive objective tests in 
healthy volunteers, in which varying test times can be incorporated into the design and 
the effects of different doses can be investigated.
1.9 Thesis Outline
As a first step in identifying the extent to which sedation is produced by AHs, chapter 2 
will investigate the extent of sedation produced by AHs in the healthy volunteers and 
chapter 3 will review the clinical literature. Based on this evidence, chapter 4 will detail 
the measures and methods chosen for the experimental work and the results of the 
experiments will be presented in three sections in chapter 5. Part one of chapter 5 will 
present the results of two experiments (1 & 2) in which the peripheral suppressing ability 
of a number of AHs were assessed and part two will present the results of four 
experiments (3-6) in which the effects of AHs on aspects of cognitive and psychomotor 
function were investigated in healthy volunteers. The final part of chapter 5 will present 
the results of an experiment which was conducted in patients within a general practice 
(GP) setting. The final chapter (chapter 6) will discuss the relevance of the findings and 
recommendations for future research.
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CHAPTER 2: PSYCHOMETRIC ASSESSMENT OF SEDATION AND
OTHER ASPECTS OF PSYCHOMOTOR FUNCTION IN 
EXPERIMENTAL STUDIES OF ANTIHISTAMINES IN 
HEALTHY VOLUNTEERS - A LITERATURE REVIEW
2.0 Chapter outline
This chapter presents a critical review of previous experimental research on the effects 
of AHs on measures of cognitive function and psychomotor performance in healthy 
volunteers. This review will aim to differentiate those AHs, which can claim to be 
completely free of sedation from those which are non-sedating when administered 
within their recommended dose regimen and those with obvious and pronounced 
sedative activity.
The present review concentrates only on psychometric assessments and takes no account 
of efficacy variables or other side effects, which may determine the clinical choice for 
use of a particular drug.
A secondary objective is the identification of those psychometrics which are reliable 
indicators of the sedative effects of AHs and therefore to be preferred when assessing the 
CNS profile of novel compounds.
2.1 Introduction
Chapter one presented an introduction to the AHs and highlighted that the 
administration of the first generation AHs is commonly associated with a number of 
undesirable CNS side effects, the most troublesome of which is sedation 
(Broolchuis et al 1993, Goetz et al 1991, Hindmarch & Shamsi 1999).
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In this review, the term ‘sedation’ is used to define a lowering of CNS activity which 
would be manifest as an impairment of superior cognitive functions such as attention, 
memory, sensorimotor co-ordination and psychomotor perfonnance and which may or 
may not be associated with subjective feelings of tiredness, fatigue, drowsiness etc 
(Hindmarch & Shamsi 1999).
As AHs are widely used for the treatment of allergic disorders such as seasonal allergic 
rhinitis (SAR), then such usage is mainly by ambulant patients including children, and 
any CNS effects could compromise performance and safety. Any psychometric 
evaluation of such potential sedative activity therefore requires the investigation of the 
effects of a given antihistamine on cognitive processes using a well-defined, valid and 
refined model of infoimation processing.
2.1.1 Information processing
To measure the action of a particular drug on human behaviour, whether to assess the 
clinical change produced by drug treatment or to profile its pharmacodynamic activity 
requires reliable and valid ratings and measurement systems as well as pertinent 
methodologies and controls to enable comparison with other drugs in the same class.
To examine the ways in which the activity of psychoactive drugs can be measured on 
psychomotor performance, Hindmarch (1980) proposed a basic model of information 
processing. In this model, the human organism is regarded as an information processing 
system, where sensory information is processed and organised centrally, before being 
formed into motor response schemes, which are ultimately realized in behaviour.
Figure 2.1 presents a simple model of information processing adapted from Hindmarch 
(1980). The model isolates the major processes as separate mechanisms
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within a linear system. Information from the environment is attended to and passed to 
higher cognitive mechanisms, where it is analysed and, if required, integrated with 
information from memory. A decision concerning appropriate response is then 
reached and the response output mechanisms activated. Although the major 
components of the model appear to be compartmentalised, they should not be 
perceived as discrete entities, but rather as a chain of events which are intrinsically 
linlced through adaptive feedback mechanisms (Fairweather 1997). The level of 
processing of one stage may affect performance at a different level or in another 
modality; for example, if the sensory processes are in error, then any subsequent 
central and motor responses will consequently be deficient, although acquired 
Icnowledge, skill and experience may ultimately provide a correct interpretation.
A psychoactive compound has the potential to affect all these sensory, central and 
motor components of information processing via both direct and indirect mechanisms. 
It must be noted however that the effect of drugs on information processing can be 
inferred from changes observed in overt behaviour or task performance. Following a 
review of the literature, Hindmarch (1980) grouped the tests according to the 
psychological variables they were thought to affect.
For the purposes of the present literature review, the tests have been categorised by 
grouping together those tests measuring similar CNS ‘behaviours’ (table 2.1).
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Table 2.1: Categories and codes for measures of performance
Psychomotor Performance
A: Actual Car Driving, Simulated Car Driving
Psychomotor Speed
B: Choice Reaction Time, Simple Reaction Time
Sensorimotor Co-ordination
C: Adaptive Tracking, Critical Tracking, Continuous Tracking,
Pursuit Rotor, Simulated Car Tracldng, Visuo-Motor Co-ordination
CNS Arousal, Information Processing
D: Critical Flicker Fusion
E: Digit Symbol Substitution Task, Letter Cancellation, Visual Search Task
F: Grammatical/Logical Reasoning, Mental Arithmetic
G: Stroop Colour Test
Memory
H: Continuous Memory Task, Short Term Memory
Sensory Sldlls
I: Vigilance Task
J: Attention Task, Continuous Attention Task, Simulated Assembly Line Task
K: Dynamic Visual Acuity
L: Spatial Perception
Motor Ability
M: Dexterity Test, Finger Tapping, Glass Bead Picking Test, Pegboard
Physiological
N: Electroencephalograph (EEG), Continuous EEG, Evoked Potentials,
Multiple Sleep Latency Test 
O; Actigraphy
Subjective Ratings
P: Profile of Moods Scale, Stanford Sleepiness Scale,
Visual Analogue Rating Scales
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Several tests measure more than one aspect of performance and these have been 
categorised according to their most relevant feature. In addition to obtaining objective 
data, it is important that subjective views are also recorded. This is particularly true 
for CNS active drugs, where cognitive appraisals of a particular scenario could 
influence overall psychomotor and cognitive function. Although this subjective 
aspect is not represented as a separate entity within the model, there is an obvious 
cognitive aspect where the subject is required to interpret and respond to the question 
by comparing present experiences of sedation and general impairments with 
memories of prior exposure.
Figure 2.2 illustrates those aspects of psychological performance assessed using a 
particular test system. It is evident that AHs have been widely tested, using a range of 
psychometrics analogous to most aspects of human information processing and daily 
function, although the effects of AHs on memory are ill-defined and it has been 
demonstrated (Cunan et al 1998, Hindmarch & Bhatti 1987, Hindmarch & Easton 
1986, Peck et al 1975, Smith & Janowski 1984, Unchern et al 1986) that this aspect of 
information processing is not affected with AHs.
The choice of a particular psychomotor test and the knowledge of its limitations are 
central to the understanding of any effects found. Thus, thorough 
psychopharmacological assessment requires a range of tests to ensure that subtle or 
specific drug effects are not overlooked. The clear need is for chosen tasks to be 
representative of key, well-defined and accepted areas of cognition and psychomotor 
performance. Theoretically one should use a test battery where separate and 
conjoined aspects of performance are measured (Hindmarch 1980, Hindmarch & 
Shamsi 1999).
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A cursory review of the literature (Rombaut & Hindmarch 1994, Hindmarch & Shamsi 
1999) reveals clearly that some ‘tests’ are more sensitive, valid and reliable than others, 
but it is also true that there is no single test that can satisfy all criteria in covering all 
aspects of human performance. A large number of trials has been carried out to 
investigate the central effects of AHs in asymptomatic subjects (Haria et al 1994, 
Hindmarch et al 1999, Hindmarch & Rombaut 1994, Hindmarch & Shamsi 1999, 
Mctavish et al 1990, Richards et al 1984, Hindmarch & Rombaut 1995, Spencer et al 
1993, Wiseman & Faulds 1996,). In assessing possible central effects of AHs, large 
numbers of tests have been employed. However, many of these tests are not valid 
indicators of CNS effects such as the kinaesthetic figurai after effect (Gupta 1974), the 
speed of putting caps on ball point pens (Lahtinen et al 1978) and flying simulators (Kay 
1995). A number of tests have not been shown to be reliable indicators of CNS activity, 
e.g. a time estimation procedures (Wittenbom et al 1976) and multiple limb coordination 
(Fleishman & Hempel 1956)] and, it is difficult to reproduce the results of particular 
experimental investigations to confirm and validate results.
A number of steps can be taken to ensure the validity and reliability of an experiment, 
such as screening volunteers to ensure sensitivity to the sedative effects of AHs, prior to 
participation. In a study by Hindmarch & Easton (1986), twenty-one volunteers were 
screened for sensitivity to a loading dose of chlorpheniramine 12mg of which only nine 
volunteers showed a significant reduction in CFF scores and were thus eligible for 
participation. It was argued that if a novel antihistamine (mequitazine in this instance) 
did not show sedation in a group of loiown ‘antihistamine responders’, then it would be 
feasible to claim that mequitazine was a non-sedating antihistamine.
This approach may not always be feasible as it is not only time consuming but also adds 
to the general workload of the trial in terms of additional testing. More importantly the
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effects of an acute antihistamine challenge may be attenuated on repeated administration. 
The simplest way of ensuring the validity of an experiment is the inclusion of a verum 
(positive control). By inclusion of a verum, the sensitivity of the test battery is 
guaranteed so long as the verum condition produces sedation as determined by the 
particular test in question. If following the use of a verum, effects are not obvious on an 
assessment measure, then it must be assumed that the test is insensitive and no credence 
can be given to any findings obtained in such an instance (Hindmarch & Shamsi 1999). 
Similarly, the reliability of an experiment is simply achieved by showing the verum 
condition producing the same results on the same tests on repeated administration 
(Pan'ott 1991a).
First generation AHs such as promethazine, hydroxyzine, clemastine and triprolidine 
have been commonly and consistently shown to impair performance on a wide range of 
tests (Alford et al 1989, Bateman & Rawlins 1984, Hindmarch et al 1999, Levander et al 
1985, Mattila et al 1986, Rombaut et al 1991, Shamsi & Hindmarch 1999a, Shamsi & 
Hindmarch 1999b, Simons et al 1995, Vermeeren & O’Hanlon 1998). For this reason, 
they are frequently included in studies as positive internal controls, when investigating 
the central effects of AHs.
The present review focuses on studies using placebo and verum controls, as the inclusion 
of both conditions is of paramount importance for the interpretation of results. A 
previous review of this kind has been conducted by Rombaut & Hindmarch (1994) and 
Hindmarch & Shamsi (1999), however the findings of both previous reviews were only 
analysed to provide an impairment/no impairment ratio for each antihistamine. This was 
achieved by calculating the number of discrete tests with which an impairment was 
detected (I) together with the number of tests administered at the same time and in the 
same study protocol with which no impairment was reported (NI). The ratio of I/NI was
45
then calculated by dividing the former by the latter value, the result of which represented 
the likelihood that a given antihistamine would produce sedative effects. The more 
impairment observed with a drug, the greater would be the I/NI ratio. Conversely, little 
evidence of sedation or impairment of cognitive and psychomotor fiinction would result 
in a value close to zero. In as much as this gave a working classification and allowed the 
AHs to be ranked according to their ability to impair performance, the ratio obtained did 
not reflect a true scenario, as the effects of all other AHs measured on the same tests 
were not taken into account. In other words, the effects of a particular antihistamine 
were considered in isolation and without reference to the properties of other AHs.
Taking the properties of all AHs into account as a ‘common denominator’ permits 
more accurate inter-drug comparisons to be made.
The use of a database of all drugs in a particular therapeutic category to provide an index 
of overall drug activity is a usefiil way of ranlcing a particular drug with respect to all 
other similar substances and ensures a more representative way of comparing one drug 
with another.
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2.1.2 Proportional Impairment Ratio (PIR)
The technique for calculation of a proportional ratio is adapted from that used in 
pharmacovigilance (Stather 1998). Proportional impairment ratio (PIR) calculates the 
effects of a particular antihistamine against all other AHs and rankings take into account 
both positive and negative findings. The calculation of PIR is explained in figure 2.3. 
The PIR shows whether the use of an antihistamine is associated with psychomotor 
impairments and if so, the extent of that impairment when compared to the effects of 
other AHs. The greater the PIR, the greater are the impairments associated with the use 
of that antihistamine. Conversely, an antihistamine with which there is no evidence of 
impairment when tested across a range of doses would have a PIR value of zero. AHs 
with detrimental effects, which become evident only when higher doses are administered, 
would have PIR values closer to zero than those which are associated with impairments 
regardless of the dose administered.
In addition to the calculation of the PIR value, it is important to calculate its statistical 
significance, which gives a measure of the confidence with which the PIR values can be 
used to rank the AHs as regards their potential to cause psychomotor impairments.
The statistical association for each PIR is calculated using the chi-squared test (X^) on 
one degree of freedom with Yate’s correction (Hinton 1995). In the calculation of the 
X^, if the cell frequencies are small, then the difference between the observed and 
expected frequencies will appear large and the X  ^will tend to be significant. This may 
result in a Type I en*or, which is the error of rejecting the null hypothesis when it is true. 
In order to compensate for this problem, the X  ^for every cell is reduced by 0.5 before it 
is squared, which results in a smaller calculated value of X ,^ thus reducing the risk of a 
Type I error (Hinton 1995).
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Figure 2.3 Calculation of a Proportional Impairment Ratio (PIR) for AHs
PIR = a + b divided by c + d
(As defined below)
Impairment No Impairment
Specific
antihistamine a b
All other AHs on 
the database c d
a, b, c and d represent a particular number of instances where 
individual psychometric tests have shown impairment or no 
impairment with a particular antihistamine.
In order to calculate a PIR for each antihistamine listed, two separate calculations were 
made. In the first instance, the number of tests with which impairments were detected 
with a specific antihistamine (a) was divided by the total number of times in which both 
impairments (a) and no impairments (b) were reported with the same compound (a + b) 
to provide an ‘impairment ratio’ for that specific antihistamine (a/a+b). Secondly, to 
calculate an ‘impairment ratio’ for all other AHs, the number of discrete tests with which 
impairments were detected when all other AHs were taken into accoimt (c) was divided 
by the total number of times with which both impairments (c) and no impairments (d) 
were reported (c+d).
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The PIR for each specific antihistamine was subsequently calculated by the division of 
the ‘impairment ratio’ for the specific antihistamine by the ‘impairment ratio’ of all other 
AHs in the database.
2.2 Literature Review
A computer-assisted MEDLINE search was conducted to identify studies which reported 
the effects of AHs on cognitive function and psychomotor performance from placebo and 
verum controlled studies reported in published papers from January 1971 up to August 
1999. MEDLINE search ensured that only studies published in peer reviewed j ouinals 
meeting specific criteria for acceptance were included in the review. Search terms 
included histamine, Hi receptor antagonists, antihistamines, psychomotor performance, 
cognitive function, psychometrics and specific drug names. The search was limited to 
studies performed in humans. Studies had to be placebo and verum controlled, 
performed in healthy asymptomatic volunteers, and of particular interest were studies 
using standardised, quantitative methods of defining both objective and subjective drug- 
induced effects of sedation, psychomotor performance and cognition. Studies using a 
parallel group design or those not employing a crossover design or where interaction with 
alcohol or other CNS substances was the primary variable and studies with children were 
excluded. A list of studies excluded with reasons for non-inclusion can be found in table 
2.2. As well as publications, data have been also included from studies published in 
abstract format in peer-reviewed journals, so long as the study satisfied the inclusion 
criteria and the data were presented in a format that enabled the PIR analysis to be 
performed.
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For each drug at all doses tested, results have been listed using the categorisation of tests 
presented in table 2.1, according to whether there was a statistically significant finding of 
‘impairmenf or ‘no impairment’. The psychometric methods used to determine CNS 
adverse effects were identified as either ‘objective’ or ‘subjective’. Using the 
categorisation listed in table 2.1, categories A-0 were considered as objective and 
category P as subjective measures of performance.
It is important to make a distinction between a drug’s tendency to induce subjective 
drowsiness and its potential to influence the objective assessment of CNS flinction and 
psychological performance (Hindmarch & Rombaut 1995). Objective tests require 
psychomotor performance of some sort by the subject. The performance measure is a 
physical one: time, number, frequency etc. Subjective tests require a subject to indicate 
an impression, feeling or opinion, usually on a questionnaire or a visual analogue rating 
scale.
Subjective tests usually form a part of a battery of tests and when combined with a 
objective measures, they can provide supportive data to the objective evidence for the 
presence or absence of CNS adverse effects. However when used in isolation, the 
outcome measures are unreliable in that for example, a given dose of an antihistamine 
may produce significant effects on a number of scales in one experiment, but no 
significant effects on the same scales in a second study, even with the same researchers 
conducting the experiments (White & Rumbold 1988).
If a statistically significant difference (p<0.05 or better) between the test drug and 
placebo was found on a specific psychometric test indicating an impaired CNS activity, 
then that test score was listed as an example of ‘impairment’. This was done for each 
and every psychometric test in all the studies reviewed.
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This sub-division of tests as objective or subjective was done because it is widely 
accepted that discrepancies exist between subjective reports of impairments and objective 
assessments of CNS function (Ahn & Barnett 1986, Mattila et al 1986, Nicholson & 
Stone 1986).
Based on objective evidence, the PIR for each antihistamine (FIR-0) was then calculated 
using the formula described in figure 2.3, which is indicative of each antihistamine’s • 
inherent potential for disrupting cognitive and psychomotor performance. The same 
procedure was repeated to calculate the PIR for each antihistamine using the subjective 
reports of sedation (PIR-S).
The objective and subjective tests were subsequently combined and an overall PIR was 
calculated for each antihistamine.
Following the calculation of PIR values for all AHs, a sub-group was then selected for 
additional analysis. This was conducted with the currently available second generation 
AHs only, in order to allow a like-like comparison without the first generation AHs 
known to cause sedation. Using the PIR formula, the PIR-0 and 
PIR-S together with an overall PIR value was recalculated for every second generation 
antihistamine to enable the ranking of these AHs (without including the first generation 
AHs) as regards their potential for disrupting psychomotor performance.
2.3 Results
A total of seventy-three placebo and verum controlled studies were reviewed 
(table 2.3). This comprised data on a total of 23 AHs, of which 14 are classed as second- 
generation AHs. Nine traditional first generation AHs were reviewed - they were almost 
always included in studies as positive internal controls.
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Both acute (A) and repeated (R) dosing regimens were included. All studies used a 
double blind crossover design.
Table 2.4 provides a summary of the number of times impairments were detected using 
both objective and subjective measures with all AHs, as well as the number of times in 
which both objective and subjective tests failed to detect impairments with all the AHs 
under review.
It is evident from these studies, which are considered to be the most adequately 
controlled, that most of the AHs under investigation do possess some sedative properties 
at some point in the dose ranges investigated. However, it is the first generation AHs, 
which consistently impair performance at all doses tested, whereas the second-generation 
AHs have a generally lower sedation index, although differences exist between the 
individual drugs.
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2.3.1 First Generation AHs
The most important finding is that the traditional AHs included as positive controls 
behave as expected in that they consistently impair performance on a large number of 
tests measuring different aspects of cognitive and psychomotor performance (Clarke & 
Nicholson 1978, Gaillard et al 1988, Goetz et al 1991, Hindmarch et al 1999, Hopes et al 
1992, Shamsi & Hindmarch 1999a, Shamsi & Hindmarch 1999b, Vermeeren &
O 'Hanlon 1998, Witek et al 1995). This impairment is evident on both objective and 
subjective measures. Of the 381 tests used to investigate the effects of traditional AHs, 
278 (73%) successfully detected impairments and 103 tests (27%) were unable to 
demonstrate significant deterioration of cognitive and psychomotor abilities. In contrast, 
587 tests were used in investigating the CNS adverse effects of the second generation 
AHs, of which only 72 tests were indicative of impairments (12%).
Chlorpheniramine (4-16mg), diphenhydramine (25-150mg), hydroxyzine (20-50mg) 
promethazine (10-30mg) and triprolidine (1.25-15mg) were exclusively used a verum, 
whereas bromphenirmaine (12mg), clemastine (l-4mg), ketotifen (l-2mg) and oxatomide 
(30mg) were included in a number of studies as a comparator rather than a positive 
control.
The administration of triprolidine in a range of doses, resulted in widespread impairment 
of various aspects of cognitive and psychomotor performance (Brooldiuis et al 1993, 
Cohen et al 1987, Riedel et al 1990b, Rombaut et al 1991, Shamsi & Hindmarch 
1999b,Volkerts et al 1992). There were however, a number of studies in which few or no 
impairments were reported but these occurred mainly when lower range of doses were 
administered (Cohen et al 1985, Hamilton et al 1982, Peck et al 1975). A number of 
other factors could have contributed to these findings. Firstly there is the use of the ‘slow 
release’ formulation of the substance, which affects both the clinical activity and
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psychometric consequences of talcing the drug across a longer time scale (Shamsi & 
Hindmarch 1999b). As a result of the administration of a slow release formulation, the 
acute dose peak of sedative activity is ‘smoothed out’ over a longer time period, which 
may well be outside the time frame of psychometric testing in the particular study. The 
times of psychometric testing were not necessarily consistent or identical across the 
various studies, which together with different pharmacodynamics brought about by 
various formulations, could have resulted in an increase in the variability of the observed 
effects. In addition, a substantial inter-individual variability exists with regard to 
antihistamine-induced sedation.
As the first generation of AHs are highly lipophilic (Simons 1995, Woodward 1988) 
and cross the blood brain barrier (Passalacqua et al 1996, Simons & Simons 1991), 
impairments frequently occur following the administration of these compounds. 
However, the lack of any objective evidence of impairment with the lower doses of 
loratadine (Betts et al 1988, Bradley & Nicholson 1987, Hindmarch et al 1999, Roth et 
al 1987) and cetirizine (Gengo & Gabos 1987, Gengo et al 1990, Shamsi & Hindmarch 
1999a, Simons et al 1995), for example, may be due to the fact that the concentrations 
achieved in the CNS are below those required to cause detrimental effects on cognitive 
and psychomotor abilities or that the lower tlireshold of sensitivity of the psychometric 
test itself has not been reached (Woodworth & Schlosberg 1958). Inter-study variability 
in dose regimens and testing programmes may also account for the difficulty in detecting 
impairment in a number of instances.
Tables 2.5 and 2.6 list the PIR values calculated for all the AHs included in the literature 
review based on objective and subjective tests used respectively. It is evident that all 
first generation AHs have a PIR value close to 2, whereas the second-generation AHs 
have a lower ratio with the majority resting under 1, regardless of whether impairments
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are detected using objective tests or subjective measures. However, there are differences 
in the ranking order of these AHs and the statistical significance of the PIR, depending 
on whether objective or subjective tests are used in the calculation of the impairment 
ratio.
As discussed previously, subjective assessments of sedation are not as reliable as 
objective measures of performance, because by their very nature, sleepiness, somnolence 
and sedation can impair the self assessment of awareness and thus result in misleading 
results (Hindmarch & Shamsi 1999). In addition, they are much more likely to be 
influenced by transient fluctuations of attention and other factors such as the cognitive 
demand characteristics of the task and the environment than are objective measures of 
performance (Walsh et al 1992). Therefore conclusions about the sedative potential of an 
antihistamine can not be made solely on data from subjective tests.
In light of the above, it is therefore evident that greater confidence can be placed on the 
PIR values calculated using objective measures of performance. Using these PIR-0 
values, the AHs are ranked as regards their potential to cause impairment of cognitive 
and psychomotor performance (table 2.5).
Promethazine possesses the highest PIR ratio with a value of 3.09, followed by 
hydroxyzine (2.25), triprolidine (2.21), clemastine (2.21), diphenhydramine (2.03) and 
chlorpheniramine (1.88). In addition, the calculated PIR values for the first generation 
AHs are all statistically significant (p<0.01) and thus can be confidently included in the 
ranldng table.
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Using the data from table 2.6, the ranldng order is changed although the PIR value for all 
first generation AHs still lies close to 2. Hydroxyzine has the highest PIR value of 2.57, 
followed by triprolidine (2.29), diphenhydramine (2.26), promethazine (2.24), clemastine 
(1.80) and chlorpheniramine (1.74).
Despite these differences in the ranldng order of the first generation AHs, depending on 
whether the PIR calculation is based on objective or subjective tests, it can be concluded 
that the first generation AHs are inherently sedative and cause significant impairment of 
cognitive and psychomotor function. Furthermore, the high and statistically significant 
PIR values obtained with these AHs provides support for the use of this method in 
predicting the sedative effects of AHs.
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Table 2.5: Calculation of PIR-O for all AHs Included in the review
Drug a b c d PIR with 
1 d.f
Fexofenadine 0 30 243 436 0.00 147g***
Ebastine 0 26 243 440 0.00 12.54***
Astemizole 0 22 243 444 0.00 10.23**
Levocabastine 0 10 243 456 0.00 3.86*
Temelastine 0 6 243 460 0.00 1.81 (NS)
Ketotifen 0 1 243 465 0.00 0.11 (NS)
Terfenadine 7 110 236 356 0.15 48.29***
Cetirizine 6 50 237 416 0.30 13.87***
Tazifylline 3 15 240 451 0.48 1.80 (NS)
Cyclizine 1 5 242 461 0.48 0.23 (NS)
Brompheniramine 1 4 242 462 0.58 0.04 (NS)
Loratadine 10 37 233 429 0.60 3.18 (NS)
Azatadine 3 10 240 456 0.67 0.32 (NS)
Mizolastine 16 46 227 420 0.74 1.77 (NS)
Acrivastine 4 10 239 456 0.83 0.03 (NS)
Mequitazine 3 5 240 461 1.10 0.03 (NS)
Chlorpheniramine 18 11 225 455 1.88 9.12**
Diphenhydramine 43 25 200 441 2.03 26.60***
Triprolidine 51 25 192 441 2.21 39.12***
Clemastine 31 13 212 453 2.21 25.58***
Hydroxyzine 12 4 231 462 2.25 10.27**
Oxatomide 3 0 240 466 2.94 3.22 (NS)
Promethazine 31 1 212 465 3.09 55.43***
a: Number o f tests showing ‘impairment’ with a named antihistamine; 
b: Number o f tests showing ‘no impairment’ with the named antihistamine; 
c: Number o f tests showing ‘impairment’ with all other antihistamines in the database; 
d; Number o f tests which show ‘no impairment’ with all other AHs in the database.
NS = Not Significant
* = Significant at 5 % level when X^is equal to or greater than 3.84 
** = Significant at 1% level when X^is equal to or greater than 6.64 
*** = Significant at the 0.1% when X i^s equal to or greater than 10.83
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Table 2.6; Calculation of PIR-S for all AHs included in the review
Drug a b c d PIR with 
1 d.f
Astemizole 0 10 107 142 0.00 5.66*
Fexofenadine 0 9 107 143 0.00 4.92*
Acrivastine 0 4 107 148 0.00 1.39 (NS)
Mequitazine 0 4 107 148 0.00 1.39 (NS)
Tazifylline 0 3 107 149 0.00 0.76 (NS)
Levocabastine 0 2 107 150 0.00 0.22 (NS)
Terfenadine 2 35 105 117 0.11 21.26***
Loratadine 1 14 106 138 0.15 6.44*
Ebastine 2 9 105 143 0.43 1.64 (NS)
Cetirizine 8 29 99 123 0.48 5.99*
Azatadine 1 4 106 148 0.48 0.27 (NS)
Mizolastine 3 9 104 143 0.59 0.77 (NS)
Brompheniramine 1 1 106 151 1.21 0.22 (NS)
Cyclizine 1 1 106 151 1.21 0.22 (NS)
Chlorpheniramine 9 4 98 148 1.74 3.27 (NS)
Clemastine 10 4 97 148 1.80 4.30*
Promethazine 8 1 99 151 2.24 6.79**
Diphenhydramine 23 5 84 147 2.26 19.74***
Triprolidine 21 4 86 148 2.29 18.99***
Temelastine 1 0 106 152 2.43 0.03 (NS)
Ketotifen 3 0 104 152 2.46 2.21 (NS)
Oxatomide 3 0 104 152 2.46 2.21 (NS)
Hydroxyzine 10 0 97 152 2.57 12.37***
a: Number of tests showing ‘impairment’ with a named antihistamine; 
b: Number of tests showing ‘no impairment’ with the named antihistamine; 
c: Number of tests showing ‘impairment’ with all other antihistamines in the database; 
d: Number of tests which show ‘no impairment’ with all other AHs in the database. 
NS = Not Significant
* = Significant at 5 % level when X^is equal to or greater than 3.84 
** = Significant at 1% level when X i^s equal to or greater than 6.64 
*** = Significant at the 0.1% when X^is equal to or greater than 10.83
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2.3.2 Second Generation AHs
The second generation AHs have much lower PIR values when compared to their 
predecessors, although the PIR for a number of these compounds is greater than zero and 
suggestive of a degree of sedative potential (tables 2.5 & 2.6). A closer look at table 2.3 
demonstrates that the lower doses of these second-generation AHs are almost free of 
CNS effects but impairments become evident when higher doses are administered 
(Gaillard et al 1988, Nicholson & Turner 1998, Riedel et al 1990, Shamsi & Hindmarch 
1999b, Vuurman et al 1994). This suggests that some passage through the blood brain 
barrier occurs with these AHs and at the lower dose range, concentrations in the CNS are 
not sufficient to cause impairments. Increasing the dose results in sufficient 
concentration of the drug in the CNS, which consequently manifests as an impairment of 
particular tests. Some of the second-generation AHs are claimed to be non-sedating (Kay 
& Hands 1999, Kay et al 1999, Roberts & Gispert 1999, Rosenzweig & Patat 1999) due 
to their inability to cross the blood brain banier. However if no penetration to the CNS 
occurs, then they must be free of sedation regardless of the doses administered and thus 
show no significant impairments on any of the tests of cognitive and psychomotor 
function. These AHs with which there is evidence of impairment at higher doses, should 
therefore not be referred to as non-sedating as this does not take into the account the 
impairments which occur with the administration of higher doses. It would be better to 
regard them as possessing a ‘window’ of non-impairment, but this in itself is of no 
interest in isolation from considerations of the clinical efficacy/potency of a particular 
dose level, which is outside the scope of this thesis.
Results from tables 2.3 & 2.4 demonstrate that impairments were evident with several of 
the second generation AHs across a range of doses. Mizolastine was investigated in a 
total of 4 studies utilising 62 objective tests, of which 16 demonstrated impairments.
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Subjective reports were utilised in 12 instances of which 9 were associated with 
impairments. In all cases, detrimental effects were demonstrated following the 
administration of higher doses. It is therefore clear that at its recommended dose of 
lOmg, mizolastine is free of adverse CNS effects and significant impairments become 
evident only after the administration of higher doses.
Terfenadine was investigated in 32 studies across a range of doses. Of the 117 objective 
tests investigating its CNS profile, there were 7 instances in which detrimental effects 
were demonstrated. The use of terfenadine resulted in subjective reports of sedation 
only in 2 instances from a total of 37 times that this measure was used. Given the large 
number of tests, which have failed to detect psychomotor impairments with this 
antihistamine, the few reports of impairments are more likely to be due to chance than 
any other factor. Cetirizine was investigated in 15 studies, utilising a total of 93 tests, 
of which 14 demonstrated detrimental CNS effects across a range of doses. Of the 56 
objective tests used in investigating the CNS profile of cetirizine, 6 were associated with 
significant impairments. These impairments were mostly evident following the 
administration of higher doses of cetirizine. There was one report of impairment on a 
tracking task following a 5mg dose of cetirizine and there was a single report of 
impairment on the multiple sleep latency task (MSLT) following the administration of 
lOmg cetirizine. This therefore indicates that with cetirizine, some penetration of the 
CNS occurs resulting in a measurable impairment, although the observed impairments at 
the lower doses may be due to a number of other factors such as inter-individual 
variability and chance.
The number of well designed and appropriately controlled studies with loratadine were 
surprisingly low, considering its position in the antihistamine market. Loratadine was 
investigated in 9 studies, which fiilfilled the criteria for inclusion in the review. Of the
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62 tests used, 11 were indicative of impairments across a range of doses. A total of 47 
objective tests were utilised in assessing the CNS profile of loratadine, of which 10 
were indicative of significant impairments, although the impairments became evident 
following the administration of higher doses (20-40mg). The high incidence of 
impairments with loratadine resulted in a PIR-0 value of 0.60, which failed to reach 
statistical significance (table 2.5). In other words, in comparing the CNS effects of 
loratadine with all other AHs, it was not possible to differentiate loratadine from all other 
AHs including the first generation AHs, which are known to cause impaiiment of 
cognitive and psychomotor function. Such findings make for difficulties in classifying 
loratadine as a non-sedating antihistamine (Kay et al 1997, Kay et al 1999) and 
emphasise the need for labelling loratadine as having a window of ‘no sedation’ at lOmg. 
Although Kay & Harris (1999) have concluded that findings with a lOmg dose of 
loratadine obviate the need for assessing the CNS effects of loratadine at the higher dose, 
the findings from this review suggest the contrary. Loratadine has been shown to cause 
impairments at the higher doses in a number of well designed studies (Gaillard et al 
1988, Riedel et al 1990, Shamsi & Hindmarch 1999a) and the PIR value of 0.60 with a 
non-significant statistic further support the claim (Howarth 1998) that loratadine 
should be classified as a 2b category antihistamine in which CNS adverse effects become 
evident when higher doses are administered.
In contrast to the objective evidence, there was only one incidence in which subjective 
sedation was reported following the administration of loratadine (Riedel et al 1990b). As 
a result, a low PIR value (0.15, p<0.05) was obtained when the subjective evidence was 
taken into consideration. However for reasons discussed before, results obtained with 
subjective assessments must be treated with caution and conclusions about the sedative 
potential of an antihistamine must not be based solely on data obtained from subjective
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measures (Hindmarch & Shamsi 1999).
Although the use of cetirizine is also associated with cognitive and psychomotor 
impairments when higher doses are administered, it is important to highlight one 
important difference between these two compounds.
Cetirizine is an extremely potent antihistamine as demonstrated by its ability to inhibit 
the histamine induced weal and flare reaction (Grant et al 1999, Rihoux et al 1990, 
Simon et al 1990, Urien et al 1999). Relief of allergy symptoms is readily achieved with 
the lower doses of cetirizine (Day et al 997, Meltzer et al 1996, Rihoux et al 1998) and 
higher doses are only rarely required in certain patient populations. In terms of potency, 
as measured by the histamine induced weal and flare test, 40mg loratadine is required to 
achieve a similar inhibition of the weal and flare response to cetirizine lOmg (Rihoux et 
al 1990).
Whereas the lOmg dose of cetirizine is free from measurable effects on cognitive and 
psychomotor performance, a 40mg dose of loratadine produces significant residual CNS 
adverse effects (Gaillard et al 1988, Riedel et al 1990b, Shamsi & Hindmarch 1999a). 
The findings from this literature review therefore, do not support the claim that the 
second-generation AHs are completely non-sedating. However, it is evident that a ‘dose 
window’ exists for a number of these AHs, within which these AHs are free of 
detrimental effects on measures of cognitive and psychomotor performance. It is only 
when these doses are exceeded, that impairments become evident.
Based on objective evidence, five of the fourteen second generation AHs achieved a PIR 
value of zero (table 2.5). These were fexofenadine, a metabolite of terfenadine, ebastine, 
astemizole, levocabastine and temelastine.
The PIR value obtained with temelastine does not warrant further discussion as it failed 
to reach statistical significance. In addition, temelastine was an investigational
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compound, which was studied in one clinical study and is not available in the 
antihistamine maiket. The findings with levocabastine must be treated with caution as 
only one controlled study employing 10 objective tests has investigated the sedative 
effects of this antihistamine and thus PIR value of zero is derived only from the results of 
one study (Rombaut et ai 1991). In line with the PIR calculated from the objective 
evidence, the PIR based on subjective reports was also zero, although only two subjective 
assessments were used in deriving this value. Further research is therefore required 
before levocabastine can be confidently placed in the non-sedating category.
In contrast to levocabastine, astemizole was studied in 9 studies employing twenty-two 
objective tests in which no impairments were detected at any of the doses tested. The 
derived PIR based on subjective evidence was supportive of the above, with no evidence 
of self-reported sedation in 10 out of 10 instances used. However reports of adverse 
cardiovascular effects (DuBuske 1999, Woosley 1996) following overdose with 
astemizole has led to the drug being withdrawn.
In assessing the CNS effects of ebastine, 26 objective tests failed to demonstrate 
impairments of performance, thus resulting in a PIR value of 0.00. However there were 
two subjective reports of sedation following the administration of a 30mg dose in one 
study (Shamsi & Hindmarch 1999b). Although subjective reports can be unreliable and 
judgements regarding the CNS profile of a drug cannot be based solely on subjective 
measures, these findings cannot be ignored. If an antihistamine is to be identified as 
‘non-sedating’ at all doses administered, the derived PIR value using both subjective and 
objective evidence must be zero and furthermore the calculated PIR value must be of 
statistical significance. As ebastine has only been studied in a small number of 
controlled studies, further research is required to establish its CNS profile and allow its
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ranking amongst those which can claim to be ‘non-sedating’ regardless of the dose 
administered.
The only remaining antihistamine with a PIR value of zero is fexofenadine.
Fexofenadine, which is the active metabolite of terfenadine, is a recent addition to the list 
of non-sedating AHs. To date, three placebo with veriim controlled studies employing 39 
tests have investigated the effects of various doses up to 240mg (Hindmarch et al 1999, 
Stone et al 1999, Vermeeren & O’Hanlon 1998). Within these doses, fexofenadine 
lacked any objectively determined sedative activity and did not impair cognitive and 
psychomotor performance. Supportive to the objective evidence, subjective tests were 
used in 9 instances and in all cases, there were no reports of sedation when tested across 
a range of doses. The clinical dosage regimen for fexofenadine in the treatment of SAR is 
120mg and 180mg for the treatment of chronic idiopathic urticaria (CIU). Trials with 
this drug have however investigated its effects up to 240mg (Stone et al 1999). This dose 
is in excess of the clinical dose and no impairments are evident on any of the tests, which 
might support Howarth’s (1998) notion that fexofenadine may need to be classified as a 
2c or even a third generation antihistamine at least for its lack of CNS activity.
According to the classification proposed by Howarth (1998), cetirizine and loratadine are 
classified as category 2b AHs, implying that some sedation may occur when higher doses 
are administered. Terfenadine and astemizole may be associated with cardiotoxic effects 
and are thus classified as class 2a AHs.
Although it may be argued that the number of studies conducted with fexofenadine were 
small to allow a comparison with other second generation AHs, it is worthy of note that 
only nine studies with loratadine were of satisfactory design to be included in the review. 
Cetirizine was investigated in 15 well designed studies, utilising a wide range of tests and 
therefore greater confidence can be placed in ranking cetirizine as fi ee of detrimental
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effects when administered within its established ‘dose window’ of lOmg. The 
confidence in cetirizine’s position is further reinforced with the highly significant 
statistic.
Increasing the cell frequencies in the formula outlined in figure 2.2 increases the 
accuracy of the calculated PIR. Therefore, following the calculation of the PIR-O and 
PIR-S all AHs (tables 2.5 & 2.6), the objective and subjective tests were combined to 
calculate an overall PIR value for each antihistamine (table 2.7). It is evident that despite 
combining the objective and subjective tests, the ranking order of the second-generation 
AHs is not generally affected, although the PIR values are slightly altered. Fexofenadine 
with a PIR value of zero is ranked at the top followed by astemizole (0.00), levocabastine 
(0.00), terfenadine (0.14), ebastine (0.14), cetirizine (0.33), loratadine (0.48) and 
mizolastine (0.70). Similarly, the combination of the objective and subjective tests has 
changed the rank order of the first generation AHs, although the values are still close to 2 
and of statistical significance. This supports the previous findings and confirms the 
ability of these compounds to cause significant impairment of cognitive and 
psychomotor function.
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Table 2.7: Calculation of an overall PIR for all AHs included in the review
Drug a b c d PIR with 
1 d.f
Fexofenadine 0 39 350 579 0.00 21.41***
Astemizole 0 32 350 586 0.00 17.16***
Levocabastine 0 12 350 606 0.00 539*
Terfenadine 9 145 341 473 0.14 71.35***
Ebastine 2 35 348 583 0.14 14.41***
Cetirizine 14 79 336 539 &39 18.85***
Tazifylline 3 18 347 600 039 3.53 (NS)
Temelastine 1 6 349 612 0.39 0.66 (NS)
Loratadine 11 51 339 567 0.47 8.90**
Acrivastine 4 14 346 604 0.61 0.99 (NS)
Azatadine 4 14 346 604 0.61 0.99 (NS)
Mizolastine 19 55 331 563 0.69 3.34 (NS)
Mequitazine 3 9 347 609 0.69 0.26 (NS)
Cyclizine 2 6 348 612 0.69 0.08 (NS)
Brompheniramine 2 5 348 613 &79 0.00 (NS)
Chlorpheniramine 27 15 323 603 1.84 13.80***
Clemastine 41 17 309 601 2.08 3030***
Ketotifen 3 1 347 617 2.08 1.21 (NS)
Diphenhydramine 66 30 284 588 2.11 47,49***
Triprolidine 72 29 278 589 222 58.60***
Hydroxyzine 22 4 328 614 2.43 25.06***
Oxatomide 6 0 344 618 2.80 8.06**
Promethazine 39 2 311 616 2.84 61.85***
a: Number of tests showing ‘impairment’ with a named antihistamine; 
b: Number of tests showing ‘no impairment’ with the named antihistamine; 
c: Number o f tests showing ‘impairment’ with all other antihistamines in the database; 
d: Number o f tests which show ‘no impairment’ with all other AHs in the database.
NS = Not Significant
* = Significant at 5 % level when X^is equal to or greater than 3.84 
** = Significant at 1% level when X^is equal to or greater than 6.64 
*** = Significant at the 0.1% when X^is equal to or greater than 10.83
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2.3.3 Currently Available First & Second Generation AHs
Of the 23 AHs reviewed in this chapter, only 11 are currently available either as
OTC preparations or as prescription only medicines in the United Kingdom. In order to
clarify the findings with the currently available AHs, tables 2.8, 2.9 & 2.10 list the PIR
values together with the calculated statistic for each of these AHs.
Table 2.8: Rank order of currently available AHs as determined by the PIRs
based on objective measures
Drug a b c d PIR X  ^ with 
1 d.f
Fexofenadine 0 30 243 436 0.00 14.78***
Levocabastine 0 10 243 444 0.00 336*
Terfenadine 7 110 236 356 0.15 48.29***
Cetirizine 6 50 237 416 0.30 13.87***
Loratadine 10 37 233 429 0.60 3.18 (NS)
Chlorpheniramine 18 11 225 455 1.88 9 12**
Diphenhydramine 43 25 200 441 2.03 26.60***
Triprolidine 51 25 192 441 2.21 39.12***
Clemastine 31 13 212 453 2.21 25.58***
Hydroxyzine 12 4 231 462 235 10.27**
Promethazine 31 1 212 465 3.09 55.43***
a: Number of tests which showed ‘impainnent’ with the named antihistamine,; 
b: Number of tests which showed ‘no impairment’ with the named antihistamine; 
c: Number of tests which showed ‘impairment’ with all other AHs in the database; 
d: Number of tests which showed ‘no impairment’ with all other AHs in the database; 
NS= Not significant compared to all other AHs in the database;
* = Significant at 5 % level when X^is equal to or greater than 3.84 
** = Significant at 1% level when X^is equal to or greater than 6,64 
*** = Significant at the 0.1% when X^is equal to or greater than 10.83
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Table 2.9: Rank order of currently available AHs as determined by the PIRs
based on subjective measures
Drug a b c d PIR with 
1 d.f
Fexofenadine 0 9 107 143 0.00 A92*
Levocabastine 0 2 107 150 0.00 0.22 (NS)
Terfenadine 2 35 105 117 0.11 21.26***
Loratadine 1 14 106 138 0.15 6.44*
Cetirizine 8 29 99 123 0A8 5.99»
Chlorpheniramine 9 4 98 148 1.74 3.27 (NS)
Clemastine 10 4 97 148 1.80 4.30*
Promethazine 8 1 99 151 234 6 79**
Diphenhydramine 23 5 84 147 236 19.74***
Triprolidine 21 4 86 148 239 18.99***
Hydroxyzine 10 0 97 152 237 12.37***
a: Number of tests which showed ‘impairment’ with the named antihistamine,; 
b: Number of tests which showed ‘no impairment’ with the named antihistamine; 
c: Number of tests which showed ‘impairment’ with all other AHs in the database; 
d: Number o f tests which showed ‘no impairment’ with all other AHs in the database; 
NS= Not significant compared to all other AHs in the database;
* = Significant at 5 % level when X^is equal to or greater than 3.84 
** = Significant at 1% level when X i^s equal to or greater than 6.64 
*** = Significant at the 0.1% when X i^s equal to or greater than 10.83
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Table 2.10; Rank order of currently available AHs as determined by the PIRs
based on both objective & subjective measures
Drug a b c d PIR with 
1 d.f
Fexofenadine 0 39 350 579 0.00 21.41***
Levocabastine 0 12 350 606 0.00 539*
Terfenadine 9 145 341 473 0.14 71.35***
Cetirizine 14 79 336 539 0.39 18.85***
Loratadine 11 51 339 567 0.47 8.90**
Chlorpheniramine 27 15 323 603 1.84 13.80***
Clemastine 41 17 309 601 238 30.30***
Diphenhydramine 66 30 284 588 2.11 47.49***
Triprolidine 72 29 278 589 232 58.60***
Hydroxyzine 22 4 328 614 2.43 25.06***
Promethazine 39 2 311 616 234 61.85***
a: Number of tests which showed no ‘impairment’ with the named antihistamine,; 
b: Number of tests which showed ‘no impairment’ with the named antihistamine; 
c: Number of tests which showed ‘impairment’ with all other AHs in the database; 
d: Number of tests which showed ‘no impairment’ with all other AHs in the database;
NS= Not significant compared to all other AHs in the database;
* = Significant at 5 % level when X^is equal to or greater than 3.84 
** = Significant at 1% level when X^is equal to or greater than 6.64 
*** = Significant at the 0.1% when X^is equal to or greater than 10.83
In the clinical context where considerations of potency/efficacy are of equal importance 
to the drug’s CNS profile of possible impairment, it still has to be remembered that the 
CNS impairments are intrinsic to the pharmacology of the particular drug, but these 
summary tables do have utility in determining those drugs which are more suitable for 
ambulant patients.
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2.3.4 PIR Re-analysis with the Second Generation AHs
In order to draw a direct like-with-like comparison between the second-generation AHs 
only, the PIR values were recalculated for these AHs using the same formula described in 
figure 2.3.
Using the data obtained from both the objective and subjective tests, an overall PIR value 
was calculated for each second-generation antihistamine (table 2.11). An individual 
analysis using only the objective or only the subjective tests was not done as the 
breakdown of the tests would significantly reduce the cell size and compromise the 
accuracy of the analysis. Furthermore, previous breakdown of the tests as either 
‘objective’ or ‘subjective’ revealed that the there were no significant differences in the 
ranking order of the AHs as regards their potential to cause cognitive and psychomotor 
impairments.
Using only the data with studies of second-generation AHs, it is clear that the overall 
ranking is not affected, although higher PIRs are obtained in the second sub-group 
analysis (table 2.11). This is explained by a smaller amount of data being entered for the 
‘all other AHs in the database’ category. It is interesting to note that only three AHs 
achieved statistical significance when compared to the rest of the second generation AHs. 
The statistical significance of the indicates a difference between that specific 
antihistamine and the rest of the AHs included in the calculation of the PIR values. 
Although indicative of a difference, the X  ^however, does not differentiate the direction 
of the change. Within the context of this review, the X  ^does not indicate whether the use 
of a specific antihistamine causes significant impairments when compared to the other 
AHs or whether it is devoid of detrimental effects in comparison to the other AHs.
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Table 2.11: Re calculation of PIRs for the second generation AHs using data
from both objective and subjective tests:
Drug a b c d PIR X^ with 1 d.f
Fexofenadine 0 39 59 423 0.00 433*
Astemizole 0 32 59 430 0.00 3.24 (NS)
Levocabastine 0 12 59 450 0.00 0.63 (NS)
Terfenadine 9 145 50 317 0.43 539*
Ebastine 2 35 57 427 0.46 0.83 (NS)
Cetirizine 14 79 45 383 1.43 1.15 (NS)
Loratadine 11 51 48 411 1.70 2.:21 (NS)
Acrivastine 4 14 55 448 233 1.22 (NS)
Mizolastine 19 55 40 317 237 16.06*
a: Number of tests which showed ‘impairment’ with the named antihistamine,; 
b: Number of tests which showed ‘no impairment’ with the named antihistamine; 
c: Number of tests which showed ‘impairment’ with all other AHs in the database; 
d; Number of tests which showed ‘no impairment’ with all other AHs in the database; 
* = Significant at 5 % level when X^is equal to or greater than 3.84
Examination of the data in table 2.11 indicates that the use of mizolastine resulted in a 
number of impairments and the statistically significant indicates that these detrimental 
CNS effects are significantly different when compared to the other second generation 
AHs. However the situation is reversed with terfenadine and fexofenadine and the 
significant X  ^statistic confirms that these AHs are free from CNS impairing effects to a 
greater degree than the other AHs included in the analysis. The data indicates that there 
were 9 reports of impairments (7 objective, 2 subjective) out of the 154 tests used to 
investigate the CNS profile of terfenadine. Similarly with fexofenadine, there were no 
reports of either objectively determined or subjectively reported impairments from 39
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tests across a range of doses. Comparison of the CNS effects of fexofenadine with all 
other AHs including the first generation AHs loiown to cause impairments differentiated 
this compound from the others indicating its non-sedative CNS profile. Furthermore, a 
comparison of these effects with only the second generation AHs, which are claimed to 
be non-sedating, once again differentiated fexofenadine as the only antihistamine with a 
PIR value of 0.00 which achieved statistical significance. Considering that the re­
analysis was conducted with a group of AHs, which are claimed to be free of CNS 
effects, it was expected that no significant differences would be evident between these 
compounds. The fact that fexofenadine is shown to be significantly different to the other 
second generation AHs confirms that fexofenadine does not belong to this second 
generation category, thus leading further support to the classification of this fexofenadine 
as a ‘third generation’ antihistamine, at least as regards its unique profile of lack of CNS 
effects.
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2.4 Psychometrics Sensitive to the Effects of AHs
The secondary objective of this review was to identify the tests, which are most sensitive 
to the central effects of AHs, i.e. to identify a psychometric test battery, which could be 
used with maximal effectiveness when investigating the CNS profiles of this class of 
compounds.
A closer look at table 2.3 clearly shows that there is a wide range of tests and techniques 
which are used in experimental studies of the effects of AHs on CNS variables.
2.4.1. Sensitivity o f psychometrics
The sensitivity of a test can be derived by looking at the number of times a particular test 
successfully detects impairment in those AHs, which have been shown to cause sedation 
(i.e. the first generation AHs).
Although the sedative activity of all first generation AHs is well established, not all 
studies have used the same tests. Therefore in order to be able to make conclusions about 
the sensitivity of psychometric tests, the findings with all first generation AHs used in the 
review were pooled together. In cases where a test measured more than one aspect of 
information processing, it was grouped under the most relevant feature. The sensitivity 
of a test or a group of similar tests i.e. the ability of a test to discriminate sedation with 
respect to placebo was calculated by dividing the number of times impairments were 
detected with a specific test/test group, by the total number of times that specific test 
group was used (table 2.12). In order, as before, to put the sensitivity of a particular 
test/test group within the context of all other psychometrics, a proportional impairment 
detection ratio (PIDR) was calculated for each group of tests using the previously 
outlined formula (figure 2.2).
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Table 2.12: Percentage detection rate of impairment with 1®* generation AHs used
as positive internal controls in all studies
Code Description of Test No of times 
impairment 
detected
Total no of 
times used
% Detection of 
impairment
A
Psychomotor Performance 
Actual Car Driving 
Simulated Car Driving
14 14 100.0
B
Psychomotor Speed
Choice Reaction Time 
Simple Reaction Time
45 52 86.5
C
Sensorimotor Coordination
Adaptive Tracking, Critical Tracking, 
Continuous Tracking, Pursuit Rotor, 
Simulated Car Tracking, Visuo- 
Motor Coordination
28 36 77.8
D
E
F
G
CNS Arousal & Information 
Processing
Critical Flicker Fusion 
Digit Symbol Substitution Task, 
Letter Cancellation, Visual Search 
Task
Grammatical/Logical Reasoning 
Mental arithmetic 
Stroop Colour Test
17
25
7
4
27
44
10
6
63.0
56.8
70.0 
66.7
H
Memory
Continuous Memory Task, Short 
Term Memory
4 16 25.0
I
J
K
L
Sensory Skills 
Vigilance Task
Attention Task, Continuous Attention 
Task, Simulated Assembly Line Task 
Dynamic Visual Acuity 
Spatial Perception
9
13
4
0
11
16
4
1
81.8
81.3
100.0
0.0
M
Motor Ability
Dexterity Test, Finger Tapping 
Glass Bead Picking Test, Pegboard
0 5 0.0
N
O
Physiological
Electroencephalograph (EEG), 
Continuous EEG,
Evoked Potentials, Multiple Sleep
Latency Test
Actigraphy
18
2
22
2
81.8
100.0
P
Subjective Ratings
Profile of Moods Scales 
Stanford Sleepiness Scale 
Visual Analogue Rating Scales
81 99 81.8
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The PIDR value for test sensitivity to sedation (PIDR-SS) was calculated by first 
deriving the discrimination rate for impairment for a specific test/test group by dividing 
the number of times that the test/test group was successful in detecting impairment (a), 
by the total number of times that impairments and no impairments were detected with 
that test/test group (a+b). The product of this first calculation (a/a+b) was then divided 
by the result of dividing the number of times that all other test groups successfully 
detected impairments (c), by the total number of times that both impairments and no 
impairments (d) were detected (c+d).
A high PIDR-SS value represents a greater sensitivity of the test/test group for CNS 
sedation. Similarly, if a group of tests are not sensitive, then the PIDR-SS will have a 
value closer to zero. The statistical significance of the PIDR-SS is again calculated 
using the test on 1 degree of freedom (with Yate’s correction).
Table 2.13 lists the calculated PIDR-SS values for the various groups of tests. The 
calculation of a PIDR-SS and its statistical significance allowed the selection of those 
tests which were deemed to be most sensitive to the central effects of AHs.
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Table 2.13: Discrimination rate of impairment (PIDR-SS) with 1®^ generation
AHs used as positive internal controls in all studies
Description of Test a b c d PIDR-SS X'
Psychomotor Performance
Actual Car Driving, Simulated Car 14 0 257 94 1.37 3.97*
Driving (A)
Psychomotor Speed
Choice Reaction Time, Simple 45 7 226 87 1.20 4.07*
Reaction Time (B)
Sensorimotor Coordination Speed
Adaptive Tracking, Continuous
Tracking, Critical Tracking, Pursuit 28 8 243 86 1.05 0.30 (ns)
Rotor, Simulated Car Tracking,
Visuo-Motor Coordination (C)
CNS Arousal & Information
Processing
Critical Flicker Fusion (D) 17 10 254 84 0.84 1.36 (ns)
Digit Symbol Substitution Task, 25 19 246 75 0.74 6.95*
Letter Cancellation, Visual Search
Task (E)
Grammatical/Logical Reasoning 7 3 264 91 0.94 0.01 (ns)
Mental arithmetic (F)
Stroop Colour Test (G) 4 2 267 92 0.90 0.01 (ns)
Memory
Continuous Memory Task, Short 4 12 267 82 0.33 18.62*
Term Memory (H)
Sensory Skills
Vigilance Task (I) 9 2 262 92 1.11 0.05 (ns)
Attention Task, Continuous 13 3 258 91 1.10 0.13(ns)
Attention Task, Simulated Assembly
Line Task (J)
Dynamic Visual Acuity (K) 4 0 267 94 1.35 0.70 (ns)
Spatial Perception (L) 0 1 271 93 0.00 0.31 (ns)
Motor Ability
Dexterity Test, Finger Tapping 0 5 271 89 0.00 10.94*
Glass Bead Picking Task, Pegboard
(M)
Physiological
Electroencephalograph (EEG), 18 3 253 90 1.11 0.34 (ns)
Continuous EEG, Evoked Potentials,
Multiple Sleep Latency Test (N)
Actigraphy (0 ) 2 0 269 94 1.35 0.01 (ns)
Subjective Ratings
Profile o f Moods Scales, Stanford 81 18 190 76 1.15 4.07*
Sleepiness Scale, Visual Analogue
Rating Scales (P)
a; Number of times that ‘impairment’ was detected with a specific test group; 
b: Number of times that ‘no impairment’ was detected with the specific test group; 
c: Number of times that ‘impairment’ was detected by all other test groups; 
d: Number of times that ‘no impairment’ was detected with all other test groups.
* = Significant at the 5% level when is equal to or greater than 3.84
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Car Driving Tests
Tests of car driving, whether it is actual highway driving, or a simulated car driving task, 
detected impairments consistently in 14 out of 14 instances. Actual car driving tests 
(Betts et al 1984, Betts et al 1988, Brookhuis et al 1993, O’Hanlon 1988, Ramaekers &
O’Hanlon 1994, Vermeeren & O’Hanlon 1998, Volkerts et al 1994) were used for a total 
of 9 times and, in all studies, sedation was successfully measured as impairment of 
standard deviation of lateral position (SDLP). These groups of tests achieved a PIDR-SS 
of 1.38 which was statistically different to the other groups of tests (X  ^=3.97, p<0.05), 
suggesting that these tests may be useful in investigating the central effects of AHs. 
However in all these tests, the parameter under investigation was the ability of the driver 
to control weaving of the car, measured as the ‘standard deviation from lateral position’ 
(SDLP), which has been suggested to be an indicator of drug-induced sedation 
(O’Hanlon 1988, Ramaekers & O’Hanlon 1994, Vermeeren & O’Hanlon 1998). 
According to the hierarchical structure of the driving task proposed by Janssen (1979) 
however, tests of car driving in which the parameter under investigation is the SDLP 
should be assigned exclusively to the lowest hierarchical level, i.e. the control level, since 
only the course-keeping tasks are evaluated and important functions such as attention, 
judgement and co-ordination are not assessed (Willumeit et al 1993). Car driving tests 
are not a suitable choice for children and non-driving patients and steering is a robust 
skill, which resists impairment even with high blood alcohol concentrations. Car driving 
is an acquired skill and despite impairments, an experienced driver can overcome and 
compensate for this effect. Furthermore, actual car driving tests are logistically, 
financially and methodologically difficult to establish and control within a crossover 
protocol employed in most AHs studies.
In addition to tests of psychomotor performance (actual & simulated car driving tests).
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the dynamic visual acuity test and actigraphy achieved a 100% discrimination rate, 
however in both cases, the calculation was based on few instances where the tests were 
utilised. In addition, when compared to the other groups of tests, these tests failed to 
achieve a statistically significant PIDR-SS.
Of the many different categories of tests, psychomotor perfoimance tests, measures of 
reaction time and subjective rating scales achieved significant PIDR-SS values to warrant 
the selection of these tests as ‘sensitive measures’ when investigating the central effects 
of AHs (table 2.13).
Reaction Time
Tests of reaction time including choice reaction time and simple reaction time were 
commonly utilised in many studies. In studies with the first generation AHs, these tests 
were used for a total of 52 times, in which impairments were detected in 45 instances 
(86.5%), resulting in a PIDR-SS of 1.20 (X  ^= 4.07, p<0.05).
Choice reaction time is used as an indicator of sensorimotor response, assessing the 
efficiency of attentional and response mechanisms in the information processing chain 
without the need for extended cognitive processing (Hindmarch 1980). Measurements of 
CRT provide information on the constant, very rapid adjustments that individuals must 
make to their environment, which require them to attend to several potential stimuli at 
once (Hindmarch 1980, Sherwood & Kerr 1993). This suggests that there is a high 
degree of construct validity inherent in reaction time measures. The sensitivity of this 
test is highlighted by the fact that it is one of few tests, which detected impairments with 
second generation AHs such as mizolastine, loratadine and terfenadine (Shamsi & 
Hindmarch 1999a, Ramaekers & O’Hanlon 1994, Vuurman et al 1994).
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Sensori-motor Coordination
Measures of sensorimotor coordination such as adaptive tracking, critical tracking task 
and visuo-motor achieved a discrimination rate of 78%. Hovyever these measures failed 
to reach statistical significance when compared to the other groups of tests. This is 
ascribed to the fact that they are not used frequently and thus the cell frequencies are 
reduced in the calculation of a PIDR-SS for these tests. Furthermore, different 
methodologies are applied in different laboratories and the lack of standardisation 
contributes to the lack of impairments detected.
Critical Flicker Fusion
Another task, which is commonly featured in studies investigating the central effects of 
AHs, is the critical flicker fusion (CFF) task. CFF appears in numerous studies with 14 
AHs including all the second-generation antihistamines. The discrimination rate with 
CFF is shown to be 63% but the calculated PIDR-SS failed to reach statistical 
significance. This value is perhaps lower than expected given the known sensitivity of 
this measure with psychoactive drugs in general (Hindmarch 1982, Wittenbom 1979) and 
may be ascribed to the different methodologies involved in measuring the CFF 
(monocular versus binocular viewing, foveal versus peripheral measurement,) as well as 
different analysis methods such as method of limits, forced choice, or method of 
adjustment. However, despite the variation, CFF demonstrated the reduction in cognitive 
capacity following the administration of first generation AHs (17 out of 27). CFF is one 
of the most commonly used tasks in the area and has proved sensitive to a wide range of 
compounds (Smith & Misiak 1976, Hindmarch 1981, Hindmarch 1982, Grunberger et al 
1982). The advantages of CFF include the simple, non-invasive nature of the test, the
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short duration of the assessment, and an absence of major practice effects (subject to 
training the subjects prior to participation in the study), (Parkin et al 1997).
Memory
The detection rate for impairment of memory following traditional AHs was somewhat 
low in memory tests (4:16). This finding is in agreement with previous literature (Curran 
et al 1998, Hindmarch & Bhatti 1987, Hindmarch & Easton 1986, Unchem et al 1986) in 
which it has been demonstrated that memory is not affected following the use of AHs. 
The highly significant statistic confirms the lack of sensitivity of these tests when 
investigating the CNS effects of AHs.
Miscellaneous tests
Of the remaining tests, measures of CNS arousal and information processing such as the 
digit symbol substitution task, logical reasoning, mental arithmetic and the Stroop colour 
test as well as attention/vigilance tasks achieved relatively high discrimination rates 
ranging between 57% for the DSST and 82% for attention and vigilance tasks. However, 
once again these measures failed to reach statistical significance when compared to the 
other groups of tests, which may be ascribed to the fact that they are not used frequently 
and that the lack of standardisation contributes to the lack of impairments detected. 
Physiological measures such as the EEG achieved high discrimination rates, however 
such measures are not utilised frequently as the use of these tests is time consuming, 
expensive and requires specialised personnel.
Measurement of motor ability using a variety of tests such as finger tapping and dexterity 
tests were only used very rarely and thus can not be relied upon to provide useful data.
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Continuons Assessment of Activity with Actigraphy 
One well-icnown problem with the use of performance-based measures in 
psychopharmacology is that individuals can compensate for the effects of a psychoactive 
compound by changing their performance strategy and/or motivation levels.
Performance testing is often intermittent and subjects are usually forewarned or aware of 
the experimental protocol and the impending test. This allows subjects to prepare 
themselves for the testing and therefore the limited period of concentration required may 
not accurately reflect typical levels of alertness thi'oughout the day (Walsh et al 1992, 
Alford et al 1989).
One way of overcoming the problems associated with the use of fixed test intervals is to 
use actigraphy to monitor behaviour throughout the day. Actigraphy provides a 
continuous measurement of the motor component of behaviour (Stanley 1997, Stanley et 
al 1997) and is thus able to detect impairments in performance throughout the day. Due 
to its recent introduction in the field of psychopharmacology, actigraphy was only used 
in two instances, however it successfully detected sedation in both studies. Further 
research is therefore required with actigraphy in the investigation of the central effects of 
AHs.
Subjective Assessments
In addition to objective measures of performance, subjective reports were also frequently 
utilised, demonstrating high discrimination rates (82%). Furthermore, the highly 
significant PIDR value (X  ^= 4.07, p<0.05) differentiates this group of tests from the 
others and indicates that they can provide important information as regards the potential 
of AHs to cause impairments of cognitive and psychomotor function. However, self- 
assessments of performance and sleepiness, although commonly used and easy to
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administer, are not as straightforward or as reliable as objective measures of sedation. 
Subjective reports are much more likely to be influenced by transient fluctuations and 
other factors such as demand characteristics and environmental stimuli than are objective 
measures of performance (Alford et al 1989, Roehi's et al 1984, Walsh et al 1992).
Despite these inconsistencies, if subjective measures are combined with sensitive and 
reliable objective tests, they can provide useful supportive data, indicating the total 
impact of an antihistamine on psychological performance.
2.5 Discussion
Findings from this review indicate that when the different sub-groups of tests are 
compared to one another, there are thi'ee groups of tests, which consistently and 
successfully detect impairments commonly associated with the use of the AHs.
These are tests of psychomotor performance (car driving), measures of reaction time and 
subjective assessments of sedation. It is also abundantly clear that memory tests and tests 
of motor ability are not sensitive and therefore of no use in detecting impairment and 
should not be included in psychometric test batteries.
Based on these findings, it was decided to recalculate the PIR values for all the available 
first and second generation AHs using only the tests which have been shown to be 
sensitive in detecting impairments with the AHs (table 2.14).
A comparison of table 2.10 and table 2.14 shows that the ranlc order of the second 
generation AHs is not affected, when only sensitive psychometrics are used.
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Table 2.14: Rank order of currently available AHs using tests which have a
proven sensitivity to impairment
Drug a b c d PIR X  ^ with 1 d.f
Fexofenadine 0 19 152 168 0.00 14.50***
Levocabastine 0 6 152 181 0.00 3.29 (NS)
Terfenadine 5 63 147 124 0.14 46.45***
Cetirizine 8 45 144 142 0.30 21.07***
Loratadine 4 24 148 163 0.30 10.23**
Chlorpheniramine 14 5 138 182 1.71 5.59**
Clemastine 19 7 133 180 1.72 7.88**
Triprolidine 39 9 113 178 2.09 28.28***
Diphenhydramine 35 7 117 180 2.12 26.97***
Hydroxyzine 15 1 137 186 2.21 14.23***
Promethazine 13 1 139 186 2.17 11.66***
a: Number of tests which showed no ‘impairment’ with the named antihistamine,; 
b: Number o f tests which showed ‘no impairment’ with the named antihistamine; 
c: Number of tests which showed ‘impairment’ with all other AHs in the database; 
d: Number o f tests which showed ‘no impairment’ with all other AHs in the database;
NS= Not significant compared to all other AHs in the database;
* = Significant at 5 % level when X^is equal to or greater than 3.84 
** = Significant at 1% level when X i^s equal to or greater than 6.64 
*** = Significant at the 0.1% when X“is equal to or greater than 10.83
It is also evident that fexofenadine (PIR value of 0.00, =14.50, p<0.001) is the only
currently available antihistamine which can claim to be completely free of adverse CNS 
effects. These findings lend further support to the claim that fexofenadine should be 
classed as a ‘third generation’ antihistamine, at least as regards its unique profile of lack 
of CNS effects.
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2.6 Conclusions
It is evident from the findings of this review that all AHs (with the exception of 
fexofenadine) possess a potential to produce sedation. This potential is a flinction of 
histaminergic mechanisms involved in the control of CNS arousal and is more likely to 
occur with those substances which cross the blood brain baiiier.
In order to be able to detect this possible sedative activity, it is important to use a battery 
of tests which have proved to be sensitive and reliable indicators of sedation.
Although a number of tests failed to achieve a significant PIDR-SS value, if standard 
methodologies are applied, information processing tasks such as the CFF as well as 
vigilance and attention tasks are extremely sensitive to the effects of CNS active 
compounds. Of the tests reviewed in this chapter, measures of reaction time, tests of car 
driving and subjective assessments were successful in detecting impairment associated 
with the use of the AHs. These were therefore used to re-calculate the PIR values for all 
currently available AHs to allow the ranking of these compounds as regards their ability 
to impair cognitive and psychomotor perfoimance.
It must be appreciated, however that regardless of the choice of a reliable and valid test 
battery, detection of sedation is in fact directly dependent on the actual presence of 
sedative effects of the drug. If the sedative effects of AHs are dose related, it is not 
surprising that even a well designed test battery is unable to detect sedation below their 
lowest threshold for stimulus detection. In the review, no distinction was made between 
the different doses of the selected AHs, as a further breakdown into different dosage 
groups would have resulted in too few tests being available to allow for comparisons 
between drugs to be made and some tests being used too infrequently to draw any 
conclusions. In addition, as indicated previously, there is a substantial inter-individual 
variability with regards to antihistamine induced sedation.
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However as indicated in table 2.3, some evidence of sedation could be seen over the 
full range of doses used with the first generation AHs.
Results obtained from the above described studies support the claim that the newer 
generation of AHs have a lower index of sedation than their predecessors, although only 
one can claim to be completely free of sedation regardless of the administered dose.
In view of the above findings, AHs should ideally be divided in to three categories 
(table 2.15).
The first generation AHs such as chlorpheniramine, clemastine, diphenhydramine, 
hydroxyzine, promethazine and triprolidine which commonly cause impairments of 
cognitive and psychomotor performance even when administered within the 
recommended therapeutic dose range; the second generation of AHs with which there is 
some evidence of sedation, particularly in higher dose regimens (cetirizine, ebastine, 
loratadine, mizolastine and terfenadine) and a third generation of AHs such as 
fexofenadine with which there is no evidence of detrimental CNS effects regardless of 
the administered dose.
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CHAPTER 3: SUBJECTIVE REPORTS OF SEDATION IN CLINICAL
STUDIES OF ANTIHISTAMINES 
3.0 Chapter Outline
This chapter presents a review of the clinical literature, surveying the data on the 
incidence of subjectively reported sedation in patient studies with AHs.
Due to the numerous ways in which inter-study differences can confound and distort 
attempts of a ‘meta-analysis’ of clinical trial results, the findings of this review can only 
be indicative of trends as regards antihistamine-induced sedation and should not be 
interpreted as an attempt to ascertain the true sedative potential of AHs.
The primary objective of this review is to examine whether patients are able to 
differentiate between those AHs with pharmacological i.e. obvious and pronounced 
sedative activities and those which do not possess a pharmacological basis for sedation, 
but which still engender subjective feelings of drowsiness/tiredness especially when 
administered at high clinical dose regimens.
3.1 Introduction
Sedation as a drug induced side effect is frequently reported in clinical studies with AHs. 
The investigation of the incidence of side effects produced by a given treatment draws on 
the patient as a primary source of information. Patient reports, however, are highly 
subjective especially when concerning personal experiences of changes in mood, energy 
levels etc., and the methods used in clinical trials for obtaining this type of information 
are either generally ill defined or non-existent (Rombaut 1995).
Although a large number of reviews (Haria et al 1994, McTavish 1990, Spencer et al 
1993, Wiseman & Faulds 1996) have been conducted with the so-called ‘non-sedative’
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AHs as regards the incidence of sedation, the conclusions are biased and must be treated 
with caution. This bias results from the intention of the reviewer to demonstrate that a 
specific drug dose regimen is not statistically different to placebo and should therefore be 
labelled as ‘non-sedative’. The reviewing technique includes data only on other AHs, 
which are included in comparative studies with the drug under investigation. A more 
neutral approach to conducting a review would be to perform a computer search to 
include all the available data on the antihistamine in question and all other AHs. 
Furthermore, as the individual study designs vary and the patient selection criteria are 
different depending on the requirements of the clinical study protocol, it is apparent that 
differences between AHs as regards sedation will become evident if a careful selection of 
studies is made according to the robustness of their underlying experimental 
methodologies.
3.2 Selection of Studies
A computer-assisted MEDLINE seaich was conducted to identify clinical studies with 
AHs, published between 1966 and 1999. Medline search ensured that only studies 
published in peer-reviewed journals meeting the specific criteria for acceptance were 
included in the review. As well as publications, data were also included from studies 
published in abstract format in peer-reviewed journals, so long as the study satisfied the 
inclusion criteria and the data were presented in a format that clearly indicated the 
incidence of sedation with each treatment condition. In order to minimise the effect of 
external factors, a number of strict criteria had to be adhered to in order to be included in 
the review. Studies had to be conducted under strict double blind conditions, with the 
aim of investigating the clinical efficacy of one or more AHs. Studies had to be of either 
a parallel or crossover design. Inclusion criteria required the studies to be placebo-
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controlled, in which the number of patients experiencing sedation was documented for 
each treatment group.
Studies conducted with children, studies in which rescue medication was allowed, or 
those with single blind designs were all excluded from the review. A selection of studies 
excluded with reasons for non-inclusion can be found in table 3.1.
For each of the selected studies, the actual number of reports of sedation for each 
treatment group was listed. Similarly, the number of patients not reporting a sedative 
effect was calculated by subtracting the number of reports of sedation from the total 
number of patients receiving each treatment (table 3.2).
The term sedation was used as a collective term to represent all statements referring to a 
general lowering of CNS activity. These included sedation (Belaich et al 1988, îrander et 
al 1990), somnolence (Bruno et al 1981, Eisen et al 1988), drowsiness (Blamoutier 1978,
Bruno et al 1989), fatigue (Docldiorn et al 1987, Girard et al 1985), tiredness (Gastpar et 
al 1988, Grant et al 1988), CNS depression (Brandon & Weiner 1982), and sleepiness 
(Dugue et al 1982, Mellillo et al 1982).
A cursory review of the clinical studies revealed that in most studies, the total number of 
reports of sedation were provided without any particular indication of the number of j
patients reporting this effect. Multiple terms were used in certain studies to report the j
sedation and it was not possible to establish from these studies whether the data referred 
to one patient experiencing these effects, or if the effect was attributed to a number of 
patients experiencing this sedation. As it was impossible to resolve this approach, it was 
assumed that each report of sedation reflected a particular patient.
No distinction was made between the methods used to assess potential sedation.
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3,2.1 Proportional Sedation Ratio (PSR)
In order to allow inter-drug comparisons to be made, the sedative properties of one 
antihistamine were compared with the properties of all other AHs. The procedure 
employed to calculate a ‘proportional impairment ratio’ for AHs in the previous chapter 
was applied to this data to enable the calculation of a respective ‘proportional sedation 
ratio’ (PSR) for each antihistamine. In the calculation of PSR, placebo was included in 
the analysis as a ‘drug’ condition.
The PSR was expected to show whether the use of an antihistamine is associated with 
subjectively reported sedation and if so, the extent of that sedation when compared to the 
sedation produced with all other AHs. The greater the PSR, the greater are the reports of 
sedation associated with the use of that antihistamine. Conversely, an antihistamine with 
which there is no subjective reports of sedation would have a PSR value of zero. Those 
AHs with which reports of sedation increase in response to higher doses, would have 
PSR values above zero but lower than those which are inherently sedative.
The formula presented in chapter two (figure 2.3) for the calculation of a proportional 
impairment ratio was adapted to allow the calculation of a PSR for each antihistamine, 
thereby enabling the ranking of these AHs as regards their potential to produce sedation. 
The PSR for each antihistamine was calculated by the division of the ‘sedation ratio’ for 
the specific antihistamine by the ‘sedation ratio’ for all the other AHs in the database. In 
order to enable the AHs to be ranlced as regards their potential produce sedation, the 
statistical association for each PSR was calculated using the test on one degree of 
freedom (with Yates’ correction).
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3.3 Results
A total 785 studies were identified by MEDLINE, of which 195 were evaluated for 
possible inclusion in the review. Of the 195 studies, however, only 77 clinical studies 
satisfied the criteria for inclusion and were accepted and included in the review. Reports 
of sedation were not routinely assessed in all studies and so the number of studies, which 
were subsequently accepted, was dramatically reduced.
Fifty nine of the 77 selected studies were conducted using parallel groups; in the 
remaining 19 studies, treatments were allocated in crossover designs (table 3.2).
Due to the small number of studies adopting a crossover design, the results of both 
parallel and crossover groups were pooled together.
The clinical indications tested in these studies were seasonal allergic rhinitis (45 studies), 
seasonal conjunctivitis (1 study), perennial allergic rhinitis (11 studies), common cold (1 
study), chronic idiopathic urticaria (18 studies), cold urticaria (1 study) and dermographia 
(1 study).
Duration of treatment ranged between 3 days (Krause & Shuster 1984) and 6 weeks 
(Tanay & Neumann 1989).
Of all the AHs reviewed, terfenadine has been the most extensively studied (33 studies), 
followed by loratadine (16 studies) and cetirizine (15 studies). A number of AHs 
included in the review featured only once (cyproheptadine, ebastine, levocabastine, 
mequitazine and norebastine).
Terfenadine featured in 33 studies with a total of 1917 patients receiving the drug at 
doses between 20mg and 200mg. In 11 of these terfenadine studies, chlorpheniramine 
was included in the study as a standard comparator and used in a total of 795 patients at 
doses ranging between 2mg and 8mg three times daily (t.i.d.).
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Loratadine was compared with placebo in a total of 16 studies, of which 5 included 
terfenadine as a positive control for efficacy. Loratadine was administered as a lOmg 
once daily (o.d.) dose in 14 of these studies and in two studies, a 40mg dose was 
administered. Of a total of 1095 patients receiving loratadine, 97 reported sedative side 
effects.
Cetirizine was compared with placebo in a total of 15 studies, of which 4 included 
terfenadine as a positive control for efficacy. Cetirizine was administered at doses 
ranging between lOmg o.d. to 40mg o.d., of which 10 studies investigated the effects of 
higher doses of cetirizine (lOmg & 20mg). Of the 1112 patients receiving cetirizine, 190 
patients reported sedative side effects.
Due to its recent introduction, the number of clinical studies performed with 
fexofenadine was low, although within these four studies, 658 patients were administered 
a dose of fexofenadine ranging from 60mg o.d. to 240mg b.d.
Three of these studies were placebo controlled with no comparator included in the study 
design, although to date, one study has compared the effects of fexofenadine with 
loratadine (Day et al 1997). Of the 658 patients receiving a dose of fexofenadine up to 
240mg, there were no reports of sedation in any of the four clinical studies.
Astemizole was investigated in 9 clinical studies, in which a lOmg dose was 
administered to 191 patients. Astemizole at a dose of lOmg produced sedation in 17 
patients.
Acrivastine was administered to 258 patients in 8 clinical studies and the use of 
acrivastine was associated with 37 reports of sedation.
Seven clinical studies investigated the effects of hydroxyzine in a total of 258 patients. 
The use of hydroxyzine was associated with significant reports of sedation (141 reports).
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To allow a comparison between AHs investigated in this review, the total number of 
reports of sedation was expressed as a percentage of patients receiving each 
antihistamine (table 3.3).
These indices of sedation demonstrated that that the second generation AHs with the 
exception of cetirizine were not significantly different to placebo, and in sharp contrast 
with the traditional AHs as regards the incidence of subjectively reported sedation.
Table 3.3 Percentage of ‘sedation’ reported by patients treated with various 
dose regimens of different AHs
ANTIHISTAMINE PERCENTAGE SEDATION (%)
Fexofenadine 0.00
Placebo 8.46
Terfenadine 8.86
Loratadine 8.86
Astemizole 8.90
Levocabastine 10.00
Acrivastine 14.50
Cetirizine 17.00
Chloipheniramine 25.60
Clemastine 33.70
Hydroxyzine 53.60
* The calculated percentage of sedation with fexofenadine is zero because t tiere were no
reports of sedation with fexofenadine.
In as much this provided the means to categorise the AHs as those which have obvious 
sedative properties, from those which are non-sedating within their dose regimen, this 
measure does not reflect a true scenario, as the effects of a specific antihistamine were 
considered in isolation and without a reference to the properties of all other AHs.
I l l
Therefore in order to make inter-drug comparisons, the PSR for each antihistamine was 
calculated using the previously described formula outlined in chapter two.
Table 3.4 lists the PSR values for all the AHs used in this clinical review.
It is evident from these studies which, within the limitations of clinical investigations, are 
considered to be the most adequately controlled, that the use of most AHs are commonly 
associated with reports of sedation. The incidence of reported sedation is greater with the 
first generation AHs that are known to possess sedative properties. The calculated PSR 
values reflect these finding in that chlorpheniramine, clemastine and hydroxyzine 
achieved highly significant PSR values in excess of 2, whereas the second generation 
AHs with the exception of cetirizine were all very close to the calculated PSR of placebo.
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Table 3.4 Proportional Sedation Ratio (PSR) for all AHs in the review
Drug a b c d PSR with 1 d.f
Fexofenadine 0 658 1517 9032 0.00 108.2***
Mequitazine 0 23 1517 9667 0.00 2.54 (NS)
Norebastine 9 179 1508 9511 0.35 11.76***
Placebo 324 3507 1193 6183 0.52 127.63***
Astemizole 17 174 1500 9516 0.65 3.57 (NS)
Terfenadine 167 1718 1350 7972 0.61 41.87***
Loratadine 97 998 1420 8692 0.63 22.69***
Levocabastine 2 18 1515 9672 0.74 0.21 (NS)
Acrivastine 37 221 1480 9469 1.06 0.08 (NS)
Ebastine 3 16 1514 9674 1.17 0.08 (NS)
Cetirizine 190 922 1327 8768 1.30 12.96***
Chlorpheniramine 218 634 1299 9056 2.04 113.30***
Clemastine 202 398 1315 9292 2.72 217.68***
Brompheniramine 98 96 1419 9594 3.92 227.46***
Hydroxyzine 141 122 1376 9568 4.26 366.08***
Cyproheptadine 12 6 1505 9684 4.96 39.06***
a: Number of reports of ‘sedation’ with specific antihistamine; 
b: Number of reports of ‘no sedation’ with specific antihistamine; 
c: Number of reports o f ‘sedation’ with all other AHs; 
d: Number of reports o f ‘no sedation’ with all other AHs.
NS = Not Significant
* = Significant at 5 % level when X'is equal to or greater than 3.84 
** = Significant at 1% level when X i^s equal to or greater than 6.64 
*** = Significant at the 0.1% when X i^s equal to or greater than 10.83
The PSR value of cetirizine appears high when compared with the other second 
generation AHs. The studies with cetirizine demonstrate that there were 190 reports of 
sedation in a total of 1112 patients receiving cetirizine. However a closer examination of 
the data reveals that of the 15 studies, higher doses of 20mg & 40mg were investigated in 
10 studies. In comparison, all studies with astemizole investigated the effects of this
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antihistamine at its recommended dose of lOmg. With loratadine, of the 16 studies 
employed in the investigation of its clinical efficacy, 14 v^ere conducted with lOmg dose 
of loratadine.
This therefore provides an explanation for the high PSR value obtained with cetirizine 
and highlights the problems of drug comparisons across their various dose regimens. A 
better methodology would be to compare clinically equivalent doses of APIs. However, 
the number of studies with these AHs in which subjective reports of sedation are 
adequately assessed and reported is very limited and therefore ‘dose equivalent’ 
comparisons are not possible.
Although the calculated PSR value of loratadine is low and close to that obtained with 
placebo, these comparisons are made with loratadine at doses at which the drug is known 
to be free of sedative effects. Objective evidence of CNS impairment as well as 
subjective reports of sedation have demonstrated the detrimental CNS effects of 
loratadine at doses above lOmg (Gaillard et al 1988, Riedel et al 1990, Shamsi & 
Hindmarch 1999a). It is highly unlikely that loratadine would maintain its low PSR 
value if data with higher doses of the drug were included.
Due to its recent introduction, fexofenadine has not been so extensively studied in 
clinical trials. Although a large number of trials have been conducted to assess its 
efficacy, the number of placebo controlled studies in which sedation has been assessed is 
low. To date, fexofenadine at doses up to 240mg has been administered to 658 patients 
and within the dose ranges studied, it is demonstrably free from any sedative activity.
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3.4 Discussion and Conclusions
In this chapter the overall incidence of sedation in patients receiving the first generation 
AHs was high with PSR values in excess of two indicating the significance of such 
findings. Sedation reported following the administration of the second generation AHs 
was lower in comparison to the traditional AHs, with PSR values between 0.35 and 1.30. 
There appears to be great variability as regards the subjective reports of sedation with 
these AHs. Subjective reports of sedation were absent following the administration of 
fexofenadine and of lower frequency with terfenadine and loratadine and the greatest 
following the administration of cetirizine.
This finding is contrary to the rankings obtained with these AHs in experimental studies 
with healthy volunteers.
The high incidence of sedation reported with cetirizine is explained by the fact that most 
studies investigating the effects of cetirizine were conducted with doses of cetirizine in 
excess of lOmg. In contrast, 14 out of the 16 studies investigating the effects of 
loratadine were performed with loratadine at its recommended dose of 1 Omg.
The CNS impairing effects of loratadine which have been previously documented may 
have been masked in these clinical studies as a result of the administration of lower 
doses.
Despite the absence of precise methods and measures and adequate controls in clinical 
studies with AHs, the results of the present review confirm that, in terms of sedation, 
patients are able to distinguish between placebo and the older, sedative Hi receptor 
antagonists such as chloipheniramine, clemastine and hydi'oxyzine. On the other hand, 
with the second generation AHs (terfenadine, loratadine, and cetirizine), the patients’ 
experiences of sedative effects were lower and not dissimilar to placebo in most cases.
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Two explanations are provided as to why patients’ discrimination of sedation were 
successful.
The first factor, which may influence the patients’ detection of sedation, is related to the 
symptomatology of the allergic disorders. It is well recognised that allergic rhinitis, may 
produce a degree of drowsiness (Spaeth et al 1996, Bousquet et al 1994). Relief of 
rhinitis symptoms may therefore alleviate the accompanying drowsiness.
As a non-active treatment, placebo does not pharmacologically modify the histamine 
receptor and as such is not able to alleviate the symptoms of the allergic disorder. It is, 
however, accepted that placebo does in certain patient populations exert a ‘clinical 
placebo’ effect, whereby the patient feels relieved of the symptoms of the disorder, 
despite the fact that the treatment is not pharmacologically active (Craen et al 1999).
This ‘placebo’ effect, however, is not experienced by all and it is possible that due to lack 
of pharmacological modification of the receptor, the patient does not experience any 
relief from allergic symptomatology and consequently the incidence of sedation is not 
reduced. As a result of the persisting sedation, the patient’s ability to differentiate 
between an active treatment and placebo may therefore be enhanced and indirectly affect 
the outcome.
The second factor is related to the principle criterion for inclusion of studies in this 
review. This required the studies to be of a double blind and placebo-controlled design. 
However, as with all clinical studies, the degree to which patients are blinded to active or 
placebo treatment is questionable. This argument holds true especially for those AHs, 
which produce a relatively fast and easily recognisable effect. AHs generally work 
within a few days and it is possible that patients realised when they were randomised to 
receive placebo as a result of persistent symptomatology.
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Depending upon the explanations provided by the treating physician, their ability to 
recognise sedation may have been further enhanced. It therefore appears that with 
clinical, as with experimental studies, the inclusion of a positive control may be prove to 
be beneficial.
The findings from this review therefore broadly confirm that patients do experience 
sedation with certain AHs. Despite the lack of standardisation of methods in these 
clinical studies, the methodology used to calculate a PSR for each antihistamine appears 
to be successful in demonstrating differences between AHs.
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CHAPTER 4: METHODS & MEASURES USED TO INVESTIGATE
ANTIHISTAMINE INDUCED PERFORMANCE 
IMPAIRMENT
4.0 Chapter Outline
A review of the effects of AHs on measures of behaviour in both healthy volunteers and 
patient populations in chapters two and three concluded that even amongst the new and 
so called non-sedative AHs, only a few can claim to be effectively free of sedative side 
effects even when administered at doses recommended by the manufacturer.
It is also evident that only a few tests can reliably discriminate between the different AHs 
as regards their effects on measures of performance. With this in mind, this chapter 
discusses the general methods and measures employed in each of the experiments. 
Descriptions of selected tests are given, along with evidence of their validity and 
reliability. The common procedures adopted are outlined, including subject selection, 
study conduct, experimental design and statistical management of data. The study 
specific procedures are outlined in chapter 5.
4.1 Introduction
The findings from the previous two chapters demonstrate that, in the study of the effects 
of AHs on performance, when the findings from all studies are all pooled together, 
general patterns of effect become apparent, confirming that the second generation of AHs 
have both a much more favourable therapeutic index than their predecessors and a much 
better side effect profile.
Discrepancies do exist however between the findings of individual investigations. These 
may be explained in terms of different testing methodologies, and also the fact that a
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diverse range of tests are adopted by different groups. Study designs differ between 
reseai’ch centres and study protocols are not standardised between research groups.
The literature is replete (Hindmarch & Shamsi 1999, Meltzer & Welch 1996, Passalacqua 
et al 1996, Rombaut & Hindmarch 1994, Seppala et al 1981, Simons et al 1996, Simons 
et al 1999, Witek et al 1995) with studies comparing the various methods of assessment 
of sedative effects, yet the greater sensitivity of one particular method over another has 
yet to be absolutely demonstrated. It is becoming increasingly important to use 
psychometric tests which are valid, reliable and sufficiently sensitive to detect minimal 
changes in cognitive functioning and psychological status. Failure to detect sedative 
effects using objective psychometrics, even though subjective evidence of sedation 
existed, has been reported in a variety of studies (Hughes & Forney 1964, Baugh & 
Calvert 1977, Moser et al 1978, Kulshrestha et al 1978, Pishlcin et al 1983).
As discussed in chapter 2, an appropriate model of information processing should be 
adopted in order to assess the effects of AHs on psychological aspects of behaviour. 
Furthermore, it is imperative that the tests are carefully selected to allow differentiation 
between types of impairment on the various cognitive and psychomotor aspects of 
behaviour.
It is evident, however, that there are many aspects to a behavioural response and therefore 
different testing strategies are utilised by different research groups, resulting in the use of 
many tests which are not reliable or valid indicators of CNS effects.
A review by Hindmarch (1980) found that many of the tests used in psychopharmacology 
lacked a history of reliability and validity and were unlikely to provide useful data. 
Reliability is often defined as the consistency of scores obtained by the same person when 
re-examined with the same test on different occasions. This concept involves the 
estimation of the error of measurement of a single score, making it possible to predict the
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range of fluctuation likely to occur as a result of chance factors (Parrott 1991a). Having 
considered the reliability of a test, it is thereby possible to establish whether differences 
occuiTing in test scores are attributable to real differences or to test error. The validity 
of a test reflects the ability of a paiticular test to measure a specific component of 
behaviour/ state against independently obtained data for that component, thereby 
indicating how well the test actually measures the particular component under 
investigation. Reliability involves the value of the task as a predictor of the impairment 
potential and validity involves the significance of the actual result obtained (Parrott 
1991b).
In addition to the availability of a wide variety of psychometric tests, certain popular tests 
are performed in various different ways. For example, the critical flicker flision task, 
although a very popular measure, is performed in a number of different ways- monocular 
versus binocular viewing, foveal versus peripheral measurement 
(Hindmarch 1987, Frewer & Lader 1993).
Bobon et al (1982) stated that discrepancies in results with the same drug may be largely 
due to the differences in the methods of measuring CFF, but goes on to say that CFF is a 
“valid and economical test of sedation versus alertness” and that if certain criteria are 
met, then CFF can provide a reliable measure of central processing capacity.
Despite complying with the pre-requisites for a standardised test battery, inadequate 
consideration of the moderator variables may also undeimine the clinical relevance of the 
test results and thus influence the outcome. These variables arise through the use of a test 
in a particular population, errors possibly emanating from factors such as age, sex, health 
status, personality and sociocultural effects etc. Therefore in order to obtain reproducible 
results, a number of factors need to be taken into consideration when designing a study.
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The most important aspect of a study design is that the tests should be selected carefully 
according to a well defined behavioural model. The tests should be easy to understand 
and perform by the subject and easy to administer, score, and interpret for the 
experimenter. The administration of the test should be standardised with regard to the 
equipment and methods employed and the environment in which the test is executed, 
with specific emphasis on minimising levels of distraction. Importance should also be 
placed on the maintenance of the order of testing sequence when more than one test is 
being utilised.
It is also important that the tests are administered by trained experimenters and that the 
volunteers are appropriately trained on the test batteries to preclude any learning effects 
(Parkin et al, 1997). Differences in instructions given to subjects may profoundly affect 
performance. The amount of help given by the experimenter should always be defined in 
order to achieve efficient standardisation.
The adoption of double blind experimental design ensures that neither the subject nor the 
experimenter is aware of the treatment regimen. Inclusion of a verum (positive control) is 
imperative in order to validate the results as a drug effect may be masked by the nature of 
the task itself. The inclusion of a verum also ensures the sensitivity of the tests to the 
drug effects at that particular time. All the experiments within this thesis included a 
verum condition in which the vera (e.g. promethazine, triprolidine) have all been 
previously shown to impair cognitive and psychomotor performance (Hindmarch et al 
1999, Kerr et al 1994, Shamsi & Hindmarch 1999a, Shamsi & Hindmarch 1999b, Stone 
et al 1999).
Motivational factors may also influence the results. The motives of the volunteers can be 
classified as financial, spiritual and psychological. The intentions of the volunteers, the 
payment or privileges afforded them and the expectations of both subject and
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experimenter can directly influence the results obtained (Ayd 1972). The process of 
direct monitoring is thought to instil sufficient motivation to enhance performance, 
irrespective of the actual test employed (Fraser 1953). However the motivation inherent 
in the task situation may also be an important factor in influencing performance, the 
impairing nature of the drug on performance being camouflaged by the stimulatory nature 
of the task.
The effect opposing motivation is the concept of boredom. Diminished performance 
efficiency is usually associated with the boredom that results from a dull, monotonous 
and repetitive performance task (O’Hanlon 1981). The search to establish a compromise 
between the two effects is imperative if validation is to be achieved.
Both culture and lifestyle can influence a person’s perception of effects such as sedation. 
This has been highlighted by Rombaut et al (1986) for tests of psychomotor performance. 
Sociocultural effects must also be considered to determine whether particular symptom 
states are of sufficient importance to merit complaint. Different cultures often vary in 
their interpretation of side effects, an admission often being akin to confessing a 
wealcness.
Volunteers should be selected carefully to ensure that they are healthy and not taking any 
concomitant medication (including social substances such as caffeine, alcohol and 
nicotine), as both illness and the use of medication can confound results and therefore 
affect the outcome of the study. All studies described in this thesis employed adequate 
screening procedures to exclude the use of any concomitant medication, alcohol etc and 
to ensure that volunteers and patients fulfilled the relevant inclusion/exclusion criteria.
A firm conclusion about whether one drug represents an improvement over another in 
terms of CNS impairment requires concunent evaluation with peripheral effects. This 
provides evidence as to whether differences between compounds in sedative potential are
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not simply due to differences in dose (Levander et al 1985). It is often recommended to 
extend the range of dosages beyond that employed therapeutically in order to ascertain at 
what dosage CNS effects become evident. A new Hi-receptor antagonist may be found 
to be devoid of CNS effects purely because it is used at a dose that induces only a weak 
Hi inhibitory effect. Of paramount importance is the balance between the desired 
peripheral effect and the undesired CNS effects.
All of the above have been taken into consideration where applicable, in the design of the 
experiments which are described in this thesis. The following section is a description of 
the measures employed to evaluate the effects of AHs on various measures of cognitive 
function and psychomotor performance.
4.2 Measures
It is widely accepted that many of the tests used in psychopharmacology lack a history of 
validity and reliability (Hindmarch 1980, Parrott 1991a, 1991b, 1991c). In order to 
produce meaningful results, a battery of tests should be used which have been shown to 
be reliable, valid and sensitive to the effects of psychoactive drugs. It is imperative that 
the tests should be able to discriminate between drugs in the same class, as well as 
differentiating between different doses of the same drug.
Since the 1970s, research at the HPRU has centred on a battery of tests, which have been 
shown to be reliable indicators of drug action. To date, this approach has been used to 
profile over 200 different psychoactive compounds in both healthy volunteers and patient 
populations. Their validity, sensitivity and reliability has been demonstrated using a wide 
variety of psychoactive compounds at various doses (Hindmarch 1975, 1980, Parrott 
1982, Sherwood & Kerr 1993). Over the years the tests have been computerised and so 
stimulus presentation and recording of results are now controlled automatically, thereby
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allowing accurate data collection. Inter-test variability is reduced by utilising the same 
systems across studies and as the data is collected electronically, the results are devoid of 
human error, thus increasing the reliability of the utilised tests. Due to the proven 
sensitivity, reliability and validity of these tests, it was decided to incoiporate these in the 
experimental design in order to facilitate the assessment of the effects of AHs on various 
aspects of information processing.
The core batteries of tests consist of Critical Flicker Fusion (OFF), Choice Reaction Time 
(CRT), Sternberg Memory Scanning task (SMST) and Compensatory Tracking Task 
(CTT). Line Analogue Ratings for Sedation (LARS) is used to assess subjectively 
overall ratings of sedation and the Leeds Sleep Evaluation Questionnaire (LSEQ) is used 
to subjectively assess various aspects of sleep. Other tests are also used in various 
experiments and these include Actigraphy (ACT), Cognitive Failures Questionnaire 
(CFQ), Milford Memory Test (MMT), Hamilton Anxiety Rating Scale (HARS), Digit 
Span (DS) and Clinical Global Impressions (CGI).
In addition to the psychometric test battery, the weal and flare test was used in 
experiments 1 & 2 to assess the ability of a number of second generation AHs to inhibit 
the weal and flare reaction- a standard method used to assess the efficacy as well as the 
potency of AHs.
4.2.1 Main Test Battery 
Critical Flicker Fusion (CFF)
CFF has been used as a research tool for many years with interest In CFF dating back to 
the 18^ ^^  century (Landis, 1953). CFF is regarded as the assessment of choice for 
investigating the change in overall integrative capacity of the CNS, the state of arousal, 
mental alertness and cognitive potential. CFF has been referred to as 'valid and
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economical measure o f  sedation versus alertness ’ which 'can be reliable i f  certain 
variables are taken into account' (Bobon 1982).
Despite the variety of experimental equipment available (monocular versus binocular 
viewing, foveal versus peripheral measurement) and different methods of measurement 
(method of limits, forced choice, method of adjustment), the literature shows a 
remarkable consistency in the observed effects of psychoactive drugs (Hindmarch 1982). 
Critical flicker frequency is defined as the point at which a flickering light gives rise to 
the subjective sensation of a steady light and fusion frequency is the opposite of this, i.e. 
the point at which steady light is perceived as a flickering light. Within the information 
processing model, CFF is defined as the ability to process discrete ‘bits’ of information 
(Hindmarch 1980, Hindmarch 1982).
An increase in CFF threshold is thus indicative of CNS arousal, whereas a reduction in 
the threshold is associated with a decrease in information processing capacity and 
therefore a decline in the overall cognitive ability.
The advantages of the measure include the simple, non-invasive nature of the test, the 
short duration of the assessment (approximately two minutes) and an absence of major 
practice effects (Parkin et al 1997).
Although there are no agreed experimental techniques for the measurement of CFF, the 
‘method of limits’ is the most frequently used. Several researchers have reviewed the use 
of CFF in psychopharmacology (Turner 1968, Smith & Misiak 1976, Hindmarch 1982), 
and have concluded that if standardised methods are adopted, CFF can be a useful 
research tool in investigating the action of drugs on the CNS.
All CFF measurements were made using the Leeds Psychomotor tester (Hindmarch 1975, 
Hindmarch & Parrott 1978, Hindmarch & Subhan 1983). With subjects sitting at a 
distance of one meter facing the CFF test apparatus, four light emitting diodes flicker on
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and off at a 50/50 light-dark ratio according to a square waveform at a constantly 
increasing or decreasing rate of IHz over a range of 12-50Hz. The diodes are viewed 
binocularly from one meter and are thus held in foveal fixation. The test requires the 
subjects to discriminate flicker from fusion and vice versa by pressing the response 
button held in the prefeiTed hand. Individual thresholds are determined by the 
psychophysical method of limits (Woodworth & Schlosberg, 1958) as an average 
response to three ascending (flicker to fiision) and three descending (fiision to flicker) 
scales presented alternately.
CFF has been shown to correlate closely with other non-performance measures such as 
EEC measures of arousal (Gortelmeyer & Weinmann 1982, Grunberger et al 1982) and 
with changes in self reported levels of alertness using visual analogue scales (Grundstrom 
1977, Grundstrom 1978; Grandjean et al 1977, Hindmarch et al 1979, Parrott 1982).
The sensitivity of CFF is such that it is able to discriminate and differentiate between 
different classes of psychoactive compounds, such as sedatives which produce a 
reduction in CFF threshold and stimulants which cause CNS arousal and consequently 
elevate the CFF threshold (Smith & Misiak, 1976, Hindmarch 1982).
In addition, CFF can differentiate compounds of the same therapeutic class such as 
hypnotics (Hindmarch & Fairweather 1994), antidepressants (Hindmarch & Kerr 1994), 
AHs (Hindmarch & Shamsi 1999), anxiolytics (Hindmarch 1979), and neuroleptics 
(Hindmarch 1994). CFF is able to detect differences in varying doses of the same drug 
e.g. temazepam (Hindmarch 1975) and oxazepam (Kerr et al 1992). CFF is also sensitive 
to subtle changes following the administration of nicotine (Sherwood 1993), tea and 
coffee (Hindmarch et al 1998) and a range of doses of alcohol (Hindmarch et al 1991, 
Kerr et al 1991). Kilminster (1991) demonstrated that in a longitudinal study of 3.5
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years, no significant regression effects on CFF were observed in a population of healthy 
elderly volunteers.
Meta-analysis of a series of five studies with a total of 101 subjects, showed the split half 
reliability of CFF to range from r = +0.92 to r = +0.97 (PaiTott 1982). The test-retest 
reliability of CFF has been examined by a number of researchers and reported to range 
between +0.85 to +0.98 (McNemar 1951, Simonson & Brozek 1952, Agurell et al 1976, 
Hindmarch 1980, Holmberg 1981, Levander 1982, PaiTott 1982).
Choice Reaction Time (CRT)
Measurement of reaction time is yet another popular test to be frequently incorporated 
into psychopharmacological study designs. CRT is used as an indicator of sensorimotor 
performance, assessing the efficiency of the attentional and response mechanisms in the 
information processing chain without the need for extended cognitive processing 
(Hindmarch et al 1988). Many of the everyday skilled activities such as car driving 
require rapid and yet co-ordinated responses in which the reaction time component is 
most crucial.
The latency of a motor response to a critical stimulus is recorded, but since this stimulus 
is one of a number of possible alternatives, attentional monitoring abilities aie also 
measured. The total reaction time (TRT) is regarded as the sum of the two separable 
components: the stimulus recognition reaction time (RRT) used as measure of attentional 
monitoring and the motor reaction time (MRT) used as a measure of the efficiency of the 
response output system.
From a central starting position, using the Leeds Psychomotor Tester (LPT) (Hindmarch 
1975) subjects are required to extinguish one of six equidistant red light-emitting diodes, 
illuminated at random, by touching the appropriate contingent response button. These
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light/button combinations are arranged in a 120° arc (24° between each light/button pair) 
of a 15cm radius circle, centred on and forward of the start button. All buttons are touch 
sensitive, and there are no switches to engage (Frewer & Hindmai'ch 1988).
Mean reaction times are obtained from the average of 20 consecutive trials. Both 
recognition (time taken to spot the light and remove the finger from the starting position) 
and motor (time taken to reach the appropriate response button) components of the total 
reaction time are recorded automatically.
Measurements of CRT provide information on the constant, very rapid adjustments 
individuals must make to their environment, which often require them to attend to several 
potential stimuli at once. This suggests that there is high construct validity inherent in 
reaction time measures. CRT has been described to be similar to the measurement of 
brake reaction time (Hindmarch et al 1983).
CRT has been used successfully to assess performance changes following the 
administration of a wide range of psychoactive compounds, from the barbiturates, which 
increase reaction times due to their sedative action through to mild cognitive enhancers 
like methylxanthines, which conversely reduce reaction times (Hindmarch 1990). 
Similarly, impairments in performance manifested as increases in reaction time have been 
demonstrated following the administration of first generation AHs (Gaillard et al 1988, 
Levander et al 1985, Mattila et al 1986). CRT has also been shown to discriminate and 
differentiate between compounds of the same pharmacological class such as the 
anxiolytic benzodiazepines (Hindmarch et al 1991). No significant regression effects of 
CRT were observed in a repeated measures longitudinal study of 3.5 years in healthy 
elderly volunteers (Kilminster 1991).
A substantial number of studies have been performed with CRT, which show the measure 
to be valid and reliable. Krause & Bittner (1982) assessed the reliability of a variety of
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reaction time tasks and reported that once a performance plateau was reached, test-retest 
reliability was in excess of r = +0.58.
Sternberg Memory Scanning Task (SMST)
High speed scanning and retrieval from short term memory was used to investigate the 
possible effects of AHs on memoiy using a technique based upon a reaction time method 
pioneered by Sternberg (1966,1969). The test involves malting simple comparisons of a 
displayed probe digit against a set of stimuli digits held in short term memory and 
indicating whether there is or is not a match to the probe in the stimulus set. Typically, 
subject reaction times are prolonged as the size of the stimulus set increases, suggesting 
that some internal data comparison takes place before a response is initiated.
When a small stimulus set is used, the memory search task is relatively simple and 
consequently the final reaction time is dominated by the peripheral processes of 
perceiving and reacting to the probe. These processes are particularly affected by the 
level of drug-induced sedation. However, where a larger stimulus set is presented, the 
reaction time contains greater central memory search and retrieval components, and it is 
possible to estimate specific effects on memory function.
Subjects are required to memorise a series of one, three or five digits (stimulus set) 
presented randomly on a visual display unit (VDU). Following the presentation of the 
stimulus set, an auditory signal is given, which is subsequently followed by a series of 
single probe digits. Subjects are required to respond to the probe by pressing the “YES” 
button (positive response) if the probe digit is contained in the stimulus set, or the “NO” 
button (negative response) if it is not. There are an equal number of positive and 
negative probe digits in each probe set. Response times are recorded for correct 
identifications.
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The SMST has been shown to be sensitive to the effects of many psychoactive 
compounds. Subhan & Hindmarch (1984) investigated the amnestic effects of several 
benzodiazepine hypnotics and reported that the test was able to clearly indicate 
impairments at both 1 and 10 hours after drug administration. Antidepressants such as 
amitriptyline and trazadone have also been shown to possess memory impairing effects, 
effects which are exacerbated when co-administered with alcohol (Hindmarch & Subhan 
1986, Kerr et al 1996). Conversely, nootropics such as vinpocentine (Subhan & 
Hindmarch 1985) and other cognitive enhancers including Ginlcgo Biloba extract 
(Subhan & Hindmarch 1984a) have been shown to improve short term memory retrieval 
ability.
Carter et al (1980) evaluated the reliability and stability of memory scanning as a 
performance measure. When used in repeated measures designs, test-retest coiTelation 
coefficients in excess of r = +0.70 were reported.
Compensatory Tracking Task (CTT)
A compensatory tracking task was used to investigate activities inherent in tasks such as 
car driving which require skilled motor activity in response to complex visual 
information. CTT assesses the response output mechanisms required for fine motor 
control, in contrast to the gross motor activity required for CRT.
The advantage of CTT over the many available simple tests is that it requires the subject 
to divide attention between competing stimuli. Since attentional mechanisms are heavily 
utilised during tracking, peripheral responses reflect the need for the subject to divide 
their attention between the tracking and the reaction time task. Simple tests by their very 
nature, allow the subject to re-allocate cognitive resources and focus on the task in hand,
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masking effects which would be salient if the subject was required to undertake 
additional tasks.
Subjects are required to attend to two tasks. Firstly, to keep a joystick controlled cursor 
(an equilateral triangle) in line with a target (a similar triangle, but inverted) moving 
along a horizontal axis in a pseudorandom fashion. Secondly, to respond simultaneously 
to a visual stimuli presented at random in comers of the screen. Tracking accuracy 
(RMS) is calculated as the mean deviation from the track program over the trial period 
with lower scores indicating a more accurate tracking. The mean reaction time (RT) to 
the peripheral stimuli is also calculated at each presentation.
Compensatory tracldng has a high degree of face validity in that it resembles real-world 
tasks such as vehicle handling (Hindmarch 1988) and target pursuit (Kennedy et al 1981). 
In a review by Hindmarch (1986), CTT was shown to be as efficient as the on-the-road 
measures of vehicle manoeuvring and braking in identifying those drugs, which impaired 
car-driving performance. This suggests that CTT has a high degree of face validity.
As a sensitive measure, CTT can differentiate compounds within the same therapeutic 
class including antidepressants (Hindmarch et al 1983), hypnotics (Hindmarch & 
Fairweather 1994) and antihistamines (Hindmarch & Shamsi 1999).
As regards the reliability of CTT, Kennedy et al (1981) calculated a test-retest correlation 
o fr-+ 0 .7 8 .
Wrist Actigraphy (ACT)
Subjects wear a wrist actigraph (Ambulatory Monitoring Inc. AMA-32C Mini 
Motionlogger, Ardsley, New York) on their non-dominant wrist for a specific time period 
according to the requirements of a study. Actigraphy has been shown to be capable of 
measuring reductions in behavioural activity (sedation) caused by psychoactive
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compounds (Stanley 1997, Stanley and Hindmarch 1997). These small wrist watch sized 
devices contain a piezoelectric transducer that detects motion and generates a signal 
voltage. In zero crossing mode the signal voltage is compared with a reference voltage for 
a change in state. The device records the number of changes in state per epoch.
Automatic sleep/wake detection algorithms have been developed and refined until they 
now correlate well with traditional sleep EEG in their measurement of sleep time. 
(Mullaney et al 1980, Cole and Kripke 1988, Sadeh et al 1989, Sadeh et al 1994, Cole et 
al 1992) and these have been incorporated into proprietary ACTIONS software. Data were 
down loaded onto an IBM compatible PC. Percentage sleep/wake for the duration of 
each visit was scored automatically using the ACTIONS software. Additional analysis of 
activity levels required data to be partitioned into larger epochs prior to statistical analysis 
using Statistica 4.5 (Stanley 1997). Epoch length was determined by the statistical 
software’s limitations in the size of ANOVA design (252 variables). Therefore in order to 
analyse each entire study period, data was averaged over consecutive 40 minute periods, 
whilst for the analysis of the daytime activity (07:30-23:00) a 30 minute period was used.
4.2.2 Visual Analogue Scales (VAS)
In addition to objective measures of performance, subjective reports are also fi'equently 
utilised in demonstrating sedation in studies of psychoactive drugs. Bond and Lader 
(1974) developed this measure for the evaluation of the effects of psychoactive drugs on 
subjective ratings, although they were originally described in early 1920s (Freyd in 1923, 
Hayes & Patterson 1921).
Rating scales usually consist of 100mm horizontal lines in which extreme states of 
various feelings are defined at either ends of the line (e.g. happy, not happy). Subjects 
are then required to mark the line according to how happy they feel.
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Freyd (1923) listed the advantages of the visual analogue scales method over other 
methods of assessment as being;
1. Simple and easy to explain and to understand.
2. Requires little motivation of the rater.
3. Quick to complete
4. Simple and easy to score.
Amongst other available subjective measures, visual rating scales have been shown to be 
by far the most accurate, reliable and valid means of obtaining changes in subjective 
feelings (Aitken 1969). However despite their common use and listed advantages, self 
assessments of performance and sleepiness are not as straightforward or reliable as 
objective measures of sedation. Subjective reports are much more likely to be influenced 
by transient fluctuations and other factors such as demand characteristics and 
environmental stimuli than are objective measures of performance. Subjective reports 
can be unreliable, because by their very nature, sleepiness, somnolence and sedation can 
impair the self assessment of awareness and thus result in misleading results. In an 
extensive review by Hindmarch & Shamsi (1999), it was evident that in all studies 
employing subjective rating scales, conflicting data were reported, and it was therefore 
concluded that statements about the sedative potential of an antihistamine could not be 
made solely on data from subjective tests.
Despite the inconsistencies however, if subjective measures are combined with sensitive 
and reliable objective tests, they can provide useful data.
Line Analogue Rating Scales for Sedation (LARS)
The LARS is employed as a measure of the subjective effects of psychoactive drugs. 
Subjects mark a series of 10 centimetre line analogue scales, indicating their present
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feeling with regards to a mid-point, which represents their normal state of mind before 
treatment began. The mean scores of ratings of ‘tiredness’, ‘drowsiness’, and ‘alertness’, 
presented among several distracter scales (anxious, happy, relaxed, dizzy, sad, depressed, 
energetic and clumsy), are taken as a measurement of perceived sedation (Hindmarch & 
Gudgeon, 1980). The higher the score (in millimetres), the less alert, more tired and 
drowsy the subject feels. This measure has been shown to correlate well with various 
objective measures (Parrott 1982) and has been used extensively to detect subjective 
sedation with many different classes of compounds (Hindmarch & Gudgeon 1980, 
Hindmarch & Subhan 1986, Hindmarch & Shamsi 1999).
Leeds Sleep Evaluation Questionnaire (LSEQ)
The LSEQ (Hindmarch, 1975, Parrott & Hindmarch 1978, Parrott & Hindmarch 1980) is 
a visual analogue rating scale designed specifically to enable the reliable assessment of 
any change of sleep and early morning behaviour following the administration of 
medications. The test is used to rate subjective impressions of the ease of getting to sleep 
(GTS), the quality of sleep (QOS), the ease of waiting from sleep (AES) and the co­
ordination of behaviour following waking (BFW).
The LSEQ is completed the morning following the day of drug administration and 
subjects are required to rate each of the aspects (described above) in relation to their 
normal state and performance. The LSEQ has been shown to be particularly sensitive to 
dmgs that produce sedation and has been used to differentiate between different drug 
classes (Panott & Hindmarch 1980, Hindmarch 1983) as well as to assess sleep 
promoting properties of various hypnotics (Parrott & Flindmarch 1980).
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4.2.3 Various Other Measures o f Cognitive and Psychomotor Performance 
The following tests were not part of the core test battery, and were added to the test 
battery in selected experiments only.
Hamilton Anxiety Rating Scale (HAM-A)
Using the HAM-A, an assessment is made during the course of an unstructured interview 
after which additional information is sought if any specific rating remains unclear. The 14 
questions are to some extent somatically biased and cover the whole range of anxiety 
neurosis. The HAM-A has been extensively used as a measure of change in treatment 
outcome studies and the overall score is based on both subjective replies and observed 
behaviour during the interview (Hamilton 1959).
The HAM-A is usually performed in patients by the general practitioner at the beginning 
and end of a study to measure the level of anxiety at the beginning and end of treatment.
A subsequent analysis of the effects of the treatments on both somatic and psychotic 
subjective-scales of the HAM-A was performed. This scale was included in experiment 
7, in which the efficacy of hydroxyzine and lorazepam in alleviating symptoms of anxiety 
together with its effects on cognitive functioning were investigated.
Cognitive Failures Questionnaire (CFQ)
The CFQ is a measure of self-reported failures in perception, memory and motor 
function, developed by Broadbent et al (1982). It comprises 25 possible failures 
covering these three general areas. Subjects rate how often they have experienced 
each problem during the last four months, using a five point scale (ranging from 
‘never’ (0) to ‘very often’ (4)). Scores have been shown to correlate significantly with 
external ratings of the respondent, for instance, by their spouse, but are not associated
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with indices of neuroticism (Broadbent et al., 1982). The CFQ was also incorporated 
into the design of experiment 7, to allow the investigation of the effects of 
hydroxyzine and lorazepam on cognitive functioning in patients suffering from 
generalised anxiety disorder.
Clinical Global Impression (CGI)
This physician rated assessment will indicate the global impression of the patient on 
cognitive functions and sleep. General practitioners were requested to rate their global 
impression of the patient’s mental functioning and various aspects of sleep (e.g. ease of 
getting to sleep, quality of sleep, number of awakenings) as very bad, bad, slightly bad, 
not bad/not good, slightly good, good or very good.
Together with use of psychometric tests and subjective evaluation of the cognitive effects 
of hydroxyzine in patients within a general practice setting, the CGI was incorporated 
into the protocol design of experiment 7 to provide a measure of the physician’s 
impression of the patients as regards their cognitive functioning and sleep following the 
administration of hydroxyzine and lorazepam.
Milford Memory Test (MMT)
The MMT was used as an objective measure of aspects of short term memory and 
recognition. In the shopping list task, subjects were shown a list of items, which they 
then recalled immediately. Following this, they were shown the cards from which they 
chose items appearing in the original list. In the names and faces task, they were shown 
photographs of named people and were then asked to recall the names when subsequently 
presented with the photographs only. The MMT can be used in both healthy volunteers
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and patient populations. The MMT was included as part of the test batteiy in experiment 
7 to provide an objective measure of the effects of hydroxyzine on memory.
Digit Span (DS)
Foiivard and backward digit span were also performed to assess the immediate effects on 
short term memory storage. In this test, subjects were asked to repeat a series of digits 
read to them. Each subject was tested for the retention of digits forward, starting with 4 
digits and increasing by 1 after each series (to a maximum of 8 digits) correctly repeated 
by the subject. Retention of digits in reverse order was also measured. The final score 
was the sum of the highest series of numbers recalled for both digits forward and 
reversed (Fudge et al, 1990).
Experiment 7 was designed to investigate the effects of hydroxyzine and lorazepam on 
various aspects of cognitive functioning including memory. The detrimental effects of the 
benzodiazepines on various aspects of memory are well documented. The DS was 
therefore included in the test battery of experiment 7 as an additional memory test to 
investigate the effects of both hydroxyzine and lorazepam on short term memory storage.
4,2.4 Peripheral Measures
Histamine-Induced Weal and Flare Response (W&F)
The use of the histamine induced weal and flare test for demonstrating pharmacodynamic 
activity of histamine receptor antagonists is widely accepted and is the standard validated 
procedure for the assessment of antihistaminic activity (Cook & Shuster 1980, Mailing 
1987).
The peripheral Hi blocking effect of the study drugs was investigated by measuring skin 
reactivity to histamine before and after drug administration. The skin prick method was
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employed using a 1 Omg/ml histamine solution. A steel lancet with a 1 mm tip and 
shoulders, thus preventing further penetration of the skin, was pressed at an angle of 90° 
to the skin surface through a drop of histamine solution. The test was performed on the 
volar surface of the forearm before and at designated time points after drug intake. 
Histamine induced weals and flares appearing on the skin were marked with inlc after 10 
minutes, transfen*ed onto transparencies and measured by a computerised planimetry 
system.
The histamine induced weal and flare areas were analysed as absolute and as a percent 
reduction of pre-drug control values. Percent inhibition of the weal and flare was 
calculated according to the following equation:
Percent suppression = W (F) areabaseitne -  W (F) areat
W (F) areabaseline
In the evaluation of peripheral effect of AHs, the skin prick method was chosen because 
it does not induce any artefacts due to the vehicle used for the preparation of the 
histamine solution.
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4.3 Methods
The general study procedures are outlined in this section, although specific study 
procedures will be fluther discussed in the following chapter.
4.3.1 General Study Procedures
All studies were performed in accordance with the Declaration of Helsinld (Tokyo and 
Venice). All studies conformed to the latest GCP/ICH guidelines and were approved by 
South West Surrey Local Research Ethics Committee and The University of SuiTey 
Ethics Committee. The protocol for experiment seven was also submitted and approved 
by Cornwall Ethics Committee.
Experiments 1-6 were conducted in healthy volunteers and were single-centre laboratory 
based studies, caiTied out at the HPRU. Experiment 7 investigated the use of AHs in 
patients suffering from Generalised Anxiety Disorder (GAD) in general practice surgeries 
in the Surrey and Cornwall areas. As the design and purpose of experiment seven is 
completely different from the other six experiments, the criteria and methods used in this 
experiment will be discussed separately.
4.3.2 Experiments 1-6 - Healthy Volunteers 
Subjects
Subjects, either selected from the extensive HPRU database or recruited through various 
advertising programmes, who fulfilled the relevant inclusion/exclusion criteria, were 
entered into the study. All were healthy non-atopic volunteers of either sex, aged 
between 18-65 years.
139
The general inclusion/exclusion criteria were as follows:
Inclusion Criteria
• Aged between 18-65 years
• Able and willing to give informed consent
• Subject whose General Practitioner consented to their paiticipation 
Exclusion Criteria
• Concomitant use of psychotropic medication
• Significant history of mental illness, drug allergy, malignancy or chronic drug abuse 
(including alcohol but excluding nicotine)
• Significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, 
neurological or haematological disease or abnormality
• Marked laboratory, biochemical or haematological abnormalities considered to be 
clinically significant by the study physician
• Pregnant or lactating females
• Females of child bearing potential not using adequate contraception
• Current participation in any other clinical study or participation in the previous 90 
days
• Any subject that, in the opinion of the investigator was not suitable.
Informed Consent
Prior to entering a study, subjects gave their written informed consent. During the 
consent procedure, adequate explanation of the aims, methods, anticipated benefits, and 
potential hazards of the study were explained by the investigator in the presence of a
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witness. It was also clearly explained that the volunteers were completely free to refuse to 
enter the study or to withdraw from it at any time or that they could be withdrawn from 
the study if they did not adhere to the instructions. The informed consent procedure was 
earned out by either the study physician or a suitable qualified person assigned by the 
physician. Subjects were required to talce two copies of the consent form home for 
consideration and sign one copy and return if they wished to participate in the study. In 
addition, information sheets clearly describing the study procedures were provided for the 
subjects.
The subject’s general practitioner was informed and agreement for participation was 
obtained prior to enrolling a subject onto the study.
Subjects were clearly instructed that participation in the study required them to adhere to 
all conditions of the study. These required that subjects should not be working overnight 
nor be engaged in shift work. They were required to go to bed at their usual bedtimes and 
avoid late nights before a study day. In addition they were instructed to abstain from 
alcohol, caffeine and nicotine on study days as well as to reduce the intake of these for 
the duration of the study. Meals were standardised and provided at set times. Subjects 
were prevented from napping by vigilant members of staff and requested to take part in 
group activities to prevent boredom.
Medical examination
Following informed consent of the subject and the general practitioner, subjects attended 
the unit for a medical examination to ensure that they were healthy and satisfied the 
relevant inclusion/exclusion criteria. During this examination, blood samples were taken 
for standard biochemical and haematological tests, as well as the measurement of vital 
signs (blood pressure, heart rate). Urine samples were screened for drugs of abuse and
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pregnancy in female volunteers. This procedure was repeated at the end of the study 
before subjects were signed off a study. In the event of any abnoimality whether related 
to the study drug or not, ftirther tests were cairied out until the condition resolved and the 
laboratory values returned to normal.
Prior to the first study day, subjects were familiarised with study procedures and fully 
trained on the psychometric test battery in order to preclude any learning effects 
(Parkin et al 1987).
4.3.3 Experiment 7 -  patient study
Unlike experiments 1-6, experiment 7 was earned out in patients suffering from GAD in 
general practice.
Subjects
Subjects were patients who presented themselves to their general practitioner. They were 
male/female patients who fulfilled the following inclusion/exclusion criteria:
Inclusion Criteria
• Aged between 18-65 years inclusive
• Able and willing to give informed consent
• Clinical diagnosis of Generalised Anxiety Disorder
• Conformity of the diagnosis according to the criteria in DSMIV.
Exclusion Criteria
• Associated major depressive disorder according to DSM IV criteria
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• Any treatment with benzodiazepines in the last two months or any other psychoactive 
drug in the last month prior to entering the study
• Concomitant psychotropic medication including AHs, which in the opinion of the 
investigator would interfere with the study
• Use of propranolol or any other beta blockers and clonidine in the week prior to the 
study.
• Patients requiring psychotherapy
• Patients suffering from acute pulmonary insufficiency and airway obstruction.
• Lactation, pregnancy or pregnancy potential (except when actively using effective 
means of contraception).
• Known alcohol or drug addiction or abuse
• Known allergy to hydroxyzine or other piperazines, lactose, com starch or cellulose
• Known allergy to lorazepam, other benzodiazepines, polyethylene glycol, propylene 
glycol, or benzyl alcohol
• Known hepatic, renal and cardiac dysfunction and organic cerebral diseases
• Concomitant treatment with scopolamine
• Any subject that in the opinion of the investigator was unsuitable.
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Informed Consent
This was obtained as described in the previous section.
Medical Examination
Following the informed consent process, a medical examination was carried out to ensure 
that the patients were healthy and fulfilled the relevant inclusion/exclusion criteria 
outlined above. This was repeated at the end of a patient’s participation prior to signing 
them off the study.
4.4 Experimental Design
All experiments were performed and analysed under double-blind conditions, where 
neither the subject nor the experimenter was of aware of the given treatment. All 
treatments were provided in identical forms so that they could not be distinguished from 
one another. A copy of the treatment code break was held at a secure location at the 
HPRU in case of an emergency.
Experiments 1-6 were carried out in healthy volunteers and experiment 7 was conducted 
with patients suffering from Generalised Anxiety Disorder (this experiment will be 
discussed separately). In all of these studies, treatments were allocated in a random 
order. In all experiments with the exception of experiment 7, treatments were 
randomised in a cross-over fashion according to a Latin square, thus each subject acted as 
their own control and treatment sequences were balanced for carry over effects. 
Treatments were separated by a washout period varying from 4-7 days depending on 
specific study criteria.
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Experiment 7 was performed in a population of patients complaining of symptoms of 
generalised anxiety disorder. Due to the use of patients in this study, several differences 
were evident in the design when compared to experiments in volunteers. One such 
difference was that a placebo was not included in this study due to the ethical reasons 
associated with the use of placebo condition in symptomatic patients. In addition, 
although the treatments were randomised, the crossover design was not employed and an 
equal number of patients received either treatment for the duration of the study.
In all studies, adverse events and the use of any concomitant medication was closely 
monitored and recorded. However as this thesis is concerned only with the psychometric 
aspects of the second generation AHs, these effects are not discussed in detail. Table 4.1 
provides a summary of the study designs.
Table 4.1: A summary of the experimental design of each study described in this
thesis
EXPERIMENTS
Design 1 2 3 4 5 6 7
Randomised X X X X X X X
Double-blind X X X X X X X
Cross-over X X X X X X
Placebo X X X X X X
Verum X X X X X X X
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4.4.1 Statistical Analysis
AU data were analysed using analysis of variance techniques (ANOVA). If the ANOVA 
revealed an overall significant effect, then differences between means were evaluated 
using post-hoc tests. In the presentation of results (chapter 5), standard statistical 
notation is used. That is, F(a,b) = X, p<Y, where F stands for the F-ratio, a and b are the 
degrees of freedom associated with the effect and error variance respectively, X is the 
particular value of F, p stands for the probability that the result was due to chance and Y 
is the particular value of that probability, which was normally set at 0.05 unless otherwise 
stated (Fairweather 1997).
4.5 Experiments
Each experiment was conducted with a few tests from the core test battery although each 
study differed from one another in that different tests were employed.
Experiments conducted and described in the thesis are listed in table 4.2.
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Table 4.2: Experiments described in thesis
EXPERIMENT TITLE
1 A double blind, placebo-controlled, crossover comparison of 
fexofenadine and loratadine versus placebo: Suppressive effects 
on histamine-induced weal and flares in healthy volunteers.
2 A double blind, placebo and verum controlled investigation of 
the peripheral suppressive effects of fexofenadine, loratadine and 
promethazine on histamine-induced weal and flare reaction in 
healthy volunteers.
3 A double blind, placebo controlled investigation of the effects of 
fexofenadine, loratadine and promethazine on cognitive and 
psychomotor function.
4 An investigation into the effects of cetirizine and loratadine on 
cognitive flinction and psychomotor performance in healthy 
volunteers.
5 The central effects of tliree doses of ebastine in healthy 
volunteers: a double blind, placebo and verum controlled study in 
healthy volunteers.
6 The effects of single and repeated administration of ebastine on 
cognitive and psychomotor performance in comparison to 
triprolidine and placebo in healthy volunteers
7 The effects of hydroxyzine and lorazepam on cognitive function 
and sleep in patients with generalised anxiety disorder.
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4.6 Summary
This chapter has outlined the general methods and measures, which have been adopted to 
evaluate the potency and psychometric profiles of a number of second generation AHs. 
The test battery has been described, together with information on specific tests and the 
importance of factors such as reliability and validity has been highlighted. Aspects of 
subject selection, informed consent, experimental design and statistical analysis have 
been outlined. Each experiment will be discussed individually and in more detail in the 
following chapter.
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CHAPTER 5: PRESENTATION OF RESULTS
5.0 Chapter Outline
This chapter presents the results of seven experiments, which with the exception of one 
were all conducted with healthy volunteers. The first part of this chapter presents the 
results of two experiments, which were designed to investigate the ability of fexofenadine 
to suppress the histamine-induced weal and flare reaction, which is the standard and 
validated procedure for the assessment of antihistaminic activity. The second part of this 
chapter is a presentation of the results of four experiments, designed to assess the 
cognitive and psychomotor profile of a number of second generation AHs. The third and 
final section of this chapter presents the results of a study, which was conducted in 
patients suffering from generalised anxiety disorder within a general practice setting.
For each experiment, all individual tests are presented graphically, however tables of 
means for all individual data can be found in Appendix I. Results of each experiment are 
briefly discussed, although a detailed discussion of the findings is presented in chapter 
six. The general methods and measures employed in each of the experiments have been 
described in the previous chapter. What follows is a description of specific procedures 
employed for each experiment.
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5.1 Experiment 1 : A double-blind, placebo controlled, crossover comparison 
of fexofenadine and loratadine versus placebo: suppressive effects on 
histamine-induced weals and flares in healthy volunteers
5.1.1 Introduction & Rationale
Suppression of the histamine induced weal and flare reaction by Hi receptor antagonists 
is a commonly used biologic assay for demonstrating the onset and duration of peripheral 
Hi blockade (Simons 1996, Simons et al 1990, Simons & Simons 1997,Woodbaker et al 
1993) and is the standard validated procedure for the assessment of antihistaminic 
activity.
The primary objective of this study was to determine the peripheral suppressing effects 
of fexofenadine in comparison to loratadine, by measuring the attenuation of the 
histamine induced weal and flare test.
The efficacy of the study drugs were assessed by the following:
1. Speed of onset, defined as the first time a weal size inhibition of >35% was obseiwed 
on day 1.
2. Duration of effect on day 1, assessed as the change from baseline in weal size 
measurement at 18 and 24 hours.
3. Speed of onset and duration of effect on day 4.
4. Time of maximum inhibition at day 1, defined as the first point when the biggest 
reduction in weal size measurement from baseline throughout the day.
5. Time of maximum inhibition at day 4.
6. Supportive to the weal measurements, the above were repeated for the flare area 
measurement.
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For statistical purposes, the null hypothesis for the study was that neither fexofenadine 
nor loratadine would have any effects on the histamine-induced weal and flare test 
when compared to placebo.
5.1.2 Methods & Measures
The general methods and measures employed in this study are outlined in chapter 
4, however the specific procedures are described in the following sections.
Subjects
Eighteen healthy male and female volunteers varying in age from 19-57 years (median 
age of 34 years) took part in the study. As part of the screening process, each subject was 
evaluated for skin reactivity to histamine. All subjects completed the study and there 
were no serious adverse events.
Design
The study was a randomised, double blind, placebo controlled, 3 way crossover study 
in a group of normal volunteers in which each subject acted as their own control. The 
treatment sequence was balanced for residual effects using a Latin Square design.
Drugs
The drugs under investigation were fexofenadine 80mg, loratadine lOmg and placebo. 
Fexofenadine was administered as 40mg twice daily and so a matching capsule was 
administered with loratadine to preserve the blinding of the study. For the same reason, 
placebo was also administered twice daily. There was a minimum of 4 days washout 
period between each treatment cycle. The washout period is calculated on the basis that
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the medication will be eliminated from the body in 3.5 half lives. The half-life for 
fexofenadine is 11-16 hours and it should therefore be largely eliminated from the body 
during the washout period of 4 days.
Procedure
Following informed consent, medical history and GP approval, all subjects underwent a 
medical examination. If subjects fulfilled the inclusion / exclusion criteria then they were 
entered into the study. Each volunteer received active medication or placebo at 08:30 
and 20:30. Each treatment was administered for 4 consecutive days with volunteers 
attending the unit on days 1 and 4. On these assessment days, the subjects stayed 
overnight at the unit and were tested on the mornings of day 2 and day 5 respectively.
On each of the test days, subjects attended the study centre where a breath alcohol 
reading was taken. Following pre-treatment baseline recordings, treatments were 
administered and further assessments were performed at 30mins, 45mins, Ihi*, 1.5hr, 2hr, 
3hr, 4hr, 5hi', 6hr, 8hr, 12hr, 18hi*, and 24 hours post dose on days 1 and 4. On days 2 and 
3 subjects were required to take their medication at home and subjects were contacted 
during these days to ensure that the medication had been taken on time.
The use of concomitant medication was discouraged but allowed at the discretion of the 
physician. The use of alcohol and nicotine were forbidden and products containing 
caffeine were prohibited on test days. Food consumption was strictly controlled and only 
allowed at the specified times.
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Tests
The peripheral Hi blocking effect of the study drugs were investigated by measuring skin 
reactivity to histamine using the standard validated weal and flare reaction test, before 
and at various time points (described above) after drug administration. Weal and flare 
circumferences were traced at 10 minutes with a felt-tipped pen, transferred onto 
transparencies and measured by a computerised planimetry system (Seescan Imaging, 
Seescan Limited, Cambridge).
Assessments of adverse events and concomitant medication were made at each visit. 
Statistical Analysis
A  two factor analysis of variance was performed with the factors treatment and sequence 
of drug allocation. Treatment had 3 levels (fexofenadine, loratadine and placebo) and 
sequence had six levels. Pairwise comparisons between treatment means were analysed 
using Newman-Keuls tests. Significance was set at p<0.05.
The percentage inhibition was calculated as:
% change ealgrea baseline W^ Gal^ rea at time t X I 00
W^  ealarea baseline
Baseline weal and flare areas were calculated as the average of the four screening 
measurements and the two pre-dose measurements.
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5.1.3 Results
The mean percentage inhibition of the weal and flare areas on both days 1 and 4, before 
and up to 24 hours after administration of fexofenadine, loratadine and placebo were 
calculated and are presented in figures 5.1-5.4. The mean values for both parameters on 
days 1 and 4 can be found in tables 1-4 of appendix 1.
The two drugs were compared with respect to their ability to suppress the histamine 
induced weal and flare response, the speed of onset, duration of effect, mean maximum 
inliibition and the time talcen to achieve maximum inhibition.
Suppression of weal and flare by fexofenadine and loratadine versus placebo 
Compared to the suppression produced by placebo, fexofenadine significantly suppressed 
the mean histamine induced weals at 18 and 24 hours on day 1 and at 3 hours on day 4. 
Fexofenadine also significantly suppressed the formation of flares from 3 to 24 hours on 
day 1 and from 0.5 to 24 hours on day 4.
Loratadine produced a significant suppression of weals at 4, 6,8, 18 and 24 hours on 
day 1, but did not cause any significant suppression on day 4. Flare formation was 
significantly suppressed at 3, 4, 5, 8,12 and 24 hours on day 1 following loratadine 
administration. Significant suppression was evident on day 4 from 0.5 to 24 hours 
inclusive following the administration of loratadine (figures 5.1-5.4).
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Figure 5.1: Percentage inhibition of weal area on day one
Mean values for each treatment 
* = p<0.05 when compared to placebo
(Fexo = fexofenadine, Lor = loratadine, o.d. = once daily, 
b.d. = twice daily)
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Figure 5.2: Percentage inhibition of weal area on day four
Mean values for each treatment 
* = p<0.05 when compared to placebo
(Fexo = fexofenadine, Lor = loratadine, o.d. = once daily, b.d. = twice 
daily)
Mean % inhibition
Time (hrs)
Fexo 4Qmg b.d. -▼-Lor 10mg o.d. -^Placebo
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Figure 5.3: Percentage inhibition of flare area on day one
Mean values for each treatment 
* = p<0.05 when compared to placebo
(Fexo = fexofenadine, Lor = loratadine, o.d. = once daily, 
b.d. = twice daily)
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Figure 5.4: Percentage inhibition of flare area on day four
Mean values for each treatment 
* = p<0.05 when compared to placebo
(Fexo = fexofenadine, Lor = loratadine, o.d. = once daily, 
b.d. = twice daily)
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Suppression of weal andflare by fexofenadine and loratadine versus baseline 
Compared to baseline, fexofenadine produced significant suppression of the weals 
from 2 to 24 hours on day 1 and from 1 to 24 hours inclusive on day 4. Fexofenadine 
also significantly suppressed flare formation from 1.5 to 24 hours on day 1 and 
from 0.5 to 8 hours, at 18 and 24 hours on day 4.
Compared to baseline, loratadine produced significant suppression of weal formation 
from 0.75 to 24 hours on day 1 and from 1 to 4 hours and then from 6 to 24 hours on 
day 4. Flare formation was significantly suppressed by loratadine on day 1 from 
2 to 24 hours inclusive and on day 4 from 0.5 to 24 hours inclusive. Administration 
of placebo did not result in any significant suppression of either weals or flares 
(table 5.1).
Table 5.1: Time in hours (hrs) during which suppression of the histamine
induced weals and flares by the three treatments was significantly different 
(p<0.05) from baseline
RESPONSE WEAL FLARE
Treatment T Day 1 
time (hrs)
Day 4 
time (hrs)
Day 1 
time (hrs)
Day 4 
time (hrs)
Fexofenadine 
(40mg b.d.)
2-24 1-24 1.5-24 0.5-8,
18& 24
Loratadine 
(lOmg o.d.)
0.75-24 1-4,
6-24
2-24 0.5-24
Placebo NS NS NS NS
NS = Not significant when compared to baseline
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Speed of onset
The speed of onset was calculated as the first time an inhibition of > 35% in weal and 
flare formation was obseiwed. Analysis of the results showed that there was a 
significant treatment effect as regards weal and flaie formation on both days 1 
[F (2,24)=3.94, p=0.033] and 4 [F(2,22)= 4.58, p=0.022]. Pairwise comparisons 
indicated that there were no significant differences between fexofenadine and loratadine, 
but that both had a significantly faster onset of action than placebo. Mean speed of action 
as regards weal inhibition was 3.57 hours for fexofenadine on day 1, dropping down to
1.5 hours on day 4. Although not statistically different from loratadine (4.56 hours on 
day 1 and 1.3 hours on day 4), this was significantly faster than placebo (8.40 hours on 
day 1 and 5.0 hours on day 4).
Table 5.2 lists the mean speed of onset for all three treatments on both days 1 and 4.
Table 5.2: Speed of onset in hours (mean ± s.d.) of weal and flare response on
days 1 & 4 following the administration of the three treatments
RESPONSE WEAL FLARE
Treatment Day 1 
time (hrs)
Day 4 
time (hrs)
Day 1 
time (hrs)
Day 4 
time (hrs)
Fexofenadine 
(40mg b.d.)
3.57* ± 4.62 1.47* ±1.30 1.61 ±1.39 0.57* ±0.15
Loratadine 
(lOmg o.d.)
4.56* ± 7.60 1.32* ±096 2.11 ±1.98 0.69* ±0.61
Placebo 8.40 ± 10.10 5.0 ±7.65 4.01 ±7.75 3.35 ±5.61
*  = p< 0.05 compared to placebo
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Duration of effect
In order to calculate the duration of effect, percentage inhibition was calculated at 18 and 
24 hours post dose on both days 1 and 4.
At 18 hours post dose, fexofenadine produced 47.2% mean inliibition of the weal area 
(p=0.027), dropping down to 38.7% at 24 hours (p=0.008). Continuous dosing for 4 days 
resulted in 54.4% inhibition at 18 hours (p=0.013) and 43.9% inhibition at 24 hours 
(p=0.001) with fexofenadine. Loratadine also achieved a similar inhibition of the weal 
area, although this was not statistically different from fexofenadine. It is evident from the 
results, that although the two treatments were similar in their duration of action, 
fexofenadine exhibited a longer duration of effect than placebo.
Analysis of day 1 results as regards % inhibition of the flare area showed a mean duration 
of action of 81.1% for fexofenadine on day 1, reaching 100% inhibition on day 4. Once 
again, loratadine appeared to be similar to fexofenadine in its duration of effect, however 
both treatments had a longer duration of action than placebo.
Table 5.3 lists the % inhibition of the weal and flare response on both days 1 and 4 by all 
three treatments.
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Table 5.3: Mean percentage inhibition of the weal and flare response at 18 & 24
hours post-dose on days 1 & 4
RESPONSE WEAL FLARE
Treatment T Day 1 Day 4 Day 1 Day 4
18 hrs 24 hrs 18 hrs 24 hrs 18 hrs 24 hrs 18 hrs 24 hrs
Fexofenadine 47.2* 38.7* 54.4* 43.9* 81.1* 66.2* 77.0* 75.0*
(40mg b.d.) ±22.9 ±23.4 ± 16.6 ±15.5 ±27.7 ±32.5 ±22.1 ±38.9
Loratadine 4L9* 35.8* 52.3* 49.7* 6L7* 56.0* 70.0* 74.0*
(lOmg o.d) ±23.0 ±27.2 ±25.4 ±16.7 ±42.2 ±43.2 ±53.6 ±43.7
Placebo 12.3 8.5 28.1 20.5 5.2 -14.0 ± 3.70 -28.0
±57.6 ±60.8 ±27.9 ±27.0 ± 56.6 64.5 ±49.2 ± 104
* = p<0.05 compared to placebo
Maximum inhibition & time to maximum inhibition
The mean maximum inhibition achieved by all three treatments was calculated as a 
percentage of pre-drug control values. In addition the mean time taken to achieve this 
inhibition was calculated for both weal and flare responses on both days 1 and 4.
As regards mean maximum inhibition of the weal area, analysis of the results 
demonstrated a significant treatment effect on day 1[F(2,24)=13.31, p=0.0001] and on 
day 4 [F(2,22)=12.95, p=0.005] with pairwise comparisons showing the two active 
treatments not be significantly different from each other but both to be superior to 
placebo. Significant treatment effects were detected for mean maximum inhibition of 
flare area on both days 1 [F(2,24)=10.45, p==0.005]and 4 [F(2,22)=9.55, p=0.001], with 
pairwise comparisons demonstrating the two active treatments to be significantly 
different from placebo.
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Fexofenadine produced a maximiun suppression of the weal area of 66% at 12.6 hours, 
and a maximum suppression of the flare area of 99% at 8.5 hours on day 1. Continuous 
dosing maintained this inhibition on day 4, with fexofenadine achieving a mean 
inhibition of 69% at 10.5 hours, and 100% inhibition at 2.1 hours for the weal and flare 
areas respectively.
Mean maximum inhibition of the weal area as a result of loratadine administration was 
62% at 10.1 hours on day 1 and 67% at 10.3 hours on day 4. Loratadine caused a 
maximum suppression of the flare area of 96% at 7.8 hours on day 1 and 98.5% 
inhibition at 1.6 hours on day 4.
Although there were no significant differences between the two active treatments, 
fexofenadine was significantly superior to placebo in achieving maximum inhibition. 
Table 5.4 lists the percentage inhibition achieved by all three treatments on both days 1 
and 4.
Table 5.4: Mean maximum inhibition (± s.d.) as a percentage of pre-drug
control values for all three treatments
RESPONSE WEAL FLARE
Treatment -I Day 1 Day 4 Day 1 Day 4
Fexofenadine 
(40mg b.d)
66.0* ± 12.40 69.0* ±10.31 99.0* ± 0.82 100.0* ±0.0
Loratadine 
(lOmg o.d.)
62.0* ± 16.20 67.0* ± 9.48 96.0* ± 10.98 98.5* ±6.13
Placebo 46.0 ±15.45 56.0 ± 11.60 75.0 ± 24.47 83.0 ± 17.75
* = p<0.05 compared to placebo
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5.1.4 Discussion of Results
In the present clinical study performed under double blind crossover conditions in 
eighteen healthy subjects, fexofenadine 40mg b.d., a novel Hi receptor antagonist was 
compared with loratadine at its recommended dose (lOmg o.d.) and placebo. The study 
was conducted in order to assess the inhibitory effects of both study drugs on the 
immediate skin reactions induced by histamine and to establish the onset of action as well 
as the duration of effect of fexofenadine compared to loratadine and placebo.
Significant differences in skin reactivity to histamine were observed between 
fexofenadine and placebo. The suppressive effects of fexofenadine were significantly 
more rapid, more pronounced and longer lasting than that of placebo.
Fexofenadine had a mean onset of action of 3.5 hours on day 1, with continuous dosing, 
reducing it to 1.5 hours on day 4. Suppressive effects were evident up to 24 hours post 
drug administration on both days 1 and 4 with levels of weal inhibition exceeding 50% 
on day 4. Flare formation was suppressed to a greater extent, with fexofenadine 
achieving 100% inhibition at 24 hours on day 4. Maximum inhibition of the weal aieas 
on days 1 and 4 were 66% and 69% respectively following fexofenadine administration. 
Although significantly superior to placebo in suppressing weal and flare formation, there 
were no detectable differences between fexofenadine and loratadine. The superiority of 
fexofenadine over loratadine may have been masked by the administration of the 
minimum dose of fexofenadine as opposed to loratadine being given at its recommended 
daily dose.
Previous clinical studies with fexofenadine have shown that 40mg is the lowest effective 
dose in healthy volunteers (Hoechst Marion Roussel, Personal Communications 1999) 
and that a dose of 160mg achieved maximum suppression of the histamine-induced weal 
and flare response (HMR 1999). Subsequent dosing of fexofenadine to 800mg did not
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cause further peripheral suppression, but was well tolerated with no increases in 
treatment related adverse events (HMR 1999). In a number of seasonal allergic rhinitis 
trials, fexofenadine in doses of 40mg to 240mg administered for two weeks was 
statistically superior to placebo in reducing SAR symptoms (Bernstein et al 1997).
Results obtained with loratadine in this study are in agreement with previous research in 
which loratadine has been shown to possess weak inhibitory effects compared to a 
number of other antihistamines such as cetirizine (Roman et al 1986; Pechadre et al 
1991), and similar effects to terfenadine (Gendrau-Reid et al 1986; Kassem et al 1988) 
and astemizole (Bateman et al 1986).
From present results, it appears that fexofenadine 40mg b.d is significantly superior to 
placebo and as effective as loratadine as regards onset of action, duration of effect and the 
ability to suppress the histamine induced weal and flare response.
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5.2 Experiment 2: A double blind, placebo and veriim controlled investigation 
of the peripheral suppressive effects of fexofenadine, loratadine and 
promethazine in healthy volunteers
5.2.1 Introduction & Rationale
In the previous experiment, the suppressive effects of fexofenadine (80mg) and 
loratadine (lOmg) were compared with placebo. Despite the use of a sub-clinical dose 
of fexofenadine, it was shown to cause significant suppression of the histamine-induced 
weal and flare reaction when compaied to placebo.
As the current recommended clinical dose of fexofenadine is 120mg in the treatment of 
seasonal allergic rhinitis and 180mg in the treatment of chronic idiopathic urticaria, this 
study was designed to determine the speed of onset and duration of effect of higher 
doses of fexofenadine (80mg, 120mg and 180mg) in comparison to loratadine lOmg, 
promethazine 30mg (as a verum) and placebo in a group of healthy non-atopic 
volunteers.
For statistical purposes, the null hypothesis for the study was that fexofenadine, 
loratadine or promethazine would not have any effects on the histamine-induced weal 
and flare in comparison with placebo.
5.2.2 Methods & Measures
Subjects
Twenty four healthy male and female volunteers, aged 19 to 58 years (mean 32.6 years) 
participated in this study. As part of the screening procedure, each subject was evaluated 
for skin reactivity to histamine.
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Design
The study was a randomised, double blind, placebo-controlled, 6 way crossover study in 
a group of non-atopic volunteers, in which each volunteer acted as their own control. 
The treatment sequence was balanced for residual effects using a Latin square design.
Drugs
The drugs under investigation were fexofenadine 80mg, 120mg and 180mg, loratadine 
lOmg, promethazine 30mg (as a verum) and placebo. Each treatment day was separated 
by a washout period of four days or more.
Procedure
Following informed consent, medical history and GP approval, all subjects underwent a 
medical examination. Subject to fulfilling the inclusion/exclusion criteria, eligible 
volunteers were entered into the study. Each volunteer received active medication or 
placebo as a single oral dose at 0830 hours.
On each of the test days, subjects attended the study centre where a breath alcohol 
reading was taken. Following two pre-treatment baseline recordings (-30mins and 
OOmins), treatments were administered and fiirther assessments were performed at 
30mins, 45mins, Ihr, 1.5hr, 2hr, 3hr, 4hr, 5hr, 6hr, 8hr, 12hr, 18hi', and 24 hours post 
dose. Weal and flare measurements were made 10 minutes after each skin prick test. 
The use of concomitant medication was discouraged but allowed at the discretion of the 
physician. The use of alcohol, nicotine and products containing caffeine was prohibited 
on test days. Food consumption was strictly controlled and only allowed at the 
specified times.
Assessments of adverse events and concomitant medication were made at each visit.
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Statistical Analysis
The results for all primary efficacy variables, i.e. speed of onset and duration of effect 
together with the secondary variable of time of maximum inhibition for both the weal 
and the flare were all analysed using distribution free methods of analysis.
Friedman ANOVA was used to assess overall treatment effects and the Wilcoxon 
matched pairs to assess pairwise treatment comparisons.
The percentage inhibition of the weal and the flare (from baseline) were calculated using 
the same formula employed in experiment I, in which the baseline was calculated as the 
average of the four screening measurements and the two pre-dose measurements 
(-30mins and OOmins).
5.2.5 Results
The mean percentage inhibition of the weal and flare areas, before and up to 24 hours 
after administration of fexofenadine (80mg, 120mg & 180mg), loratadine (lOmg), 
promethazine (30mg) and placebo were calculated and are presented in figures 5.5 & 5.6. 
Tables 5.5 and 5.6 present the mean values for both parameters together with the 
statistical significance obtained at various time points.
The three drugs were compared with respect to their ability to suppress the histamine 
induced weal and flare response, the speed of onset, duration of effect, mean maximum 
inhibition and the time taken to achieve maximum inhibition.
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Suppression of weal and flare by fexofenadine, loratadine & promethazine versus 
placebo
Compared to the suppression produced by placebo, fexofenadine administered at all three 
doses significantly inhibited both the weal and flare reaction at various time points 
throughout the 24 hour period (tables 5.5 & 5.6). To avoid confusion in the graphs, the 
significant time points are not indicated on the graph but highlighted in tables 5.5 and 
5.6.
The formation of weals were significantly suppressed with fexofenadine 80mg at 2-5 
hours and 8 houis post drug administration (p<0.05). The 120mg dose of fexofenadine 
significantly inhibited weal formation from 2-12 hours (inclusive) and the administration 
of the highest dose of fexofenadine (180mg) resulted in significant suppression of weal 
from 1-18 hrs inclusive (p<0.005). Similarly, the 80mg dose of fexofenadine inhibited 
flare formation from 2-18 hours post-dose (p<0.005), the 120mg dose suppressed flare 
formation from 2-18 hours (p<0.005) and the highest dose of fexofenadine (180mg) 
inhibited flare formation from 1.5-24 hours (p<0.005).
Loratadine also produced a significant suppression of both the weal and flare formation, 
however the inhibitory effects of loratadine were weak when compared to the other 
treatments. Loratadine significantly suppressed weal formation only at 8 and 12 hours 
post dose (p<0.005), whereas flare formation was significantly suppressed at 4 hrs and 6- 
24 hours inclusive following the administration of loratadine (p<0.05). Promethazine 
suppressed the formation of weals at 1,2-5, 8 and 12 hours (p<0.05) and similarly the 
formation of flares at 2-5 and 8-18 hours following drug administration (p<0.05).
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Figure 5.5: Percentage inhibition of weal area
Mean values for each treatment
(Fexo = fexofenadine, Lor = loratadine, Prom == promethazine)
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Figure 5.6: Percentage inhibition of flare area;
Mean values for each treatment
(Fexo = fexofenadine, Lor. = loratadine, Prom = promethazine)
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Table 5.5: Weal Area - percentage change from true baseline and standard
deviations (s.d.) for all treatment conditions
(Fexo = fexofenadine, Lor = Loratadine, Prom = promethazine)
TIME
(HRS)
FEXO
80mg
FEXO
120mg
FEXO
180mg
LOR
lOmg
PROM
30mg
PLACEBO
0.5 -1.85
(35.82)
3.66
(28.58)
-0.22
(37.40)
-13.25
(30.69)
3.31
(31.81)
-1.19
(31.39)
0.75 -7.08
(38.48)
2.82
(29.76)
1.73
(28.41)
-3.75
(26.48)
0.38
(31.23)
-8.84
(32.34)
1.0 7.38
(29.35)
0.31
(39.79)
16.69**
(31.26)
0.98
(28.28)
14.19*
(28.58)
-7.65
(31.39)
1.5 18.49
(30.70)
19.69
(32.74)
26.39*
(41.12)
-0.72
(22.08)
23.08
(36.84)
10.66
(25.56)
2.0 26.46*
(32.30)
35.92**
(26.03)
49.62**
(30.57)
10.25
(38.15)
29.77*
(38.15)
3.24
(41.96)
3.0 45.02**
(23.13)
54.36**
(25.24)
59.30**
922.76)
20.96
(27.71)
42.91**
(27.89)
7.26
(38.03)
4.0 51.03**
(27.65)
55.10**
(20.95)
62.35**
(21.70)
20.30*
(32.80)
39.18**
(26.27)
-0.93
(32.93)
5.0 60.30**
(21.01)
61.84**
(16.85)
68.87**
(23.36)
43.88
(31.96)
57.14**
(17.35)
31.18
(25.98)
6.0 54.14
(21.88)
55.21**
(23.53)
73.88**
(15.49)
52.82
(22.49)
52.58
(22.75)
41.73
(22.86)
8.0 55.99**
(22.92)
54.19**
(22.76)
63.61**
(23.42)
50.20**
(54.05)
52.29**
(22.53)
22.06
(23.87)
12.0 30.63
(28.71)
44.20**
(29.47)
52.44**
(23.85)
50.49**
(16.38)
41.34*
(28.23)
17.52
(27.29)
18.0 42.17
(20.01)
33.20
(29.92)
48.64**
(23.19)
40.90
(26.70)
28.30
(37.11)
31.68
(27.10)
24.0 34.79
(21.81)
35.55
(31.30)
33.63
(29.56)
39.48
(23.52)
34.32
(23.82)
23.25
(39.68)
*  = p<0.05 compared to placebo, ** = p< 0.005 compared to placebo
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Table 5.6: Flare Area - percentage change from true baseline and standard
deviations (s.d.) for all treatment conditions
(Fexo = fexofenadine, Lor = Loratadine, Prom = promethazine)
TIME
(HRS)
FEXO
80mg
FEXO
120mg
FEXO
180mg
LOR
lOmg
PROM
30mg
PLACEBO
0.5 -20.75
(68.77)
-9.76
(52.17)
-0.71
(50.69)
-33.72
(72.69)
-22.58
(92.70)
-16.20
(52.63)
0.75 -6.23
944.12)
-19.99
(74.68)
-11.31
(39.74)
-32.33
(78.71)
-13.59
(80.18)
-39.10
(110.58)
1.0 2.40
(56.90)
-5.85
(60.89)
-6.83
(62.69)
-0.09
(56.85)
-4.23
(67.87)
-2.63
(58.70)
1.5 10.46
(49.94)
32.08
(49.81)
46.39**
(45.12)
10.69
(60.25)
17.79
(77.30)
4.92
(51.93)
2.0 47.56**
(39.27)
64.99**
(36.33)
72.82**
(39.32)
8.26
(71.07)
41.58**
(54.66)
-9.74
(69.50)
3.0 74.00**
(35.52)
78.84**
(46.00)
89.61**
(10.27)
35.01
(47.04)
63.23**
(40.10)
7.16
(72.58)
4.0 87.50**
(14.15)
87.92**
(14.87)
92.64**
(6.94)
28.29*
(50.93)
48.82**
(37.76)
-23.59
(116.45)
5.0 93.85**
(8.63)
94.47**
(9.70)
95.86**
(7.41)
74.98
(31.15)
84.08**
(18.87)
45.77
(47.94)
6.0 93.43**
(9.14)
96.99**
(5.08)
96.68»*
(4.17)
82.64*
(22.24)
75.54
(36.55)
53.10
(42.02)
8.0 92.18**
(9.45)
92.32**
(8.65)
89.63**
(13.79)
69.55*
(39.14)
71.85*
(30.03)
-82.49
(552.32)
12.0 80.82**
(34.02)
86.11**
(21.00)
92.42**
(14.12)
77.37**
(21.35)
66.55**
(35.04)
-85.93
(438.95)
18.0 69.43**
(38.05)
73.40**
(29.67)
77.84**
(27.54)
74.34**
(31.07)
59.85**
(44.20)
17.21
(50.12)
24.0 59.81
(47.68)
67.03
(36.81)
74.37**
(26.37)
78.00**
(25.73)
60.55
(37.34)
-30.07
(285.02)
* = p<0.05 compared to placebo, * *  -  p< 0.005 compared to placebo
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Pairwise comparisons between treatments
Pairwise comparisons between the treatments indicated that the effects of fexofenadine 
were significantly different from loratadine and promethazine at various time points. 
There were no differences between the two lower doses of fexofenadine as regards the 
inhibition of either the weal or flare formation, although the highest dose (180mg) was 
shown to be significantly superior to the former two in inhibiting the histamine-induced 
weal and flare response. In comparison to loratadine, all three dose of fexofenadine were 
significantly superior in suppressing the formation of both weals and flares. The effects 
of fexofenadine occurred in a dose-dependent manner, in which the highest dose (180mg) 
maintained its superiority over loratadine for a longer period than the other two doses of 
fexofenadine. The effects of fexofenadine were also significantly different from 
promethazine as regards the inhibition of both the weal and flare formation at various 
time points throughout the 24 hour period (tables 5.7).
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Table 5.7: Inhibition of weal and flare formation during 24 hours (hrs)
Painvise comparisons between treatment conditions (p<0.05)
TREATMENT COMPARATOR WEALS FLARES
(hrs) (hrs)
Fexofenadine 80mg Fexofenadine 120mg NS NS
Fexofenadine 180mg 2-3, 5-6, 1.5,3
Loratadine lOmg 12 2-4
Promethazine 30mg 1.5, 3-5, 12 4 ,8
NS
Fexofenadine 120mg Fexofenadine 180mg 2,5-6,12 18
Loratadine lOmg 1.5-5 2-4
Promethazine 30mg NS 4,8
Fexofenadine 180mg Loratadine lOmg 1-8 1.5-5, 12
Promethazine 30mg 3-8,18 2-24
Loratadine lOmg Promethazine 30mg 0.5, 1.5-3 2-3
NS = Not significant
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Suppression of weal and flare by fexofenadine and loratadine versus baseline 
Compared to baseline, fexofenadine at all doses produced significant suppression of both 
the weals and flares from 2 to 24 (p<0.005). However the 180mg dose of fexofenadine 
significantly inhibited the weal and flare formation at 1.5 hours post dose and significant 
suppression of the flare was evident with the 120mg dose at 1.5 hours post drug 
administration (p<0.005).
Compared to baseline, loratadine produced significant suppression of weal formation 
from 2 to 24 hours (p<0.05) and of the flare formation at 1.5 hours and 3-24 hours post 
drug administration (p<0.05). Promethazine significantly suppressed the formation of 
weals from 1-24 hours post dose (p<0.05) and inhibited the formation of flares from 1.5- 
24 hours post dose (p<0.005). Administration of placebo resulted in significant 
inhibition of the weal formation at 1.5, 3, and 5-24 hours (p<0.05), as well as inhibition 
of the flares at 5-8, 18 and 24 hours post-dose (p<0.05) (table 5.8).
Table 5.8: Time in hours (hrs) during which suppression of the histamine
induced weals and flares by all treatments was significantly different (p<0.05) 
from baseline weal and flare areas
RESPONSE WEAL FLARE
Fexofenadine (80mg) 1.5-24 hrs 2-24 hrs
Fexofenadine ( 120mg) 2-24 hrs 1.5-24 hrs
Fexofenadine (180mg) 1.5-24 hrs 1.5-24 hrs
Loratadine (lOmg) 2-24 hi's 1.5-24 hrs
Promethazine (30mg) 1-24 hrs 1.5-24 hrs
Placebo 1.5, 3 & 5-24 hrs 5-8, 18 & 24 hrs
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Speed of onset
The speed of onset was calculated as the first time an inhibition of > 35% in weal and 
flare formation was observed. Analysis of the results indicated a significant treatment 
effect (X  ^= 28.52 on 5 d.f., p<0.001). Pairwise comparisons showed that fexofenadine 
80mg, 120mg, 180mg and promethazine 30mg had a significantly faster onset of action 
(P<0.05) than placebo. In addition, it also revealed that all three doses of fexofenadine 
were significantly faster than loratadine lOmg. Fexofenadine 180mg was also shown to 
be significantly faster than the lowest dose of 80mg.
Mean speed of action as regards weal inhibition was 2 hours for fexofenadine 80mg, 1.5 
hours for both 120mg and 180mg fexofenadine, 3 hours for loratadine, 1.5 hours for 
promethazine and 3 hours for placebo (table 5.9). Similarly analysis of the flare results 
indicated a significant treatment effect (X  ^=13.43, p<0.020), with pairwise comparisons 
revealing that fexofenadine at all dose, loratadine and promethazine were significantly 
faster than placebo (p<0.05).
Table 5.9: Speed of onset in hours (mean ± s.d.) of weal and flare response for all
treatment conditions
RESPONSE WEAL
(hrs)
FLARE
(hrs)
Fexofenadine 80mg 2 hrs* 1.3 hrs*
Fexofenadine 120mg 1.5 hrs* 1.3 hrs*
Fexofenadine 180mg 1.5 hrs* 1.5 hrs*
Loratadine lOmg 3 hrs 1.8 hrs*
Promethazine 30mg 1.5 hrs* 1.0 hrs*
Placebo 3 hi's 3.5 hrs
* = p< 0.05 compared to placebo
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Duration of effect
In order to calculate the duration of effect, percentage inhibition of both the weal and the 
flare were calculated at 18 and 24 horns post dose for all treatments.
As regards the inhibition of the weal, analysis of the results indicated the lack of a 
significant treatment effects at both 18 hours (X^= 8.52 on 5 d.f, p=0.13) and 24 hours 
(X  ^=3.60 on 5.d.f, p=0.61).
However analysis of the percentage flare inhibition data were indicative of significant 
treatment effects at both 18 hours (X  ^= 26.79 on 5 d.f, p<0.001) and 24 hours 
(X^= 24.58 on 5 d.f, p<0.001). At both time points, fexofenadine at all doses, loratadine 
lOmg and promethazine 30mg had significantly greater percentage inhibition than 
placebo (table 5.10).
Table 5.10: Mean percentage inhibition of the weal and flare response at 18 & 24
hours post-dose for all treatment conditions
RESPONSE WEAL FLARE
18 hrs 24 hrs 18 hrs 24 lirs
Fexo 80mg 42.63 37.21 88.97* 68.89*
Fexo 120mg 32.68 42.50 87A5* 74^%*
Fexo 180mg 56J5 40.61 87.25* 71.47*
Lor lOmg 43.80 41.63 87.50* 90.32*
Prom 30mg 36.73 34.08 71.86* 67.16*
Placebo 35^8 30.50 17.47 34.91
p<0.05 compared to placebo
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Maximum inhibition & time to maximum inhibition
The mean maximum inhibition achieved by all treatments was calculated as a percentage 
of pre-drug control values. In addition, the mean time taken to achieve this inhibition 
was calculated for both the weal and flare responses.
Analysis of the results demonstrated a significant treatment effect for both the mean 
maximum inhibition of the weal area (X^ = 29.39, p<0.000) as well as the flare area 
(X  ^= 33,27, p<0.00001). Pairwise comparisons revealed significant differences between 
the three treatments when compared to placebo as well as differences between the three 
different doses of fexofenadine as regards the maximum inhibition of the weal and flare 
areas (table 5.11).
Table 5.11: Mean maximum inhibition (+ s.d.) of the weal and flare response
as a percentage of pre-drug controls with all treatment conditions
(Fexo = fexofenadine. Lor = loratadine, Prom = promethazine)
RESPONSE WEAL FLARE
Fexo 80mg 74.4*'(r-±_11.5 98.5*±3.6
Fexo 120mg 76.3*4h±_8.5 99.4*±1.8
Fexo 180mg 83.3*±_12.7 99.7*± 1.0
LorlOmg 69.7*4h± 15.1 95.9*± 7.2
Prom 30mg 71.3*ihdLl2.2 95.9*± 8.8
Placebo 60.3ih+ 16.5 83.1+26.1
*= p<0.05 compared to placebo 
= p<0.05 compared to fexofenadine 180mg
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As regards time to maximum inhibition of the weal area, analysis of the results 
demonstrated a significant treatment effect (X  ^= 16.72 on 5 d.f., p<0.005), with pairwise 
comparisons showing significant differences between loratadine 1 Omg and fexofenadine 
80mg, 120mg and 180mg. In each case, loratadine had a slower time to maximum 
inhibition (7 hours) than fexofenadine (5 hours). Fexofenadine 180mg was also 
significantly faster to maximum inhibition than placebo and promethazine 3 Omg 
In contrast, analysis of the flare data as regards time to achieve maximum inhibition 
did not reach significance at the 5% level (X  ^= 10.98 on 5 d.f., p<0.052).
Table 5.12: Time (hrs) taken to achieve maximum inhibition of both the weal
and flare response with all treatment conditions
(Fexo = fexofenadine, Lor = loratadine. Prom = promethazine)
RESPONSE ^ WEAL
(hrs)
FLARE
(hrs)
Fexo 8 Omg 5 hrs* 5 hrs
Fexo 120mg 5 hrs* 4 hrs
Fexo '80mg 5 hrs*‘ir’ 4.5 hrs
Lori Omg 7 hi's 6 hrs
Prom 3 Omg 6.5 hrs 5 hrs
Placebo 6 hrs 5 hrs
*= p<0.05 compared to loratadine
■¥■ = p<0.05 compared to placebo and promethazine
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5.2,4 Discussion o f Results
This experiment was a follow-up of the previous investigation (experiment I), in order to 
assess the inhibitory effects of higher doses of fexofenadine (120mg and 18Omg) on the 
immediate skin reactions induced by histamine.
Significant differences in skin reactivity to histamine were observed between 
fexofenadine at all three doses and placebo. The suppressive effect of fexofenadine was 
significantly more rapid, more pronounced and longer lasting than that of placebo.
The mean onset of action of fexofenadine at the three doses was significantly superior to 
placebo (fexofenadine 80mg: 2 hrs, 120mg: 1.5 hi's & 180mg: 1.5 hrs). Suppressive 
effects were evident up to 24 hours post drug administration at all doses of fexofenadine 
with levels of weal inhibition exceeding 80% with the 180mg. Flare formation was 
suppressed to a greater extent, with fexofenadine achieving 100% inhibition at 24 hours. 
Although significantly superior to placebo in suppressing weal and flare formation, the 
inhibitory effects of loratadine were weaker when compared to fexofenadine. 
Fexofenadine at all doses had a significantly faster onset of action than loratadine 
(p<0.05). The maximum inhibition of the weal areas achieved with fexofenadine were 
higher at all doses when compared to loratadine and the time in which this maximum 
inhibition was achieved was significantly higher with all doses of fexofenadine when 
compared to loratadine. Findings in this study with loratadine are in agreement with 
similar investigations in which fexofenadine has been shown to have a significantly 
faster onset of action than loratadine (Simons & Simons 1997).
Administration of promethazine caused significant suppression of the histamine-induced 
weal and flare response. However considering that promethazine was administered at 
three times its recommended dose, the inhibitory effects were weak. This finding is in 
agreement with previously published literature, in which it has been consistently
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demonstrated that high doses of the first generation AHs are required to demonstrate 
peripheral effects and at these doses, the use of these AHs is associated with excessive 
CNS side effects (Gendreau-Reid 1986, Simons et al 1986, Simons et al 1990).
From present results, it appears that fexofenadine is significantly superior to placebo and 
at its dose of 120mg and 18Omg significantly superior to loratadine as regards onset of 
action, and the ability to suppress the histamine induced weal and flare response.
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5.3 Experiment 3; A double-blind placebo controlled investigation of the effects 
of fexofenadine, loratadine and promethazine on cognitive and psychomotor 
function
5.3.1 Introduction &. Rationale
This investigation is the first of a series of experiments designed to assess the cognitive 
and psychomotor profile of a number of second generation AHs using a battery of 
sensitive, valid and reliable tests.
In the previous two experiments, the suppressive effects of fexofenadine at doses up to 
18Omg were compared with loratadine, promethazine and placebo. Fexofenadine was 
shown to cause significant suppression of the histamine-induced weal and flare reaction 
when compared to placebo.
The main objectives of this experiment were therefore to assess whether within these 
doses, fexofenadine has any disruptive effects on aspects of cognitive and psychomotor 
function in comparison to placebo, loratadine and promethazine, an antihistamine known 
to produce psychomotor and cognitive impairments.
For statistical purposes, the null hypothesis 'for the study was that fexofenadine, 
loratadine or promethazine would not have any effects on cognitive and psychomotor 
function in comparison to placebo.
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5.3.2 Methods & Measures
Subjects
Twenty four healthy male and female volunteers, aged 19 to 58 years (mean 32.6 years) 
participated in this study. Subjects were required to sleep at the test centre overnight. 
Subjects were instructed to avoid late nights and to go to bed at their usual bedtime 
(minimum of 6-8 hours sleep). All subjects completed the study and there were no 
serious adverse events.
Design
The study was a randomised, double blind, placebo-controlled, 6 way crossover study in 
a group of healthy volunteers, in which each volunteer acted as their own control. The 
treatment sequence was balanced for residual effects using a Latin square design.
Drugs
The drugs under investigation were fexofenadine 80mg, 120mg and 18Omg, loratadine 
lOmg, promethazine 3Omg (as a verum) and placebo. Each treatment day was separated 
by a washout period of four days or more.
Procedure
Following informed consent, medical history and GP approval, all subjects underwent 
a medical examination. Subject to fulfilling the inclusion/exclusion criteria, eligible 
volunteers were entered into the study. Subjects were familiarised with the study 
procedures and fully trained on the test battery to preclude any learning effects (Parkin et 
al 1997). Each volunteer received active medication or placebo as a single oral dose at 
0830 hours.
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On each of the test days, subjects attended the study centre where a breath alcohol 
reading was taken. Subjects were then given an actigraph to be worn on the non­
dominant wrist for 24 hours. Following pre-treatment baseline recording, treatments 
were administered and further testing carried out at 1.5, 3, 6, 9, 12 and 24 hours post­
dose.
The use of alcohol, nicotine and products containing caffeine were prohibited on test 
days. Food consumption was strictly controlled and only allowed at the specified times. 
Subjects were prevented from napping during the day.
Assessments of adverse events and concomitant medication were made at each visit.
Test Battery
The test battery consisted of Critical Flicker Fusion (CFF), Choice Reaction Time (CRT), 
Actigraphy (ACT) and Line Analogue Rating Scales for Sedation (LARS). Full 
description of these tests is provided in chapter 4.
Statistical Analysis
The data were analysed as changes from baseline using a 2 factor repeated measures 
analysis of variance (ANOVA). The factors were treatment (6 levels: fexofenadine 
80mg, fexofenadine 120mg, fexofenadine 180mg, promethazine 3Omg, loratadine lOmg 
and placebo) and time (6 levels: 1.5, 3, 6,9, 12 and 24 hours). Post hoc pairwise 
comparisons between the treatment means were performed using Newman-Keuls tests. 
All the statistical tests were performed two tailed at the 5% level of significance.
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5.3.3 Results
Analysis of the changes from baseline showed significant main effects of treatment (F(5, 
85) = 3.51; p< 0.01) and time of testing (F(5, 85) = 2.69; p<0.05). The results for 
promethazine 3 Omg showed a very different pattern from all other treatment regimens,- 
with a marked decrease in the CFF threshold, throughout the 24 hour period, the lowest 
mean thresholds being from 3-9 hours post medication.
Post hoc analysis revealed that overall, promethazine scores were significantly different 
from placebo, fexofenadine 80mg and loratadine lOmg.
Examination of the results of the drug x interaction showed a consistent reduction in the 
CFF thieshold following the administration of promethazine at 3, 6, 9 and 12 hours when 
compared to placebo (p<0.05). Promethazine was also significantly (p < 0.05) different 
from fexofenadine 8Omg at 3, 6, 9 and 12 hours post medication, from fexofenadine 
120mg and loratadine lOmg at 3, 6 and 9 hours and from fexofenadine 18Omg at 3 and 9 
hours post medication. None of the other treatments could be distinguished from 
placebo, (figure 5.7).
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Figure 5.7: CFF (Hz): Mean change from baseline with all treatments
* = p<0.05 when compared to placebo
(Fexo = Fexofenadine, Lor = Loratadine, Prom = Promethazine)
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-2 .5
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Fexo 80mg ^ F e x o  120mg ^ F e x o  180mg 
LorlOmg -^Prom 30mg
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CRT
The results for recognition reaction time (RRT, a component of the total reaction time 
task), showed no significant main effects of treatment, but there was a significant effect 
of time (F(5, 100) = 11.05; p<0.001) with an increase in reaction time from 1 to 9 hours 
following the administration of promethazine.
Pairwise comparisons revealed that promethazine 3 Omg was significantly different from 
placebo at 3 and 6 hours (p<0.05), and from fexofenadine 80mg, 120mg and 180mg and 
loratadine lOmg at 3 hours, with promethazine having higher mean increases and thus 
slower reaction times, than the other treatment regimens.
MRT was similar with all drugs.
The results for total reaction time (TRT) showed that there was a significant time effect 
(F(5,100)=7.13, p<0.001) but no significant treatment effect. The post hoc pairwise 
comparisons did not show any significant differences between the six drugs at any one 
time point, however the pattern of results show that there was a trend for promethazine to 
slow reaction times at 3 and 6 hours post dose.
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Figure 5.8: RRT: Mean change from baseline for all treatments
* = p<0.05 when compared to placebo
(Fexo = Fexofenadine, Lor = Loratadine, Prom = Promethazine)
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LARS
No main effects of drug were evident in the subjective ratings of sedation (LARS), but 
there were significant effects of time (F(5, 95) = 5.70; p<0.001) and the treatment x time 
interaction was significant (F(25, 475)=192; p<0.01). Ratings of sedation were lower 
with promethazine than with placebo at 12 hours post dose, and this difference was 
significant at 24 hours post dose (p<0.05), (fig 5.9).
Figure 5.9: LARS: Mean change from baseline for all treatments
* = p<0.05 when compared to placebo
(Fexo = Fexofenadine, Lor = Loratadine, Prom = Promethazine)
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Actigraphy
An analysis of percentage sleep measured by actigraphy revealed a significant increase in 
the percentage of sleep with promethazine across the study period as compared to all 
other treatments (F(5,70)= 2.59; (p< 0.05). There was a significant increase in the 
percentage of epochs staged as ‘sleep’ during the day (F(5,75)= 4.46; p< 0.002) with 
promethazine, however there was no significant difference in the amount of sleep during 
the night. There was a highly significant main effect of time which, undoubtedly 
represented the normal circadian and ultradian rhythms.
Figure 5.10: Percent daytime ‘sleep-like’ activity: Mean change from baseline 
for all treatments
* = p<0.05 when compared to placebo
(Fexo = Fexofenadine, Lor = Loratadine, Prom = Promethazine)
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5.3.4 Discussion o f Results
The present study, which was performed in healthy volunteers under double blind, 
crossover conditions, was designed to evaluate the central effects of three doses of 
fexofenadine given as single oral doses.
Fexofenadine, at all three doses tested, was not significantly different from placebo in its 
effects on psychomotor performance and cognitive flinction. This is in contrast to the 
positive control, promethazine, which produced significant impairment of cognitive and 
psychomotor function as measured by CFF and CRT, for up to 12 hours after drug 
intake. Loratadine included in this study as a negative internal control and as a 
comparator, is a non-sedating antihistamine and the present results are in agreement with 
previous studies (Belaich et al 1990, Mann et al 1989), demonstrating the lack of CNS 
effects following a lOmg dose of this drug.
These present results are commensurate with the findings of Vermeeren et al (1998), in 
which they report a lack of CNS effects with fexofenadine at doses up to 240mg on tests 
of choice reaction time and sustained attention. However, the authors also report an 
impairment on a critical tracking task with fexofenadine. This observed effect is not 
consistent, as it appears following single daily doses of 120mg and 240mg but not after a 
divided dose of 120mg b.i.d.
Vermeeren et al (1998) also claim to have evidence of the activating effects of 
fexofenadine in that the administration of the higher divided dose reduced the mean 
SDLP on day 4 compared to placebo and that the combined effects of alcohol and the 
higher divided dose was significantly less impairing than that of alcohol alone. These 
present data from our study are contrary to the findings of Vermeeren et al (1998) as CFF 
thresholds, an objective measure of CNS arousal, show a non significant but dose related 
trend in the opposite direction to that needed to support notions of intrinsic activation.
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Present RRT scores also show no evidence of any dose related activation and thus, 
speculations regarding the possible activating properties of fexofenadine are not 
confirmed in this study.
Promethazine, the positive internal control, significantly reduced the CFF threshold by
2.5 Hz up to 9 hours post dose and also increased the recognition reaction time by 40 
msec at 3 and 6 hours post dose when compared to placebo. These impairments are 
greater than those seen with 5Omg % of alcohol (Kerr et al 1993) which is the legal limit 
of alcohol in many countries.
Promethazine has previously been shown to cause a reduction in daytime behavioural 
activity for up to six hours post dose (Stanley et al 1997). Periods of very low 
behavioural activity are scored as sleep by the ACTI0N3 algorithm, so a reduction in 
activity is mirrored in an increase in ‘sleep like’ behaviour. In this, and our previous 
study (Stanley et al 1997), we have demonstrated that reduced behavioural activity, here 
expressed as an increase in daytime ‘sleep like’ behaviour, is reflected as a reduction in 
psychomotor performance and can thus be regarded as a measure of sedation.
There were no subjective reports of sedation as measured by LARS with any of the 
treatments including promethazine. Ratings of sedation were lower with promethazine 
than with placebo at 24 hours post dose and given the overall pattern of results, this is 
likely to be a type I error.
It is of concern that a 3Omg dose of promethazine, reduced the CFF threshold by 2.5Hz 
up to 12 hours post dose and yet subjects reported themselves as being mentally alert 
thioughout the 24 hour test period. This implies that although subjects feel alert, they are 
objectively compromised as far as their ability to process information is concerned. Such 
discrepancies have important implications for the use of AHs in practice where patients 
are warned not to operate machinery or drive if they feel sedated (Hindmarch 1999).
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The aim of this study was to investigate the effects of fexofenadine on a widely validated 
test battery known to be sensitive to the effects of psychoactive drugs on cognitive and 
psychomotor performance. The general conclusion that can be drawn from the present 
study is that there were no subjective or objective effects on psychomotor performance 
following the administration of fexofenadine and thus allow the conclusion that 
fexofenadine at doses up to 18Omg is free from disruptive effects on the central nervous 
system.
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5.4 Experiment 4: An investigation into the effects of cetirizine and loratadine
on cognitive function and psychomotor performance in healthy volunteers
5.4.1 Introduction & Rationale
In the previous experiment, the cognitive and psychomotor effects of various doses of 
fexofenadine were compared to loratadine, promethazine and placebo in a group of 
healthy volunteers. In order to extend our investigation into the effects of other second 
generation AHs, the effects of various doses of cetirizine were compared with loratadine, 
promethazine (as a verum) and placebo.
The main objectives of this experiment were to determine if in healthy non-atopic 
volunteers, cetirizine (2.5mg, 5mg & lOmg) has any impact on cognitive and 
psychomotor frinction and how the psychomotor profile of cetirizine compares to that 
loratadine, promethazine and placebo.
For statistical purposes, the null hypothesis 'for the study was that cetirizine, loratadine 
or promethazine would not have any effects on psychomotor function as assessed by a 
battery of valid, sensitive and reliable tests, in comparison to placebo.
5.4.2 Methods & Measures
Subjects
Twenty four healthy non-atopic volunteers (16 female, 8 male) aged between 18 and 58 
years (mean age of 34.7yrs) participated in this study. Subjects were instructed to avoid 
late-nights and to go to bed at their usual bedtime (minimum of 6-8 hours sleep). All 
subjects completed the study and there were no serious adverse events.
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Design
The study was a randomised, double blind, placebo-controlled, 8 way crossover study in 
a group of healthy volunteers, in which each volunteer acted as their own control. The 
treatment sequence was balanced for residual effects using a Latin square design.
Drugs
The drugs under investigation were cetirizine 2.5mg, 5mg & lOmg, loratadine lOmg, 
20mg & 40mg, promethazine 25mg (as a verum) and placebo. Each treatment day was 
separated by a washout period of six days or more.
Procedure
Following informed consent, medical history and GP approval, all subjects underwent a 
medical examination. Subject to fiilfilling the inclusion/exclusion criteria, eligible 
volunteers were entered into the study. Subjects were familiarised with the study 
procedures and fully trained on the test battery to preclude any learning effects (Parkin et 
al 1997). Each volunteer received active medication or placebo as a single oral dose at 
0900 hours.
On each of the test days, subjects attended the study centre where a breath alcohol 
reading was taken. Pre-treatment baseline recordings were made on each of the 
psychometrics (described below) after which medications were administered and further 
testing carried out at 1.5, 3 and 6 hours post-dose.
The use of alcohol and nicotine were forbidden and products containing caffeine were 
prohibited on test days. Food consumption was strictly controlled and only allowed at 
the specified times.
Assessments of adverse events and concomitant medication were made at each visit.
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Test Battery
The test battery consisted of Critical Flicker Fusion (CFF), Choice Reaction Time (CRT), 
Compensatory Tracking Task (CTT) and Line Analogue Rating Scales for Sedation 
(LARS).
Statistical Analysis
The data were analysed as changes from baseline using a 2 way repeated measures 
analysis of variance (ANOVA). The factors were treatment (8 levels: cetirizine 2.5mg, 
5mg & lOmg, loratadine lOmg, 20mg, 40mg, promethazine 25mg & placebo) and time 
(3 levels: 1.5, 3 and 6 hours). Post hoc pairwise comparisons between the treatment 
means were performed using Newman-Keuls tests. All the statistical tests were 
performed two tailed at the 5% level of significance.
5.43 Results
The mean response data are presented in tables 11-13 of Appendix 1.
CFF
Analysis of the results showed a significant treatment effect (F(7,161)=2.309, p<0.029) 
and a highly significant time effect (F(2,46)= 14.186, p< 0.001), although the treatment x 
time interaction was not significant. Pairwise comparisons, using Newman-Keuls, 
between treatment means showed that promethazine 25 mg was significantly (p<0.05) 
different from cetirizine 2.5mg, cetirizine lOmg, loratadine lOmg and loratadine 40mg, 
there being a significantly greater reduction in CFF on promethazine. The other 
comparisons did not reach significance at the 5% level (p=0.07 for placebo & cetirizine 
5mg; p=0.069 for loratadine 20mg). Examination of the treatment comparisons at each
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time point showed that promethazine 25mg had a significantly greater reduction than all 
other treatments at 3 and 6 hours post dose, (fig 5.11).
Figure 5.11: Critical Flicker Fusion (Hz): Mean change from baseline for all 
treatments
* ~ p<0.05 when compared to placebo
+ = p<0.05 when compared cetirizine & loratadine at all doses
(Cet = Cetirizine, Lor = Loratadine, Prom = Promethazine)
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CRT
Analysis of the total reaction time (TRT) component of the CRT task revealed a 
significant treatment effect [F(7,l 19)=3.21, p=0.003]. Pairwise comparisons, using 
Newman Keuls, between treatment means showed that promethazine was significantly 
different from placebo, cetirizine 2.5 and 10 mg, and loratadine 10 and 20 mg at three 
hours post drug administration, (figure 5.12). This analysis was based on 18 subjects with 
complete data as a few problems were encountered with the test equipment, which 
consequently led to some data loss.
Analysis of the results for the recognition reaction time component of the CRT task 
failed to reach significance at the 5% level [F(7,l 19)= 1.99, p=0.061], although at 3 hours 
post drug administration results were suggestive of a main treatment effect with 
loratadine 20 & 40 mg causing large increases in reaction time, a result also reflected in 
the total reaction time means.
There were no significant differences on motor reaction time component between any of 
the treatments.
199
Figure 5.12: Total Reaction Time (msec): 3 hours post-dose with all
treatments
* = p<0.05 when compared to placebo 
+ = p<0.05 when compared to verum
(Cet = Cetirizine, Lor = Loratadine, Prom = Promethazine)
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CTT
For CTT, analysis of the results showed that there were no significant treatment, time or 
treatment x time interaction on either tracking error or peripheral reaction time.
LARS
The average of the two scores for ‘tired’ and ‘drowsy’ of the LARS was used to given an 
overall score of subjective sedation. Analysis of the results showed a significant 
treatment effect [F(7,161)= 3.530, p=0.001] but no significant time or treatment x time 
interaction. Pairwise comparisons, using Newman Keuls, between treatment means 
showed that promethazine 25 mg was significantly (p<0.05) different from all the other 
seven treatments, there being a greater increase in sedation with promethazine.
Neither of the three doses of cetirizine nor loratadine were associated with subjective 
reports of sedation at any point throughout the day.
Promethazine caused significantly greater increase in subjective reports of sedation when 
compared to placebo at all time points (p<0.05), (figure 5.13).
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Figure 5,13: Line Analogue Rating Scales for Sedation (mm): Mean change 
from baseline for all treatments 
* = p<0.05 when compared to placebo
(Cet = Cetirizine, Lor = Loratadine, Prom = Promethazine)
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5.4.4 Discussion of Results
Cetirizine, at all three doses tested, was not significantly different from placebo in its 
effects on psychomotor performance and cognitive function. This is in contrast to the 
positive control, promethazine, which produced significant impairment of cognitive and 
psychomotor function as measured by CFF, CRT and LARS, for up to 6 hours after drug 
intake. Promethazine, the positive internal control, significantly reduced the CFF 
threshold by 2.30Hz up to 6 hours post dose when compared to placebo 
These present results are commensurate with previous published literature in which 
cetirizine has been shown to be free of CNS adverse effects at doses up to 20 mg 
(Schweitzer et al 1994, Tharion et al 1994, Simons et al 1995, Simons et al 1996). At 
therapeutic doses (5-20 mg), cetirizine did not produce daytime sedation, as indicated by 
its lack of effect in the MSLT (Seidel et al 1987, Seidel et al 1990). Cetirizine did not 
cause any significant impairment of psychomotor performance, as assessed by CFF, 
simple reaction time, finger tapping and Stroop word tests (Gengo et al 1987). In 36 
healthy volunteers included in a placebo-controlled double-blind cross-over trial, 
cetirizine lOmg did not significantly affect psychomotor performance as assessed by 5 
objective psychometric tests or subjective assessments of mood and health, and the 
concomitant administration of cetirizine lOmg and alcohol did not significantly 
potentiate the impairment occurring after alcohol alone (Doms et al 1988).
A number of studies have also reported subjective and objective evidence of sedation 
with high doses of cetirizine and evidence exists to support the notion that cetirizine does 
possess sedative activity when it is administered at doses higher than those recommended 
by the manufacturer (Gengo & Gabos 1987, Riedel et al 1990a).
Loratadine included in this study as a comparator, is a non-sedating antihistamine and the 
present results are in agreement with previous research demonstrating a general lack of
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detrimental CNS effects following a 10 mg dose of this drug (Bradley & Nicholson 1987, 
Roth et al 1987).
Administration of higher doses of loratadine has been reported to cause sedation (Bradley 
& Nicholson 1987, O'Hanlon 1988, Riedel et al 1990b, Roth et al 1987) and the results 
from this study support these findings. Following the administration of the 40mg dose of 
loratadine in this study, impairments were noted on the total reaction time component of 
the CRT task at 3 hours after drug intake. The increase in reaction time with loratadine 
at its highest dose closely resembled the impairments evident with promethazine, 
although it failed to reach statistical significance at the 5% level.
A review of the effects of loratadine at doses ranging from 10-40 mg, on cognitive 
function and psychomotor performance (Hindmarch & Shamsi 1999), clearly 
demonstrated that loratadine was free of CNS adverse effects when administered at its 
recommended therapeutic dose of 10 mg daily. However when the dose was increased, 
reports of sedation measured both objectively and subjectively increased accordingly. As 
a whole, loratadine was investigated in 8 studies in which 16 different psychometrics 
were used. Impairments were found with 11 of which 8 were associated with the 20 and 
40mg dose.
It would therefore appear that loratadine at doses above that recommended by the 
manufacturer, does influence psychomotor function in the CNS even if this action is 
difficult to discern. What the tests show in this trial as well as those observed in other 
published studies is that some blood-brain barrier passage is occurring with loratadine. 
While the doses which appear to be causing the sedation are higher than those 
recommended by the manufacturer, a powerful reduction in the histamine induced weal 
and flare response is only achieved with a 40mg dose of loratadine which in terms of
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antihistaminic efficacy has been shown to correspond to a lOmg dose of cetirizine 
(Rihoux 1990).
The present study, which was performed in 24 healthy volunteers under double blind, 
crossover conditions, was aimed at evaluating and comparing the central effects of thiee 
doses of cetirizine with three doses of loratadine given as single oral doses. A positive 
control was included in the study to ensure the validity of the methods employed. The 
choice of the doses was based on previous clinical pharmacological studies, which have 
shown cetirizine 10 mg to be a more potent inhibitor of histamine induced skin reactions 
than loratadine 10 mg (Rihoux et al 1990).
The subjective evaluation of the central effects did not show any significant modification 
with either cetirizine or loratadine when compared with placebo. With respect to the 
objective measures, all the measurements were unchanged after cetirizine intake 
irrespective of the dose and time after administration, a result that is in agreement with 
previous studies. In addition, there were no significant modifications in the objective 
tests following the administration of the lower doses of loratadine.
The general conclusion that can be drawn from the present study is that there were no 
subjective or objective effects on psychomotor performance following the administration 
of cetirizine. This is in contrast to the effects of older, traditional AHs on various tests of 
psychomotor and cognitive function (Alford et al 1989, Clarke & Nicholson 1978, Cohen 
et al 1985, Gengo et al 1987, Hindmarch & Shamsi 1999, Seidel et al 1987).
Findings from this study allow the conclusion that cetirizine at its recommended daily 
dose of lOmg is free from disruptive effects on the CNS and should therefore prove 
valuable in the treatment of various allergic disorders in patients who wish to continue 
with their everyday activities without experiencing decrements in their psychomotor and 
cognitive abilities.
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5.5 Experiment 5: The central effects of three doses of ebastine: a double blind 
placebo and verum controlled study in healthy volunteers
5.5.1 Introduction & Rationale
Further to the investigation of the effects of fexofenadine, loratadine and cetirizine on 
cognitive and psychomotor function, this study was undertalcen to assess the CNS profile 
of various doses of yet another second-generation antihistamine in healthy volunteers. 
Ebastine is a selective and long acting Hi receptor antagonist, which penetrates the brain 
poorly, thus allowing an effective blockade of peripheral Hi receptors without CNS side 
effects when administered within its ‘dose window’ (Wiseman & Faulds 1996).
This study was therefore designed to detennine if in healthy non-atopic volunteers, 
ebastine (lOmg, 20mg & 40mg) has any impact on cognitive and psychomotor flmction 
and how the psychomotor profile of ebastine compares to that terfenadine, triprolidine (as 
a verum) and placebo.
For statistical purposes, the null hypothesis Tor the study was that ebastine, terfenadine, 
or triprolidine would not have any effects on psychomotor function as assessed by a 
battery of valid, sensitive and reliable tests, in comparison to placebo.
5.5.2 Methods & Measures
Subjects
Twelve healthy non-atopic volunteers (6 female, 6 male) aged between 18 and 55 yeais 
(mean age of 36.2yrs) participated in this study. Subjects were instructed to avoid late- 
nights and to go to bed at their usual bedtime (minimum of 6-8 hours sleep). All subjects 
completed the study and there were no serious adverse events.
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Design
The study was a randomised, double blind, placebo-controlled, 6 way crossover study in 
a group of healthy volunteers, in which each volunteer acted as their own control. The 
treatment sequence was balanced for residual effects using a Latin square design.
Drugs
The drugs under investigation were ebastine lOmg, 20mg & 40mg, terfenadine 60mg, 
triprolidine 5mg (as a verum) and placebo. Each treatment day was separated by a 
washout period of seven days or more.
Procedure
Following informed consent, medical history and GP approval, all subjects underwent a 
medical examination. Subject to fulfilling the inclusion/exclusion criteria, eligible 
volunteers were entered into the study. Subjects were familiarised with the study 
procedures and fully trained on the test battery to preclude any learning effects (Parkin et 
al 1997). Each volunteer received active medication or placebo as a single oral dose at 
0900 hours.
On each of the test days, subjects attended the study centre where a breath alcohol 
reading was taken. Pre-treatment baseline recordings were made on each of the 
psychometrics (described below) after which medications were administered and frirther 
testing carried out at 1.5, 3.5 and 6.5 hours post-dose. In addition to these testing times, 
a number of tests (CFF, CRT & LARS) were also performed at 0.5 hours post drug 
administration.
The use of concomitant medication was discouraged but allowed at the discretion of the 
physician. The use of alcohol and nicotine were forbidden and products containing
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caffeine were prohibited on test days. Food consumption was strictly controlled and only 
allowed at the specified times.
Assessments of adverse events and concomitant medication were made at each visit.
Test Battery
The test battery consisted of Critical Flicker Fusion (CFF), Choice Reaction Time (CRT), 
Compensatory Tracking Task (CTT), Sternberg Memory Scanning Task (SMST), and 
Line Analogue Rating Scales for Sedation (LARS).
Statistical Analysis
The data were analysed as changes from baseline using a 2 way repeated measures 
analysis of variance (ANOVA). The factors were treatment (6 levels: ebastine lOmg, 
20mg & 40mg, terfenadine 60mg, triprolidine 5mg & placebo) and time (4 levels: 0.5,
1.5, 3.5 and 6.5 hours). Post hoc pairwise comparisons between the treatment means 
were performed using Newman-Keuls tests. All the statistical tests were performed two 
tailed at the 5% level of significance.
5.5.5 Results
The mean response data are presented in tables 14-19 of Appendix 1.
CFF
Analysis of the results showed a significant treatment effect (F(5,85)=3.51, p<0.01). 
Pairwise comparisons, using Newman-Keuls, between treatment means showed that 
triprolidine 5 mg was significantly (p<0.05) different to placebo at 1.5 hours post drug 
administration. Triprolidine was also shown to cause significant decrements in the CFF 
thresholds at 1.5 and 3.5 hours post-dose when compared to its own baseline (p<0.05).
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CFF scores were not affected with any dose of ebastine or terfenadine at any point during 
the day (figure 5.14).
Figure 5.14: Critical Flicker Fusion (Hz) -  Mean change from baseline following 
the administration of ebastine, terfenadine, triprolidine and placebo 
* = p<0.05 when compared to placebo 
+ = p<0.05 when compared to baselineHz1
0.5
0
-0 .5
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Time (hrs)
^ P la ceb o  Ebastine lOmg Ebastine 20mg
•e-Ebastine 40mg -^Terfenadine 60mg -^Triprolidine 5mg
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CRT
Analysis of the total reaction time (TRT) component of the CRT task revealed no 
treatment related effects. However, significant treatment effect
[F(5,85)=3.21, p<0.01] were evident with the recognition reaction time component of the 
CRT.
Pairwise comparisons, using Newman Keuls, between treatment means showed that 
ebastine lOmg caused a significant increase in recognition reaction time at 1.5 hours 
post-dose (p<0.05) in comparison to placebo (figure 5.15).
Compared to baseline, ebastine 20mg caused a significant increase in recognition 
reaction time at 6.5 hours. Increasing the dose of ebastine to 40mg resulted in a dose 
related increase in RRT at 3.5 and 6.5 hours post-dose when compared to baseline.
There were no significant differences in the motor reaction time component of the CRT 
between any of the treatments.
Although the TRT results failed to achieve statistical significance at the 5% level 
(F(5,87)=l .99, p=0.061), results were suggestive of a main treatment effect with ebastine 
40mg causing large increases in reaction time, a result also reflected in the total reaction 
time means (figure 5.16).
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Figure 5.15; Recognition Reaction Time (msec) -  Mean changes from baseline
following the administration of ebastine, terfenadine, triprolidine and 
placebo
* = p<0.05 when compared to placebo 
+ = p<0.05 when compare to baseline
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Figure 5.16; Total Reaction Time (msec): Mean change from baseline following 
the administration of ebastine, terfenadine, triprolidine and placebo
msec
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CTT
Analysis of the results demonstrated significant treatment effects for both the peripheral 
reaction time (RT) and the tracking accuracy measure. Triprolidine showed a statistically 
significant increase in reaction time at 1.5 hours post-dose when compared to placebo 
(figure 5.17). Similarly, the highest dose of ebastine (40mg) also resulted in significant 
increases in reaction time at 1.5 and 6.5 hours post-dose.
When compared to baseline, ebastine 20mg increased the reaction time at 6.5 hours post­
dose (p<0.05). The administration of terfenadine did not affect either the reaction time or 
the tracking accuracy at any time point during the day.
The tracking accuracy was not affected by triprolidine or terfenadine. However 
compared to placebo, the highest dose of ebastine (40mg) was shown to significantly 
impair tracking accuracy at 1.5 and 6.5 hours post drug administration (figure 5.18). The 
impairment caused by the 40mg ebastine was also significantly greater than its baseline 
at 1.5 hours post-dose (p<0.05).
The lower doses of ebastine did not demonstrate any effects on this parameter.
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Figure 5.17: Critical Traeldng Task- Reaction time (msec) 
Mean change from baseline for all treatments 
* = p<0.05 when compared to placebo 
+ = p<0.05 when compared to baseline
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Figure 5.18: Critical Traeldng Task -  Traeldng Accuracy 
Mean change from baseline for all treatments 
* = p<0.05 when compared to placebo 
+ = p<0.05 when compared to baseline
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LARS
The average of the thiee scores for ‘tired’, ‘drowsy’ and ‘alert’ of the LARS was used to 
given an overall score of subjective sedation. Analysis of the results showed a 
significant treatment effect with pairwise comparisons demonstrating that triprolidine 
significantly increased the subjective reports of sedation at 1.5 hours post drug 
administration when compared to placebo (p<0.05). Subjective reports of sedation were 
not affected with any of the three doses of ebastine or terfenadine at any point throughout 
the day (figure 5.19).
Figure 5.19: Line Analogue Rating Scales for Sedation (mm) -  Mean change from 
baseline for all treatments 
* = p<0.05 when compared to placebo
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5.5.4 Discussion o f Results
The investigation of the effects of ebastine at doses up to 40mg revealed interesting 
results.
While completely free of CNS impairing effects at the lOmg dose, ebastine caused 
significant impairment of cognitive and psychomotor function when the doses were 
increased. The detrimental effects produced by the higher dose of ebastine were very 
similar to results obtained with the positive control, triprolidine.
Triprolidine produced significant impairment of cognitive and psychomotor function as 
measured by CFF, CRT, SCTT and LARS for up to 6.5 hours after drug intalce. 
Terfenadine, a second-generation non-seating antihistamine, was included in the study 
design as a comparator. Findings with terfenadine are in agreement with previous 
literature, in which it has been demonstrated that terfenadine is free of CNS adverse 
effects when the dose is not excessively increased (Gaillard et al 1988, Kerr et al 1993, 
Tharion et al 1994, Witek et al 1995).
With regards to the findings with ebastine, these present results are commensurate with 
previous published literature in which ebastine has been shown to be free of CNS adverse 
effects at doses up to 20mg (Azcona et al 1992, Brooldiuis et al 1993, Hopes et al 1992, 
Mattila et al 1992, Vincent et al 1988a). However at doses above the therapeutic range 
(50-90 mg), ebastine has been shown to cause sedation and impairment of performance 
(Vincent et al 1988a, Barbanoj 1988). The drug is clearly not sedative within its ‘dose 
window’, however it appears to be capable, at higher doses, of inducing a decrement in 
performance. This is evidenced by the increase in reaction time component of the CRT 
together with increases in reaction time component of the tracking test as well as 
reducing tracking accuracy.
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It is also evident that the CNS impairing effects were still present at 6.5 hours post-dose. 
This has important implications for the use of ebastine as it has been shown that the 
maximal anti-histaminic action of ebastine occurs between 8 to 12 hours post-dose 
(Wiseman & Faulds 1996).
The present study, which was performed in 12 healthy volunteers under double-blind, 
crossover conditions, was aimed at evaluating and comparing the central effects of three 
doses of ebastine with triprolidine, a sedative antihistamine Icnown to produce cognitive 
and psychomotor impairments (Betts et al 1984, Brookhuis et al 1993, Riedel et al 
1990a).
Although this study only uses twelve subjects, the power was sufficient to show 
triprolidine acting as a positive internal control and ebastine having an effect on various 
tests of cognitive and psychomotor performance.
Given the importance of using AHs that are without unwanted CNS effects, a follow-up 
experiment (experiment 6) was designed to investigate the effects of repeated dosing of 
ebastine on various aspects of cognitive and psychomotor function.
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5.6 Experiment 6: The effects of single and repeated administration of ebastine 
on cognition and psychomotor performance in comparison to triprolidine 
and placebo in healthy volunteers
5.6.1 Introduction & Ration ale
The investigation of the central effects of single doses of ebastine in the previous 
experiment clearly showed that at higher doses (40mg), ebastine is associated with 
significant impairments of cognitive and psychomotor functioning.
This experiment was therefore designed to investigate the effects of repeated doses of 
ebastine (10-30mg) on various aspects of cognitive and psychomotor performance in 
healthy volunteers. Triprolidine lOmg (sustained release formulation) was included in 
the study as positive internal control.
For statistical purposes, the null hypothesis 'for the study was that neither ebastine, nor 
triprolidine would have any effects on cognitive and psychomotor function as assessed 
by a battery of valid, sensitive and reliable tests, in comparison to placebo.
5.6.2 Methods & Measures
Subjects
Ten healthy non-atopic female volunteers aged between 22 and 39 years (mean age of 
27.3yrs) participated in this study. Subjects were requested to avoid late-nights and 
refrain from consuming alcohol the night before each study period.
All subjects completed the study and there were no serious adverse events.
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Design
The study was a randomised, double blind, placebo-controlled, 5 way crossover, repeated 
dosing study in a group of healthy volunteers, in which each volunteer acted as their own 
control. The treatment sequence was balanced for residual effects using a Latin square 
design. Each treatment period comprised of five days in which testing was performed on 
days 1 and 5.
Drugs
The drugs under investigation were ebastine lOmg, 20mg & 30mg, triprolidine lOmg 
(sustained release formulation as a verum) and placebo. Each treatment day was 
separated by a washout period of seven days or more.
Procedure
Following informed consent, medical history and GP approval, all subjects underwent a 
medical examination. Subject to fulfilling the inclusion/exclusion criteria, eligible 
volunteers were entered into the study. Subjects were familiarised with the study 
procedures and fiilly trained on the test battery to preclude any learning effects (Parkin et 
al 1997).
On each of the test days, subjects attended the study centre where a breath alcohol 
reading was taken. Each test day began with pre-treatment baseline assessments on the 
psychometric (described below) after which the first treatment dose was administered. 
Performance using a full test battery was assessed at 2,4, and 8 hours after drug 
administration on day 1, (D1H2, H4 & H8). In addition to these testing times, a number 
of tests (CFF, CRT & LARS) were also performed at one hour post drug administration 
(DlHl).
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On day 5, the same tests were performed before the administration of the treatments 
(D5H0) and at the same time intervals thereafter (D5H1, H2, H4 & H8). A Leeds Sleep 
Evaluation Questionnaire (LSEQ) was completed on the morning of day 1 (DIHO), 2 
(D2H0) and 6 (D6H0). Medication was administered under supervision at the same time 
on days 2, 3 and 4.
Reports of all adverse events and use of concomitant medication were recorded at each 
visit. Caffeine, nicotine and alcohol were forbidden on study days. Subjects were 
prevented from napping during the day by members of staff and were encouraged to keep 
themselves occupied by engaging in group activities.
Test Battery
The test battery consisted of Critical Flicker Fusion (CFF), Choice Reaction Time (CRT), 
Compensatory Tracking Task (CTT), Sternberg Memory Scanning Task (SMST), Line 
Analogue Rating Scales for Sedation (LARS) and the Leeds Sleep Evaluation 
Questionnaire (LSEQ).
Statistical Analysis
The data were analysed as changes from baseline using a three way repeated measures 
analysis of variance (ANOVA). The factors were treatment (5 levels: ebastine lOmg, 
20mg & 30mg, triprolidine lOmg & placebo, time (4 levels: 1,2,4 and 8 hours) and day 
(2 levels: 1 & 5). Post hoc pairwise comparisons between the treatment means were 
performed using 2 tailed 95% confidence intervals. All the statistical tests were 
performed two tailed at the 5% level of significance.
The assumption of normality of data was examined by probability plots and found to be 
acceptable.
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5.6.3 Results
The mean response data are presented in tables 20-27 of Appendix 1.
CFF
Analysis of results did not reveal any significant placebo versus treatment differences on 
either day lo r  5. Ho’wever a decrement in CFF threshold was seen with all treatments on 
both days, reflecting a general lowering of alertness during the course of the day (figure 
5.20).
Figure 5.20: Critical Flicker Fusion (Hz) -  Mean change from baseline (HO) on 
day 1 following the administration of ebastine, triprolidine and 
placebo
(Eba = Ebastine, Tri = Triprolidine)
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Figure 5.21; CFF (Hz): Mean change from baseline (DIHO) on day 5 following 
the administration of ebastine, triprolidine and placebo
(Eba = Ebastine, Tri = Triprolidine)
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CRT
Analysis of the CRT results did not demonstrate any significant treatment, time or 
treatment x time interaction on either the recognition, motor or total reaction time. These 
findings were not even suggestive of a particular trend and are therefore not discussed 
further.
CTT
Analysis of the reaction time (RT) component of the SCTT revealed a significant 
treatment effect. Triprolidine lOmg produced an overall increase of the peripheral 
reaction time, the difference with placebo reaching statistical significance on day 1, 8 
hours after drug intake (p<0.05).
None of the other treatments however were found to be significantly different from 
placebo at any time point, (figure 5.22).
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Figure 5.22; Compensatory Tracldng Task -Reaction Time (msec) 
Mean change from baseline (HO) on day 1 following the 
administration of ebastine, triprolidine and placebo 
* = p<0.05 when compared to placebo
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Compensatory Tracking Task (CTT) -  Tracking Accuracy
In line with the above findings, the mean tracking accuracy scores (RMS), a different 
component of the SCTT, were significantly impaired at 8 hours following the 
administration of triprolidine on day 1 (p<0.05), (figure 5.23). Further testing on day 5 
did not detect any significant placebo versus treatment differences on this task.
Figure 5.23: Compensatory Tracking Task -  Tracldng Accuracy
Mean change from baseline (HO) on day 1 following the 
administration of ebastine, triprolidine and placebo 
* = p<0.05 when compared to placebo
(Eba = ebastine, Tri = triprolidine)
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Sternberg Memory Scanning Task (SMST)
Significant treatment differences were evident with the SMST. Triprolidine 10 mg 
produced a clear decrement (increase in reaction time) on this measure of short term- 
memory (fig 24), which was significantly different to placebo at 4 and 8 hours after drug 
administration (p<0.05). By day 5, the mean scores for all treatments were closely 
ranged together and no statistically significant differences were evident.
Figure 5.24: Sternberg Memory Scanning Task -  Reaction time (msec)
Mean change from baseline (HO) on day 1 following the 
administration of ebastine, triprolidine and placebo 
* = p<0.05 when compare to placebo
(Eba = ebastine, Tri = triprolidine)
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LARS
The average of the three scores for ‘tired’, ‘drowsy’ and ‘alert’ of the LARS was used to 
given an overall score of subjective sedation. Subjective reports of sedation were greatly 
increased following triprolidine administration. At 2 and 4 hours after the first 
administration of triprolidine, subjects felt clearly more sedated; this difference was 
statistically significant when compared to placebo (p<0.05). Analysis of the LARS 
results revealed no detectable effects of ebastine (10 & 20 mg) compared to placebo 
(figure 5.24). However, ebastine administered at its highest dose of 30mg significantly 
increased sedation scores at 4 hours on day 5 when compared to placebo (p<0.05),
(figure 5.25).
Figure 5.25: Line Analogue Rating Scales for Sedation -  Mean change from 
baseline (HO) on day 1 following the administration of ebastine, 
triprolidine and placebo 
* = p<0.05 when compared to placebo
(Eba = ebastine, Tri = triprolidine)
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Figure 5.26: Line Analogue Rating Scales for Sedation (mm)- Mean change from 
baseline (HO) on day 5 following the administration of ebastine, 
triprolidine and placebo 
* = p<0.05 when compared to placebo
(Eba = ebastine, Tri = triprolidine)
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LSEQ
Analysis of the LSEQ results revealed significant placebo versus treatment differences 
for the night after the first administration only (p<0.05), indicating that both triprolidine 
and the highest dose of ebastine (30mg) had an effect on the ease of getting to sleep 
(GTS) (figure 5.27), while the effect on the quality of sleep (QOS) fell short of being 
significantly different from that seen under placebo (fig 5.28). None of the experimental 
treatments were found to interfere with the ease of waking from sleep (WFS) and the 
integrity of behaviour following waking (BFW). No placebo-treatment differences could 
be seen with regard to the night after the fifth administration.
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Figure 5.27; Leeds Sleep Evaluation Questionnaire -  Getting to Sleep: Mean
change from baseline (HO) on days 2 & 6 following the administration 
of ebastine, triprolidine and placebo 
* = p<0.05 when compared to placebo
(Eba = ebastine, Tri = triprolidine)
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Figure 5.28: Leeds Sleep Evaluation Questionnaire - Quality of Sleep: Mean 
change from baseline (HO) on days 2 & 6 following the 
administration of ebastine, triprolidine and placebo 
* = p<0.05 when compared to placebo
(Eba = ebastine, Tri = triprolidine)
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5.6.4 Discussion o f Results
Ebastine, at all three doses tested, was not significantly different from placebo in its 
effects on psychomotor performance and cognitive fhnction. This is in contrast to the 
positive control, triprolidine, which produced significant impairment of cognitive and 
psychomotor function as measured by SCTT, SMST, LARS and LSEQ, for up to 8 hours 
after drug intake on day 1. However, impairment of performance tests and subjective 
reports of sedation lessened with repeated dosing and the detrimental effects of 
triprolidine were not detected at day 5, a finding which is consistent with previous 
literature (Bye et al 1977). This effect of triprolidine has been reported previously in a 
study in which the authors suggested the development of tolerance to the effects of 
triprolidine following repeated dosing. It was speculated that this effect was possibly a 
result of central receptors becoming less responsive to the drug or that different central 
homeostatic mechanisms served to counteract the induced sedation (Bye et al 1977). 
These present results are commensurate with previous published literature in which 
ebastine has been shown to be free of CNS adverse effects at doses up to 20 mg (Azcona 
et al 1992, Brooldiuis et al 1993, Hopes et al 1992, Vincent et al 1988). Single oral doses 
of ebastine (10-30 mg) did not impair psychomotor performance, assessed by vigilance 
(EEG changes), cognitive performance, visual-motor co-ordination and subjective 
estimates of sedation in healthy volunteers (Hopes et al 1992, Mattila et al 1992, Vincent 
et al 1988a). Scores for ail parameters were similar after placebo or ebastine 
administration, whereas the Hi-receptor antagonist, clemastine caused drowsiness, 
impairment of psychomotor performance, and had a selective effect on cognitive 
processes (Hopes et al 1992), and triprolidine significantly adversely affected aspects of 
driving ability compared to placebo (Brooldiuis et al 1993). Ebastine 10 to 30 mg/day 
did not impair driving performance; however, doses above the therapeutic range (50-90
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mg) caused sedation and impairment of performance, as evidenced by significantly 
increased reaction time at 4 and 8 hours, and a reduction in CFF threshold at 5.5 hours 
compared with placebo (Barbanoj et al 1988) (p<0.05). Using a battery of psychomotor 
tests and visual analogue scales (including a simulated driving test), investigators failed 
to find any effects of ebastine 10 or 20 mg/day for up to 7 days on the depressant activity 
of alcohol in healthy volunteers (Azcona et al 1992, Mattila et al 1992). A number of 
studies have reported subjective and objective evidence of sedation with high doses of 
ebastine and evidence exists to support the notion that ebastine does possess sedative 
activity when it is administered at doses higher than those recommended by the 
manufacturer (Barbanoj et al 1988, Vincent et al 1988a).
The present study, which was performed in 10 healthy female volunteers under double­
blind, crossover conditions, was aimed at evaluating and comparing the central effects of 
three doses of ebastine with triprolidine, a sedative antihistamine loiown to produce 
cognitive and psychomotor impairments (Betts et al 1984, Brooldiuis et al 1993, Riedel 
et al 1990a).
A positive control was included in the study to ensure the validity of the methods 
employed. The objective evaluation of the central effects did not show any significant 
modification with ebastine when compared with placebo and all the measurements were 
unchanged after ebastine intake irrespective of the dose and time after administration, a 
result which is in agreement with previous studies. In addition, there were no significant 
modifications in the subjective tests following the administration of the lower doses of 
ebastine (10-20mg). Following the repeated administration of the highest dose of 
ebastine, there were subjective reports of daytime tiredness on day 5, and a night-time 
‘sleep-inducing’ effect after the first administration.
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The general conclusion that can be drawn from the present study is that there were no 
significant objective effects on psychomotor performance following the administration of 
ebastine. This is in contrast to the effects of older, traditional AHs on various tests of 
psychomotor and cognitive function (Cohen et al 1985, Gengo et al 1987, Hindmarch & 
Shamsi 1999, Seidel et al 1987, Shamsi & Hindmarch 1999a).
Triprolidine included in this study as a positive control produced significant impairment 
between 4 and 8 hours after the first administration on objective measures (SCTT, 
SMST), and between 2 and 4 hours after the first administration on the subjective 
measures (LARS). This might indicate that antihistamine-induced sedation is 
subjectively experienced before it becomes evident in a performance test, and 
furthermore, that it is possible to tolerate and compensate for this sedation in 
performance tests so that impairment can not be detected objectively.
Although this study only uses ten subjects, the power is sufficient to show triprolidine 
acting as an internal control and ebastine having an effect only on the subjective rating 
scales. Given the importance of using AHs that are without unwanted CNS effects, 
confirmation of these findings should be made in a larger subject population. However, 
given this caveat, we have shown that ebastine at its recommended daily dose of 10 mg is 
free from disruptive effects on the CNS, in a study where the test battery proved sensitive 
to CNS impairment.
235
5.7 Experiment 7: The effects of hydroxyzine and lorazepam on cognitive 
function and sleep in patients with generalised anxiety disorder
5.7.1 Introduction & Rationale
The six previous experiments were conducted with healthy volunteers in which the 
cognitive and psychomotor profile of a number of second generation AHs were 
investigated.
However it is also important to investigate the cognitive and psychomotor effects of 
AHs in symptomatic patient populations who may or may not be already cognitively 
compromised as a result of the underlying disease.
Recently it has been shown that hydroxyzine is efficacious in relieving symptoms of 
anxiety in patients suffering from generalised anxiety disorder (Fererri et al 1995,
Lader & Scotto 1998).
This experiment was therefore designed to assess the cognitive and psychomotor effects 
of hydroxyzine in patients suffering from generalised anxiety disorder.
For statistical purposes, the null hypothesis for the study was that neither hydroxyzine 
nor lorazepam would have any effects on cognitive and psychomotor function as 
assessed by a battery of valid, sensitive and reliable tests.
5.7.2 Methods & Measures
Subjects
Eighty one patients (35 male, 46 female), aged 21-71 years (median age of 42 years), 
were entered into the study. Inclusion criteria required the patients to meet the DSMIV 
criteria for GAD including excessive anxiety and worry, occurring more days than not 
for at least 6 months. Treatment with benzodiazepines in the previous two months or any
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other psychoactive medication in the last month excluded the patients from participation 
in the study.
Design
The study was a randomised, double blind, parallel group, multi-centre design. Patients 
were randomised to receive a treatment for a period of 28 days. All medication was 
supplied in identical capsules and patients were instructed to take one dose in the 
morning, one at lunchtime and the third dose in the evening, half an hour before retiring 
to bed. Compliance was controlled by counting capsules returned by patients at each 
visit.
Drugs
Hydroxyzine 50mg/day in three divided doses (12.5mg/moming, 12.5mg/mid-day and 
25mg/evening) or lorazepam 3mg in three divided doses (Img/moming, 1 mg/mid-day 
and 1 mg/evening).
Procedure
Following informed consent, medical history and GP approval, all patients underwent a 
medical examination. Subject to fulfilling the inclusion/exclusion criteria, eligible 
patients were entered into the study and familiarised with the study procedures.
Patients were required to attend the clinic (GP surgery) once a week for five weeks, in 
which they underwent a series of tests to measure the effects of hydroxyzine and 
lorazepam on cognitive function, memory recall, various aspects of sleep, clinical 
intensity of anxiety and the presence of any undesirable side effects. Pre-treatment
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baseline recordings were then made on the first visit on each of the psychometrics 
(described below) and further testing was carried out on days 8,15, 22 and 29.
As the consumption of alcohol in counter-indicated with hydroxyzine, patients were 
instructed to avoid alcohol during the trial period of 28 days.
Adverse events were recorded at each visit, with a description of frequency, nature, 
severity and causation. The use of all concomitant medication was also recorded at 
each visit.
Test Battery
The test battery consisted of Hamilton Anxiety Rating Scale (HAM-A), Cognitive 
Failures Questionnaire (CFQ), Clinical Global Impression (CGI), Critical Flicker Fusion 
(CFF), Milford Memory Test (MMT) and Leeds Sleep Evaluation Questionnaire 
(LSEQ).
Statistical Analysis
Due to the large number of dropouts in the lorazepam group, the two treatments could 
not be compared against one another and so each treatment was compared to its own 
baseline.
For all primary and secondary variables, apart form the LSEQ, the change from baseline 
was calculated and used in the analyses. The analysis of primary and secondary efficacy 
variables for the intention to treat (ITT) population was performed using paired ‘t’ tests 
to investigate within treatment differences. All statistical tests were two tailed at the 5% 
level of significance. In the intention to treat analysis, the Last Value Canied forward 
(LVCF) technique was used in the case of missing observations. If no such value was 
available, the baseline value was used.
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5. 7.3 Results
A high proportion (36%) of withdrawals occurred in the lorazepam group (n = 39) 
compared to the hydroxyzine group (12%) (n -  42). The majority of non-responders 
reported that they could not tolerate the side effects produced by lorazepam. As a result, 
all comparisons were made to each treatment’s own baseline and the two treatments 
could not be compared against one another.
The mean response data are presented in tables 27-33 of Appendix 1.
HAM-A
HAM-A overall scores were significantly decreased with both hydroxyzine and 
lorazepam. The mean decrease in scores for the hydroxyzine and lorazepam groups were 
11.69 (t=8.85 on 41 d.f., p<0.001) and 7.01 (t=5.33 on 38 d.f., p<0.001) respectively 
(figure 5.29). In line with the overall HAM-A scores, both treatments showed a 
significant decrease in both the psychic and somatic elements of the HAM-A score. 
Hydroxyzine showed a mean decrease of 3.76 on the psychic score (t=6.65 on 41 d .f ,  
p<0.001) and 7.92 on the somatic score (t=9.33 on 41 d.f; p<0.001) of the HAM-A 
whereas lorazepam produced a mean reduction of 1.94 (t=4.23 on 38 d .f ,  p<0.001) on 
the psychic score and 5.08 (t=5.44 on 38 d.f;  p<0.001) on the somatic score 
(figures 5.30 & 5.31).
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Figure 5.29: HAM-A: Mean Overall Scores following the administration of 
hydroxyzine and lorazepam 
* = p<0.001 compared to baseline
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Figure 5.30: HAM-A Somatic Scores: Mean scores following the 
administration of hydroxyzine and lorazepam 
* = p<0.05 when compared to baseline
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Figure 5.31: HAM-A Psychic Scores: Mean scores following the administration 
of hydroxyzine and lorazepam 
* = p<0.05 when compared to baseline
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Cognitive Failures Questionnaire
Cognitive failures questionnaire scores showed a significant improvement with 
hydroxyzine at days 15 (t = 3.27 on 41 d.f., p<0.005), 22 (t = 2.82 on 41 d.f, p<0.01) 
and 29 (t = 3.31 on 41 d.f, p<0.005). In contrast, there were no changes in the CFQ 
score following the administration of lorazepam (figure 5.32).
Figure 5.32: Cognitive Failures Questionnaire: Mean change from baseline 
following the administration of hydroxyzine and lorazepam 
* “ p<0.01 when compared to baseline 
** = p< 0.005 compared to baseline
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Clinical Global Impression
Clinical global impression results were indicative of significant improvements with 
hydroxyzine in both cognitive function and quality of sleep. Cognitive function was 
rated as significantly improved at day 29 (t =2.90 on 40 d.f, p<0.01) (figure 5.33), 
whereas there were significant improvements in the physician rated quality of sleep at 
all visits for both drugs (figure 5.34). There were no significant changes in cognitive 
function reported with lorazepam, although the quality of sleep was significantly 
improved at all visits.
Figure 5.33: Clinical Global Impressions - Cognitive Function
Mean change from baseline following the administration of 
hydroxyzine and lorazepam
= p<0.01 compared to baseline
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Figure 5.34: Clinical Global Impressions -  Quality of Sleep
Mean change from baseline following the administration of 
hydroxyzine and lorazepam 
* = p< 0.05 compared to baseline
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CFF
No significant impairments were detected with CFF in the lorazepam group 
(figure 5.35). However an impairment in scores was evident with hydroxyzine at days 
(t = 2.90 on 41 d.f., p< 0.01) and 15 (t = 2.84 on 41 d.f., p<0.01).
Figure 5.35: Critical Flicker Fusion (Hz) -  Mean change from baseline 
following the administration of hydroxyzine and lorazepam 
* = p<0.05 when compared to baseline
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Milford Memory Test
Analysis of the Milford Memory Test results showed improved performance with 
hydroxyzine in a number of tasks including the shopping list recall, names to faces 
and forward and backward digit span, (table 5.13).
Hydroxyzine caused improvements in the shopping list recall task at day 29 (t =2.45 on 
41 d.f., p=0.018), whereas lorazepam produced impairments on this task (t =4.27 on 38 
d.f., p<0.001) on day 8 (figure 5.36). Significant improvements were evident on the 
names to faces task at day 22 (t = 2.25 on 41 d.f., p=0.029) following the administration 
of hydroxyzine. No significant changes were evident following lorazepam treatment. 
The forward recall of digits was significantly improved following hydroxyzine (figure 
5.37) at day 15 (t =2.84 on 41 d.f, p<0.01) and 22 (t =2.89 on 41 d.f, p<0.01). 
Significant improvements were also reported at day 8 (t =2.35 on 41 d.f; p<0.05) for the 
backward recall of digits following hydroxyzine. Lorazepam treatment did not result in 
significant changes in this task.
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Figure 5.36: Milford Memory Test - Shopping List Recall
Mean change from baseline following the administration of 
hydroxyzine and lorazepam 
* -  p<0,05 when compared to baseline
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Figure 5.37: Milford Memory Test - Digit Span (Forwards)
Mean change from baseline following the administration of 
hydroxyzine and lorazepam 
* = p<0.05 when compared to baseline
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Analysis of the LSEQ results demonstrated that neither treatment group significantly 
affected getting to sleep nor the quality of sleep measures of the LSEQ. The awakening 
from sleep was significantly improved from visit 3 (F(3,l 17)=4.964, p<0.01) following 
hydroxyzine administration (figure 5.38).
Figure 5.38: Leeds Sleep Evaluation Questionnaire -  Awakening from Sleep 
Mean change from baseline following the administration of 
hydroxyzine and lorazepam 
* = p<0.05 when compared to baseline
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5. 7.4 Discussion
The aim of this study was to investigate the effects of hydroxyzine 50mg and lorazepam 
3mg on cognitive function and various aspects of sleep in patients suffering from GAD. 
The results demonstrate that hydroxyzine and lorazepam were both efficacious in 
alleviating symptoms of anxiety as assessed by the HAM-A rating scales. However a 
high proportion of withdrawals occurred in the lorazepam group (36%) compared to the 
hydroxyzine group (12%). The majority of non-responders reported that they could not 
tolerate the side effects produced by lorazepam. This result is consistent with previous 
findings in which side effects such as cognitive impairments, memory loss, withdrawal 
and dependence have been demonstrated with benzodiazepines (BDZs) including 
lorazepam (Hindmarch & Gudgeon 1980, Hindmarch & Tiplady 1994, Simon & Pollack 
1998, Subhan et al 1986).
As regards the effects on cognitive function, differences were evident on a number of 
tasks following both treatments.
As CFF is an indicator of central processing ability, it was expected that the 
administration of lorazepam would be associated with a decrease in CFF thresholds. 
However, no impairments were observed with CFF in this group. In line with this 
finding, cognitive failures questionnaire scores were not significantly affected by 
lorazepam and no significant changes in cognitive function were reported with the 
clinical global impression. Similarly, various tasks of the MMT such as the forward and 
backward recall of digits, picture of objects, names to faces task did not demonstrate any 
detrimental effects following the administration of lorazepam but significant impairments 
were demonstrated on the shopping list recall task at day 8. There were no significant 
effects on any aspects of the LSEQ.
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These current findings with lorazepam are surprising given the fact that the drug is well 
Icnown to impair memory (Curran 1998, Preston et al 1992), produce sedation 
(Hindmarch & Gudgeon 1980, Hindmarch & Tiplady 1994), and disrupt cognitive and 
psychomotor abilities in general (Subhan et al 1986).
Of the eighty one patients randomised in to the study, fourteen patients (36%) in the 
lorazepam group and five (12%) in the hydroxyzine group dropped out and did not 
complete the study. The majority of dropouts could not tolerate the side effects produced 
by lorazepam. It is also possible that the remaining patients who could actually tolerate 
the unwanted side effects of lorazepam were resistant to its effects.
The most likely explanation is that the severity of the side effects may have led to non- 
compliance. Although compliance was checked at every visit by counting the number of 
tablets returned, this is by no means an absolute indicator of drug intalce. It was evident 
from the CFF results that the scores did not change throughout the 28 day period. This 
was further supported by lack of cognitive impairments reported by patients on the CFQ, 
CGI and various tasks of the MMT. It was also interesting that there were no significant 
differences reported on any aspect of the LSEQ, considering the sedative profile of 
lorazepam. Whatever the reason for these findings, it was clear that no comparisons 
could be made between the two treatments and it was for this reason that it was decided 
to perform a within treatment analysis in which differences for each treatment group 
were compared to baseline.
Contrary to the findings with lorazepam, improvements were evident following the 
administration of hydroxyzine on a number of tasks throughout the 4 week treatment 
period.
Results from the cognitive failures questionnaire clearly indicated an improvement over 
the 4 week period following the administration of hydroxyzine. This finding was further
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supported with the results of the clinical global impression, in which physicians indicated 
significant improvements at days 8 and 15. In line with this, the quality of sleep aspect 
of the CGI was significantly improved throughout the 4 week treatment period. 
Performance on a number of tasks of the MMT such as the shopping list recall, picture 
of objects recall, forward and backward recall of digits clearly demonstrated an 
improvement following the administration of hydroxyzine throughout the 4 week 
treatment period. Although the getting to sleep and quality of sleep aspect of the LSEQ 
were not significantly affected by hydroxyzine, significant improvements were reported 
with hydroxyzine for the awakening from sleep aspect of the LSEQ from day 15.
Despite the reported improvements on a number of tasks with hydroxyzine, CFF scores 
were significantly reduced at days 8 and 15. However the maximum decrease in 
thresholds, although statistically significant when compared to baseline, was 0.85Hz.
The clinical significance of this decrease is questionable as a number of factors such as 
diurnal variation, time of day effect or an interaction of these and other variables could 
account for this finding.
The impairment of cognitive ftinction is an important factor to consider when treating 
anxious patients. Firstly, the majority of patients suffering from anxiety are out patients 
and any impairment caused could increase the likelihood of accidents. Secondly, anxious 
patients are cognitively compromised and therefore the administration of a psychoactive 
compound known to cause impairments can be counter-therapeutic as it exacerbates the 
existing problems. Therefore if a patient is going to be effectively treated by 
pharmacotherapy, then a non-behaviourally toxic anxiolytic not only produces a good 
clinical response, but also ensures that patients are free from unwanted secondary side 
effects (Shamsi & Hindmarch 1999).
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In view of the emphasis on maintaining the integrity of cognitive functions during 
treatment with anxiolytics, it is interesting to note that in a controlled study, treatment of 
GAD patients with hydroxyzine lOOmg/day for a month showed better and more rapid 
improvement of cognitive functioning, when compared to lorazepam 4mg/day as 
assessed by Beck scale (Samuelian et al 1995). A placebo-controlled study revealed that 
in contrast to lorazepam (2mg), hydroxyzine (50mg) did not affect short and long term 
memory span. In the measurement of verbal memory using 15 Words of Rey, no 
difference was observed between the number of words remembered under hydroxyzine 
and placebo, compared with fewer words with lorazepam, indicating that hydroxyzine 
causes no attention deficit or impairment of immediate memory (De Brabander & Debert 
1990). Another study using continuous EEG and a number of validated psychometric 
tests including the critical flicker fusion task (CFF) showed that hydroxyzine at 25mg or 
50mg did not result in psychological dysfunction either immediately or the next day. In 
addition, unlike many BDZs, hydroxyzine did not impair short-term memory the morning 
following nocturnal administration (Fererri & Hantouche 1998).
Despite the demonstration of hydroxyzine’s efficacy in GAD (Fererri et al 1995, Lader & 
Scotto 1998, Samuelian et al 1995), the mechanisms of the anxiolytic effects are not well 
understood. However it is known that antihistamines primarily affect hyperarousal 
(Hoehn-Saric 1998). An ‘inverted U’ relationship exists between behavioural arousal 
and performance. If hyperarousal is responsible for the poor cognitive performance of 
anxious patients, then a small reduction in arousal by hydroxyzine may improve 
cognition by shifting them along and up the performance curve. In contrast the profound 
sedative action of most of the 1,4-BDZs reduces arousal to such an extent that 
performance remains poor and cognitive functioning is compromised (Hindmarch et al 
1999).
255
This present study broadly supports these findings and shows that hydroxyzine has no 
significant detrimental effects, which would permit the full therapeutic value of the drug 
to be realised.
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CHAPTER 6 MEASUREMENT OF DRUG ACTION IN MAN.-
PSYCHOMETRIC ASPECTS OF ANTIHISTAMINES: 
RESULTS AND CONCLUSIONS
6.0 Chapter Outline
The preceding chapter outlined the results of the experimental studies. The findings of 
the results together with the relevance of these findings are discussed in terms of the 
impact they may have on the management of allergic disorders.
6.1 Introduction
Chapter one provided an introduction to the AHs and highlighted that despite achieving 
their greatest therapeutic role in the treatment of various allergic disorders, the use of 
AHs, especially those of the first generation category, is commonly associated with a 
number of undesirable side effects, the most troublesome of which is sedation.
A review of the literature including experimental studies with all AHs in healthy 
volunteers demonstrated the detrimental CNS effects following the administration of all 
first generation AHs at all doses. Furthermore, the review identified a number of second 
generation AHs with which objective and subjective evidence of CNS impairment 
became apparent when administered at higher doses. Of the 23 AHs investigated in the 
review, fexofenadine at doses up to 240mg was shown to be significantly different to all 
other AHs as regards its effects on aspects of cognitive functioning and psychomotor 
performance (PIR value of 0.00, =14.50, p<0.001), thus providing further support to
the notion that it should be classed as a ‘third generation’ antihistamine, at least as 
regards its unique profile of lack of CNS effects.
In investigating the sensitivity of the psychometrics to antihistamine-induced 
impairment, the overall findings were disappointing, in that only three categories of tests
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were identified as useful for discriminating between AHs as regards their potential to 
cause cognitive and psychomotor impairment. Many individual tests were used 
infrequently and data from these tests did not represent a broad range of AHs.
With certain tests, despite an overtly clear categorisation (e.g. CFF), it was not possible 
to guarantee that the apparatus used to measure the thieshold was identical in all studies 
and as Bobon (1982) reports, there is more disagreement between CFF results and certain 
psychometric tests due to the equipment used to measure the threshold than any other 
source of variance. Furthermore, other intervening variables such as time course of 
pharmacodynamic action, time of test administration etc. could not be talcen into account 
for the overall analysis, as it would have fragmented the available data even further.
In order to reduce these sources of variability and allow conclusions about the sensitivity 
of psychometric tests, the findings with all first generation AHs used in the review were 
pooled together.
Tests of car driving, reaction time and subjective assessments were the only three 
categories, which were shown to obtain a significant proportional impairment detection 
ratio (PIDR). However, tests of car driving were used too infrequently and the parameter 
under investigation was the standard deviation from lateral position (SDLP). According 
to the hierarchical structure of the driving task proposed by Janssen (1979) however, tests 
of car driving in which the parameter under investigation is the SDLP should be assigned 
exclusively to the lowest hierarchical level, i.e. the control level, since only the course- 
keeping tasks are evaluated and important functions such as attention, judgement and co­
ordination are not assessed (Willumeit et al 1993).
The clinical review surveyed and analysed the data on the incidence of subjectively 
reported sedation in patient studies with AHs in order to investigate the value and 
accuracy of patient reports with regard to antihistamine-induced sedation. The analysis
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of this selected sample of studies confirmed the general consensus published in numerous 
articles and reviews, namely that second generation AHs were relatively free from 
sedation when compared to the traditional AHs which were associated with frequent 
subjective reports of sedation.
It was therefore concluded that the compilation of subjective reports obtained in clinical 
studies with AHs, even though not standardised, were not to be discarded as a means for 
gathering information on the sedative potential of AHs. It was also evident that patients 
seemed to be able to discriminate successfully between AHs with and without sedative 
effects, despite the lack of validated assessment tools available for such assessments in 
the clinical setting.
As the majority of the studies which were analysed in this review were conducted using a 
parallel group design, it could not be guaranteed that the subjects comprising the placebo 
and the antihistamine treatment groups were comparable in terms of their sensitivity to 
antihistamine-induced sedation. Nevertheless, it was assumed that the relatively large 
number of patients per treatment group in these studies was able to compensate for the 
variability due to intraindividual differences in sensitivity to AHs.
Although this analysis demonstrated that subjective reports in clinical studies can 
successfully distinguish between first and second generation AHs, it was felt that there 
was scope for more objective and refined ways of assessing antihistamine-induced 
sedation.
In clinical studies the perceived clinical effect, or lack of it, may have partly unblinded 
the patients and affected the outcome. In some cases, a perceived lack of a clinical effect 
could have caused the subjects to report no side effects. It is clear that the vagaries of 
psychological reporting of subjective experiences would make any outcome possible 
(Rombaut 1995).
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6.3 Summary of Experimental Studies
A series of controlled experiments in non-atopic volunteers investigated the effects of a 
number of second generation AHs on various aspect of cognitive flinctioning and 
psychomotor performance. In addition to these, an additional experiment was conducted 
to investigate the cognitive and psychomotor effects of hydroxyzine and lorazepam in 
patients suffering from generalised anxiety disorder.
Experiment 1 demonstrated that a low dose of fexofenadine (40mg b.d.) was as effective 
as loratadine lOmg in suppressing the histamine-induced weal and flare response. 
Although there were no significant differences between the two treatments, both were 
superior to placebo in their peripheral blocking effects. Experiment 2 was a follow-up of 
the previous study, in which the peripheral blocking effects of higher doses were 
compared with loratadine and promethazine in a double-blind placebo-controlled 
crossover study. Fexofenadine (120mg & 180mg) was shown to be significantly superior 
to loratadine lOmg with regards to speed of onset, duration of effect and the time taken to 
achieve maximum suppression of the skin weal and flare response. These findings are in 
agreement with previous research in which 120mg fexofenadine has been shown to have 
a faster onset of action than loratadine (Simons et al 1997).
Having established the peripheral blocking effect of fexofenadine, the CNS profile of 
fexofenadine at doses up to 180mg was investigated in a double blind placebo controlled 
cross-over study in which loratadine was included as a comparator and promethazine as a 
positive internal control (experiment 3). Results clearly indicated the lack of 
impairments with fexofenadine at doses up to 180mg using a battery of tests, which 
clearly indicated the detrimental effects of the positive internal control.
Experiment 4 investigated the central effects of three equipotent doses of cetirizine and 
loratadine. Impaired performance was demonstrated with the positive control. Cetirizine
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at all doses tested was free of CNS impairing effects, whereas the highest dose of 
loratadine (40mg) caused an increase in reaction time.
Experiment 5 investigated the central effects of single doses of ebastine at doses up to 
40mg. Impairments were demonstrated with the positive control as well the highest dose 
of ebastine on a number of tests, indicating that although ebastine is free of adverse CNS 
effects at its recommended dose of lOmg, detrimental effects become evident when this 
dose is exceeded.
Experiment 6 was an extension of the previous experiment in which the effects of 
repeated dosing of ebastine at doses up to 30mg were investigated in a group of healthy 
volunteers. The results of this experiment lend further support to the conclusions made 
about the CNS profile of ebastine in the previous experiment.
Experiment 7 was distinct from the others in that it was conducted in patient populations 
within a general practice setting. Hydroxyzine and lorazepam were both shown to be 
alleviate symptoms of anxiety as assessed with the Hamilton Anxiety Rating Scale. 
Hydroxyzine was well tolerated and patients reported improvements in their cognitive 
functioning following treatment with hydroxyzine. This improvement was also 
objectively documented using a battery of tests.
Overall, the positive controls (promethazine and triprolidine) behaved as expected in that 
they consistently impaired performance on a number of different tests used across the 
different studies. The second generation AHs were shown to be free of CNS adverse 
effects when administered within their ‘dose window’. Impairments became evident on 
both objective and subjective measures when these doses were exceeded. The higher 
doses of loratadine (20mg & 40mg) and ebastine (20mg, 30mg & 40mg) caused 
significant CNS impairments, whereas cetirizine (at doses up to lOmg) and fexofenadine
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(at dose up to 180mg) were demonstrably free of detrimental effects on various aspects 
of cognitive and psychomotor performance.
6.4 Conclusions and Recommendations for Future Research
As AHs are widely used for the treatment of allergic disorders such as seasonal allergic 
rhinitis (S AR), then such usage is mainly by ambulant patients including children, and 
any CNS effects could compromise performance and safety. In addition to efficacy, the 
side effect profile of an antihistamine should therefore be the second most important 
aspect to be considered.
It is generally accepted that there is little to choose between AHs in terms of efficacy. 
The evidence gathered in the literature review and the experimental data presented in this 
thesis suggest, however, that there are differences in the extent to which these drugs 
influence performance.
The extensive review of the clinical data as well as experimental studies with AHs in 
healthy volunteers clearly demonstrated the significant detrimental CNS effects of the 
traditional AHs. The differences between the second generation AHs, however, did not 
appear to be so clear cut, although it was clearly evident that the use of the second 
generation AHs also resulted in cognitive and psychomotor impairment especially when 
higher doses were used.
The conclusions to be drawn from this work are that the administration of the first 
generation AHs is frequently associated with performance impairments, whereas the 
second generation AHs cause detrimental CNS side effects when higher doses are 
administered. To date, fexofenadine is the only antihistamine, which at doses up to 
240mg is free from adverse CNS effects.
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Despite the lack of CNS effects at doses up to 240mg in a number of well designed and 
adequately controlled studies with fexofenadine, hirther research is required with this 
antihistamine at higher doses.
Other second generation antihistamines such as cetirizine and loratadine have been 
investigated at doses up to four times the recommended dose regimen. It is therefore 
crucial to investigate the CNS profile of fexofenadine at doses of 360mg & 480mg.
In addition, the effects of co-administration with alcohol must be studied with this 
antihistamine at various doses. The central effects of fexofenadine following repeated 
administration should also be investigated.
Actigraphy appears to be a usehil tool in the measurement of drug action, and so fliture 
experiments should utilise this measure in order to allow continuous monitoring of 
activity, in addition to psychometric testing at discrete time points.
Sleep disturbance often occurs in patients with chronic allergic disorders such as chronic 
idiopathic urticaria, and therefore the investigation of the effects of these compounds on 
sleep should provide interesting and useful data.
If future research into the effects of AHs follows standardised designs and procedures, 
and adopts an accepted battery of measurements such as those outlined in this thesis, it 
would be possible to perform a meta-analysis of the effects of AHs on performance, 
thereby creating international indices of behavioural toxicity which would subsequently 
allow the classification of the AHs into three distinct groups; AHs with which sedation is 
experienced at all doses, AHs with which sedation becomes apparent when higher doses 
are administered and finally AHs devoid of adverse CNS effects regardless of the 
administered dose.
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Appendix 1
Experiment One
Table of Means
Table One: Day One -  Mean Weal Area (mm ) and standard deviations (s.d.):
Time (hrs) Fexofenadine 40mg b.d. Loratadine lOmg o.d Placebo
-0.5 29.77 (10.03) 31.43 (11.95) 31.08 (8.89)
0.0 28.30 (7.57) 28.90 (7.82) 28.47 (5.73)
0.5 30.98 (8.40) 30.57 (8.44) 31.11 (12.76)
0.75 29.43 (9.59) 27.72 (5.97) 30.23 (6.29 )
1.0 30.70 (9.44) 26.93 (9.71) 31.50 (9.67)
1.5 28.38 (7.38) 24.85 (7.08) 31.80(10.47)
2.0 26.69 (9.03) 23.56(10.19) 29.62(11.93)
3.0 21.56(6.44) 21.00 (7.45) 28.86 (10.63)
4.0 20.29 (8.23) 19.93 (7.13) 30.57 (13.66)
5.0 22.96 (11.34) 22.59 (8.70) 27.78 (11.29)
6.0 20.71 (8.91) 18.72 (6.00) 28.10(10.25)
8.0 22.03 (8.94) 21.60 (7.77) 30.23 (13.39)
12.0 22.46 (9.06) 19.42 (6.34) 27.99 (8.92)
18.0 17.12(8.51) 17.11 (5.41) 28.32 (16.55)
24.0 19.46 (7.31) 20.60 (7.88) 28.21 (15.30)
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Table Two: Day Four -  Mean Weal Area (mm^) and standard deviations (s.d.):
Time (hrs) Fexofenadine 40 mg b.d. Loratadine lOmg o.d Placebo
-0.5 23.83 (9.21) 19.27 (6.98) 25.89 (9.77)
0.0 20.58 (7.28) 19.41 (6.52) 28.62 (9.75)
0.5 21.66 (5.66) 23.10(6.96) 28.03 (12.10)
0.75 23.63 (6.93) 22.59 (8.92) 27.08 (8.17)
1.0 21.06 (7.39) 19.15(7.59) 23.77 (6.02)
1.5 18.38 (6.99) 17.39 (6.36) 24.74 (6.92)
2.0 17.81 (8.10) 19.39(9.34) 21.38 (7.90)
3.0 15.66 (6.70) 18.04 (8.14) 24.54 (7.08)
4.0 18.08 (7.51) 16.96 (6.65) 26.14(9.79)
5.0 17.96 (8.89) 21.13(7.71) 24.91 (6.32)
6.0 19.39 (8.04) 15.58 (5.40) 24.26 (7.01)
8.0 18.82 (5.02) 19.21 (10.68) 24.63 (7.05)
12.0 18.22 (5.02) 16.65 (6.96) 27.09 (8.84)
18.0 13.54 (5.25) 13.39(6.91) 23.07 (9.85)
24.0 16.55 (4.49) 14.22 (4.49) 24.91 (9.37)
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Table Three: Day One -  Mean Flare Area (mm^) and standard deviations (s.d.):
Time (hrs) Fexofenadine 40 mg b.d. Loratadine lOmgo.d. Placebo
-0.5 460.72 (273.59) 491.02 (353.55) 562.03 (368.56)
0.0 526.41 (414.75) 501.14(349.98) 567.67(231.37)
0.5 547.56 (293.63) 537.01 (349.74) 552.27 (313.50)
0.75 426.53 (331.64) 490.25 (377.43) 463.12 (398.34)
1.0 496.02 (345.69) 413.46 (268.62) 493.44 (334.58)
1.5 373. 10 (288.07) 418.77 (317.94) 483.(95 (185.35)
2.0 316.51 (297.69) 338.70 (280.40) 412.27 (267.20)
3.0 248.83 (270.90) 263.56 (261.97) 507.16 (280.04)
4.0 122.79 (186.48) 227.50 (234.99) 566.46 (273.27)
5.0 53.59 (93.81) 101.61 (165.41) 383.51 (272.69)
6.0 104.22 (158.32) 205.56 (239.01) 462.59 (393.96)
8.0 147.21 (183.95) 200.90 (283.57) 501.32 (235.27)
12.0 308.32(212.86) 329.46 (382.68) 832.54 (444.24)
18.0 114.91 (289.69) 224.75 (265.94) 621.26 (566.02)
24.0 166.42 (162.82) 260.98 (356.15) 583.69 (366.76)
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Table Four: Day Four -  Mean Flare Area (mm^) and standard deviations (s.d.):
Time (hrs) Fexofenadine 40 mg b.d. Loratadine lOmg o.d Placebo
-0.5 143.49 (178.01) 111.61 (197.13) 467.03 (214.66)
0.0 162.43 (282.33) 86.67 (134.18) 527.71 (363.21)
0.5 161.26 (188.98) 126.66 (172.34) 501.02(291.60)
0.75 188.03 (205.82) 115.85 (253.59) 533.86 (456.58)
1.0 217.50 (262.02) 96.99 (181.96) 434.73 (290.22)
1.5 126.23 (314.54) 75.26 (109.03) 409.82 (231.16)
2.0 76.19(104.99) 80.74(161.92) 343.73 (304.04)
3.0 40.51 (107.17) 28.87 (75.33) 386.43 (250.06)
4.0 38.29 (81.61) 75.21 (164.47) 396.07 (240.94)
5.0 15.14(35.96) 52.75 (120.41) 302.48 (181.72)
6.0 48.55 (74.61) 26.69(114.97) 362.15 (251.54)
8.0 60.04 (124.30) 68.51 (216.66) 464.09 (291.12)
12.0 266.93 (259.70) 113.74(221.59) 716.24 (459.05)
18.0 68.96 (67.48) 142.66 (303.77) 579.44 (420.66)
24.0 78.41 (101.25) 110.58 (265.61) 638.86 (463.30)
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Experiment Two
Table 5; Mean Weal Area (mm^) and standard deviations (s.d.):
(Fexo = fexofenadine, Lor = loratadine. Prom = promethazine)
Time Fexo Fexo Fexo Lor Prom Placebo
(hrs) 80mg 120mg 180mg lOmg 30mg
-0.5 34.33
(9.50)
35.68
(10.06)
37.04
(12.37)
32.28
(7.29)
35.60
(12.92)
35.88
(11.83)
0.0 34.44
(10.75)
31.80
(7.80)
36.43
(7.91)
36.70
(9.07)
33.68
(8.97)
36.50
(10.87)
0.5 33.37
(9.57)
32.04
(10.15)
33.96
(11.84)
36.97
(6.91)
32.09
(10.52)
34.03
(8.79)
0.75 35.60
(12.57)
32.44
(10.69)
33.32
(8.53)
34.74
(10.17)
32.54
(6.80)
37.08
(11.58)
1.0 30.75
(9.69)
32.69
(12.57)
28.31
(10.09)
33.13
99.89)
28.42
(9.27)
36.57
9.94)
1.5 26.71
(8.72)
26.23
(8.94)
24.63
(12.06)
33.61
(7.58)
25.08
(10.73)
30.22
(7.81)
2.0 24.05
(9.12)
21.10
(7.90)
17.21
(10.53)
29.48
(10.55)
22.98
(10.85)
32.07
(11.54)
3.0 18.18
(6.84)
14.49
(6.26)
13.81
(7.43)
26.17
(8.91)
19.08
(10.01)
31.38
(13.47)
4.0 16.19
(8.73)
15.28
(8.15)
12.81
(7.52)
26.31
(9.66)
20.49
(9.92)
34.35
(11.13)
5.0 12.90
(6.45)
12.63
(5.13)
10.65
(7.55)
18.03
(8.21)
14.57
(6.52)
23.28
(8.06)
6.0 15.26
(7.58)
14.51
(6.90)
9.18
(5.39)
15.20
(6.60)
16.27
(8.73)
19.89
(7.73)
8.0 14.27
(6.90)
15.08
(6.93)
12.49
(7.42)
16.34
(7.23)
16.48
(9.22)
26.77
(8.91)
12.0 23.32
(9.92)
18.29
(9.16)
16.37
(8.97)
16.61
(6.04)
19.73
(9.51)
27.78
(8.32)18.0 19.81
(8.20)
22.56
(11.46)
17.39
(6.63)
19.47
(8.36)
24.59
(14.53)
23.08
(8.94)
24.0 21.87
(7.44)
22.30
(13.67)
22.80
(10.62)
20.26
(8.39
22.67
(10.10)
26.43
(14.37)
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Table 6: Mean Flare Area (mm^) and standard deviations (s.d.):
(Fexo = fexofenadine, Lor = loratadine. Prom = promethazine)
Time Fexo Fexo Fexo Lor Prom Placebo
(hrs) 80mg 120mg 180mg lOmg 30mg
-0.5 728.45
(384.34)
631.77
(334.50)
682.53
(283.19)
703.07
(381.84)
710.51
(436.33)
680.83
(514.65)
0.0 757.24
(504.48)
641.99
(441.29)
785.48
(424.72)
789.69
(537.55)
728.05
(473.29)
777.43
(460.32)
0.5 699.40
(453.99)
587.57
(327.58)
579.98
(408.29)
705.55
(444.55)
690.89
(532.82)
666.98
(378.87)0.75 670.84
(424.24)
719.46
(547.47)
651.59
(367.77)
702.69
(395.25)
618.48
(396.11)
724.57
(417.73)
1.0 555.84
(358.46)
623.29
(397.99)
620.75
(458.94)
613.09
(431.25)
562.18
(411.81)
581.78
(383.20)1.5 548.70
(421.12)
394.61
(334.11)
366.48
(406.48)
507.45
(340.34)
460.18
(406.66)
606.32
(407.22)
2.0 331.57
(306.79)
223.08
(262.96)
200.80
(316.18)
603.85
(533.61)
365.14
(365.10)
627.23
(373.62)
3.0 170.29
(209.32)
108.00
(165.15)
72.84
(113.08)
435.81
(399.68)
220.78
(277.86)
553.20
(385.27)
4.0 81..01
(117.74)
84.80
(155.60)
51.66
(75.20)
455.05
(403.16)
315.53
(291.54)
605.13
(409.98)
5.0 45.02
(70.62)
45.11
(103.83)
31.56
(66.95)
153.88
(228.13)
101.34
(116.14)
268.98
(188.88)6.0 40.81
(58.86)
16.54
(26.72)
20.52
(22.93)
124.04
(251.98)
192.11
(353.53)
290.25
(244.88)8.0 53.97
(88.39)
49.77
(69.97)
85.05
(153.93)
187.83
(268.84)
206.58
(264.41)
491.48
(466.04)
12.0 146.48
(245.18)
107.16
(192.09)
75.38
(159.08)
177.49
(180.50)
233.98
(276.67)
683.24
(590.30)
18.0 219.87
(298.55)
183.66
(223.96)
150.32
(203.33)
188.09
(227.84)
310.07
(397.99)
530.28
(444.20)24.0 295.86
(436.13)
239.00
(326.45)
187.85
(234.68)
176.69
(219.42)
299.06
(370.25)
435.11
(322.10)
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Experiment Three
Table 7: Critical Flicker Fusion: Mean values (Hz) and standard errors
(S.E.M.) for all treatment conditions:
(Fexo = fexofenadine, Lor = loratadine, Prom = promethazine)
Time Fexo Fexo Fexo Lor Prom Placebo
(hrs) BOmg 120mg 180mg lOmg 30mg
0.0 30.16
(0.56)
30.45
(0.56)
30.80
(0.60)
30.22
(0.64)
29.89
(0.62)
29.98
(0.52)
1.5 30.31
(0.60)
29.88
(0.66)
30.05
(0.70)
29.93
(0.59)
28.91
(0.69)
29.87
(0.61)
3.0 29.99
(0.68)
29.83
(0.58)
30.06
(0.69)
29.81
(0.52)
27.60
(0.66)
29.95
(0.62)
6.0 30.08
(0.66)
30.14
(0.45)
29.41
(0.64)
29.54
(0.72)
27.74
(0.74)
30.17
(0.60)
9.0 29.87
(0.68)
29.82
(0.65)
29.95
(0.66)
29.55
(0.76)
27.59
(0.77)
29.66
(0.63)
12.0 29.41
(0.55)
29.51
(0.68)
29.54
(0.68)
29.23
(0.79)
28.34
(0.75)
29.48
(0.64)
24.0 30.25
(0.59)
30.00
(0.62)
29.95
(0.64)
29.55
(0.68)
29.09
(0.61)
29.87
(0.64)
Table 8: Total Reaction Time: Mean values (msec) and standard errors
(S.E.M.) for all treatment conditions:
(Fexo = fexofenadine. Lor = loratadine. Prom = promethazine)
Time Fexo Fexo Fexo Lor Prom Placebo
(hrs) 80mg 120mg 180mg lOmg 30mg
0.0 564.06
(9.70)
568.04
(15.51)
575.92
(13.79)
555.62
(14.45)
569.09
(12.69)
573.22
(16.71)
1.5 567.48
(13.34)
577.81
(15.75)
584.33
(14.44)
562.72
(14.74)
584.47
(15.64)
588.0
(17.29)3.0 564.82
(12.92)
573.97
(14.29)
597.97
(16.50)
566.01
(15.79)
613.11
(19.40)
598.50
(17.61)6.0 572.05
(10.95)
582.41
(14.74)
585.31
(17.70)
566.60
(13.35)
615.88
(15.74)
589.35
(15.74)9.0 586.65
(11.11)
576.50
(14.40)
574.29
(14.81)
581.55
(17.58)
590.80
(17.42)
578.78
(15.14)12.0 571.55
(13.16)
556.45
(15.92)
568.60
(16.62)
555.01
(19.39)
564.16
(16.10)
566.0
(17.94)24.0 562.50
(11.09)
569.00
(13.24)
571.10
(14.37)
550.46
(14.72)
550.72
(14.89)
578.73
(15.06)
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Table 9: Recognition Reaction Time: Mean values (msec) and standard errors
(S.E.M.) for all treatment conditions:
(Fexo = fexofenadine, Lor = loratadine. Prom = promethazine)
Time Fexo Fexo Fexo Lor Prom Placebo
(hrs) 80mg 120mg 180mg lOmg 30mg
0.0 372.20
(8.90)
366.30
(10.0)
375.60
(10.60)
368.50
(10.50)
373.80
(8.30)
380.20
(12.0)
1.5 379.40
(6.90)
384.90
(10.70)
374.70
(9.70)
370.5
(8.90)
383.80
(9.60)
381.90
(14.40)
3.0 379.60
(11.0)
374.70
(8.80)
385.10
(10.20)
371.70
(8.90)
412.20
(13.70)
390.60
(12.90)
6.0 383.50
(8.90)
385.60
(9.50)
384.70
(11.20)
376.50
(7.90)
409.30
(12.70)
384.20
99.50)
9.0 390.80
(9.70)
375.60
(8.90)
375.70
(11.50)
375.90
(10.80)
389.60
(11.90)
380.20
(10.20)
12.0 376.60
(9.80)
362.60
(10.0)
373.10
(9.80)
364.50
(9.0)
374.60
99.10)
371.7
(9.60)
24.0 365.80
(7.20)
363.90
(9.90)
369.70
(9.80)
359.20
(8.60)
367.50
(9.70)
382.80
(11.10)
Table 10: Line Analogue Rating Scales for Sedation: Mean values (msec) and
standard errors (S.E.M.) for all treatment conditions:
(Fexo = fexofenadine. Lor = loratadine, Prom = promethazine)
Time Fexo Fexo Fexo Lor Prom Placebo
(hrs) 80mg 120mg 180mg lOmg 30mg
0.0 50.56
(1.14)
51.54
(1.81)
48.93
(1.08)
50.64
(1.43)
54.09
(1.89)
49.59
(1.23)
1.5 49.59
(0.65)
52.33
(1.58)
50.69
(1.09)
51.59
(1.52)
55.78
(1.99)
50.71
(1.60)
3.0 52.81
(1.07)
52.11
(1.22)
52.82
(1.31)
52.40
(1.59)
57.34
(1.71)
53.12
(1.83)
6.0 52.37
(1.46)
51.77
(1.53)
55.27
(1.95)
51.62
(1.79)
58.15
(25.18)
54.68
(1.78)
9.0 51.72
(1.29)
53.24
(1.64)
54.55
(1.80)
52.45
(1.89)
56.28
(2.03)
51.38
(1.72)
12.0 51.92
(1.20)
52.09
(1.43)
51.85
(1.62)
51.31
(1.72)
52.92
(1.32)
50.88
(1.72)
24.0 50.67
(1.34)
51.05
(1.17)
51.06
(1.41)
48.90
(2.13)
47.96
(1.47)
48.20
(1.77)
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Experiment Four
Table 11: Critical Flicker Fusion: Individual data, together with mean values
(Hz) and standard deviations (s.d.) for all treatment conditions:
Variable Mean Minimum Maximum s.d.
AO 32.18056 27.66667 37.16667 2.419684
A1 31.18750 26.83333 36.33333 2.235156
A3 30.68056 25.00000 37.16667 2.744743
A6 30.63889 26.50000 35.50000 2.173994
BO 31.60833 25.66667 38.33333 3.106488
B1 30.90278 27.33333 38.00000 2.579240
B3 30.70833 26.16667 38.00000 2.709016
B6 30.78472 25.66667 34.66667 2.274347
CO 31.75694 26.50000 36.33333 2.724898
Cl 30.25833 24.50000 35.50000 2.746667
C3 29.43056 25.66667 34.16667 2.457325
C6 29.45833 24.16667 35.33333 2.789408
DO 31.88194 27.00000 38.00000 2.631782
D1 31.1111 26.00000 35.16667 2.349667
D3 30.57639 25.66667 34.66667 2.138320
D6 30.60417 26.66667 35.00000 2.343050
EO 32.09722 27.66667 35.16667 2.228990
El 31.03472 26.66667 35.16667 2.557540
E3 30.65278 25.50000 34.50000 2.191285
E6 30.99306 26.83333 35.50000 2.290750
FO 32.06944 27.33333 36.66667 2.522803
FI 31.19444 27.00000 35.33333 2.269131
F3 30.86111 25.66667 35.00000 2.465544
F6 30.68056 26.50000 34.50000 1.931756
GO 31.71528 24.83333 37.83333 2.671861
G1 30.80556 25.66667 35.33333 2.500564
G3 30.46528 26.16667 35.16667 2.374370
G6 30.27083 24.66667 34.00000 2.255863
HO 32.02778 26.33333 38.16667 2.478734
HI 31.08333 25.83333 37.33333 2.722690
H3 30.75000 25.00000 36.00000 2.449490
H6 30.69458 24.83333 35.17000 2.455007
A = cetirizine lOmg, B = loratadine lOmg, C = promethazine, D = placebo,
E = cetirizine 2.5mg, F = cetirizine 5mg, G = loratadine 40mg, H = loratadine 20mg
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Table 12: Total Reaction Time: Individual data, together with mean values
(msec) and standard error (s.e.) for all treatment conditions:
Variable Mean Minimum Maximum s.e.
AO 687.6662 537.1200 915.990 19.75810
A1 686.3664 520.4100 1008.160 25.77675
A3 666.9529 500.0100 885.360 18.38329
A6 665.2227 527.1700 1058.520 24.27497
BO 689.9724 501.1000 947.860 24.22007
B1 701.3371 530.0000 895.470 18.28741
B3 662.7408 522.1100 841.250 15.60357
B6 682.9104 513.4500 1067.360 27.21389
CO 642.9713 528.3900 739.290 15.68890
Cl 705.2615 558.0100 822.100 17.44788
C3 742.1495 485.4500 1035.490 29.52368
C6 722.4152 549.4700 1008.200 24.55320
DO 676.1100 504.8100 1110.460 29.33147
D1 673.5912 433.4800 805.160 17.38363
D3 664.3996 564.3700 808.580 13.51443
D6 661.8896 446.1900 869.220 17.69174
EO 674.5150 550.1700 865.300 21.96636
El 683.7477 568.1700 986.440 18.29951
E3 681.1422 532.2500 882.930 17.49408
E6 685.5808 525.7600 878.530 20.23489
FO 651.7572 493.2000 816.730 21.21553
FI 682.9695 510.1400 998.560 24.57795
F3 674.0909 487.9500 932.690 22.05655
F6 672.9730 459.0300 797.750 17.71705
GO 665.9624 525.5100 940.010 22.83415
G1 746.2314 507.5300 1466.840 40.11808
G3 744.9796 547.1300 1431.050 40.45568
G6 685.5045J 539.9500 824.110 16.49654
HO 691.9379 552.9900 1236.610 35.22485
HI 728.8043 539.4800 1221.720 36.57697
H3 678.8718 527.8300 966.200 22.21604
H6 714.0019 524.1500 1573.040 46.70329
A = cetirizine lOmg, B = loratadine lOmg, C = promethazine, D = 
E = cetirizine 2.5mg, F = cetirizine 5mg, G = loratadine 40mg, H =
placebo,
= loratadine 20mg
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Table 13: Line Analogue Rating Scales for sedation: Individual data, together
with mean values (mm) and standard deviations (s.d.) for all treatment conditions:
Variable Mean Minimum Maximum s.d.
AO 50.97917 27.00000 61.5000 6.33053
A1 55.00000 33.50000 78.0000 8.84652
A3 55.54167 38.00000 82.5000 9.50391
A6 55.02083 37,50000 71.0000 7.81787
BO 52.16667 45.00000 75.0000 5.47458
B1 54.33333 21.00000 99.0000 13.16506
B3 54.68750 37.00000 80.5000 8.74122
B6 52.85417 33.50000 67.5000 8.24948
CO 51.04167 45.50000 64.0000 3.56894
Cl 61.93750 44.00000 89.0000 10.54113
C3 65.66667 43.50000 95.5000 14.08412
C6 60.62500 33.00000 90.0000 13.73685
DO 51.66667 40.00000 87.0000 8.25499
D1 53.66667 45.50000 74.0000 6.46507
D3 54.52083 46.00000 74.0000 8.38539
D6 51.72917 36.50000 79.0000 7.51806
EO 50.47917 16.00000 67.5000 9.09907
El 51.87500 23.50000 80.5000 10.84701
E3 55.29167 30.50000 83.5000 10.94345
E6 54.56250 38.50000 85.5000 11.28419
FO 52.68750 39.00000 80.0000 9.02028
FI 57.22917 46.00000 80.0000 10.38810
F3 53.83333 35.50000 83.5000 10.18062
F6 53.89583 41.00000 88.0000 9.35412
GO 51.66667 39.00000 64.0000 5.59244
G1 58.56250 49.00000 86.0000 9.78610
G3 55.14583 33.00000 72.5000 8.35942
G6 57.89583 40.00000 84.0000 11.72046
HO 48.89583 33.50000 63.0000 6.10413
HI 54.91667 41.50000 70.5000 7.58813
H3 50.87500 14.00000 78.0000 11.02098
H6 53.16667 14.50000 100.000 14.79253
A = cetirizine lOmg, B = loratadine lOmg, C = promethazine, D = placebo,
E = cetirizine 2.5mg, F = cetirizine 5mg, G = loratadine 40mg, H = loratadine 20mg
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Experiment Five
Table 14: Critical Flicker Fusion: Individual data, together with mean values (Hz)
and standard deviations (s.d.) for all treatment conditions:
(Eba = ebastine, Trip = triprolidine, Terf = terfenadine)
Placebo EbalOmg Eba 20mg Eba 40mg Trip 5mg Ter 60mg
Baseline 2&2 2&2 28.5 27.7 28.2 283
(Z5) C22) (25) (26) (23) (33)
0.5 27.90 27.9 28^ 28.0 27.7 2&2
(23) (2 8) (23) (23) (23) (3.4)
1.5 27.6 27.8 228 27.7 26.3 283
(25) (2 8) (22) (24) (19) (24)
3.5 28.0 27.7 27.9 225 27.4 283
(2.2) (28) (1.7) (22) (2.1) (24)
6.5 28.1 27.9 27^ 228 27.7 28.0
(22) (3 1) (24) (20) (27) (23)
Table 15: Recognition Reaction Time: Individual data, together with mean values
(msec) and standard deviations (s.d.) for all treatment conditions:
(Eba = ebastine. Trip = triprolidine, Terf = terfenadine)
Placebo Eba lOmg Eba 20mg Eba 40mg Trip 5mg Ter 60mg
Baseline 380.7
(54.1)
385.8
(61.4)
363^
(42.3)
3653
(39.5)
371.7
(46.2)
376.3
(56.2)
0.5 372.1
(43.8)
379.8
(50.0)
380.1
(49.9)
381.4
(421)
373.6
(533)
375.9
(54.6)
1.5 372.6
(46.9)
398.7
(43.7)
377.8
(45.3)
386.7
(46.1)
383.8
(62.6)
375.0
(54.7)
3.5 385.9
(49.4)
392.4
(60.6)
378.4
(46.2)
394.4
(78.5)
385.8
(51.40
377.0
(64.1)
6.5 386.4
(59.3)
389.8
(49.7)
392.8
(50.7)
391.8
(42.7)
378.5
(49.6)
375.3
(54.0)
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Table 16: Total Reaction Time: Individual data, together with mean values (msec)
and standard deviations (s.d.) for all treatment conditions:
(Eba = ebastine, Trip = triprolidine, Terf = terfenadine)
Placebo Eba lOmg Eba 20mg Eba 40mg Trip 5mg Ter 60mg
Baseline 555.2
(65.1)
555.1
(70.1)
563.2
(57.4)
546.4
(66.5)
5383
(57.7)
554.0
(75.3)
0.5 545.2
(56.4)
556.6
(59.5)
556.1
(64.9)
558.0
(60.0)
544.2
(68.1)
539.3
(66.6)
1.5 553.6
(64.4)
567.8
(52.8)
556.0
(75.2)
565.2
(80.1)
563.3
(78.5)
547.1
(69.3)
3.5 561.9
(72.0)
566.1
(68.8)
554.2
(68.2)
571.3
(111.5)
563.0
(56.9)
549.8
(79.0)
6.5 555.4
(71.6)
563.8
(64.4)
575.3
(86.6)
5693
(75.40
562.9
(63.4)
554.2
(78.3)
Table 17: Compensatory Tracking Task -  Reaction time: Individual data, together
with mean values (msec) and standard deviations (s.d.) for all treatment conditions: 
(Eba = ebastine. Trip = triprolidine, Terf = terfenadine)
Placebo EbalOmg Eba 20mg Eba 40mg Trip 5mg Ter 60mg
Baseline 408.3
(79.8)
405.4
(68.8)
398.3
(54.60
418.9
(79.3)
412.0
(68.3)
403.8
(69.401,5 410.3
(74.8)
419.5
(72.3)
408.5
(67.9)
435.0
(87.0)
434.2
(71.9)
418.6
(68.8)
3.5 414.2
(85.6)
425.2
(73.9)
416.9
(65.8)
430.1
(74.4)
421.8
(68.0)
410.2
(64.3)
6.5 406.7
(67.3)
420.5
(71.7)
422.5
(80.6)
439.6
(89.3)
428.8
(78.0)
409.8
(56.5)
326
Table 18: Compensatory Tracking Task -  Tracking Accuracy: Individual data,
together with mean values (RMS) and standard deviations (s.d.) for all treatment 
conditions:
(Eba = ebastine. Trip = triprolidine, Terf = terfenadine)
Placebo Eba lOing Eba 20mg Eba 40mg Trip 5mg Ter 60mg
Baseline 8.3 8.3 8.0 8.2 8.4 7.8
(2.2) (2.5) (1.7) (1.6) (1.7) (1.2)
1.5 8.1 8.0 7.6 9.6 9.0 7.7
(22) (20) (1.9) (5.5) (24) (1.5)
3.5 7.9 8.6 7.6 9.3 8.5 7.8
(2T) (28) (21) (4.7) (2.6) (1.7)
6.5 8.1 8.6 8.5 9.5 8.2 7.7
(2T) (3.1) (3.5) (4.9) (20) (1.5)
Table 19: Line Analogue Rating Scales for Sedation: Individual data, together with
mean values (mm) and standard deviations (s.d.) for all treatment conditions:
(Eba -  ebastine. Trip = triprolidine, Terf = terfenadine)
Placebo Eba lOmg Eba 20mg Eba 40mg Trip 5mg Ter 60mg
Baseline 52.1 52.0 54.0 55.6 53^ 55.0
(25) (6.7) (5.6) (7.6) (5.8) (&0)
0.5 53.6 55.0 52.8 55.1 52.1 533
(6.6) (4^) (6.6) (6.8) (3.8) (&0)
1.5 56.7 55.4 54.2 58.0 61.8 56.6
(9J) (5.8) (5.9) (23) (8.2) (5.9)
3.5 56.3 55.7 55.3 57.8 56.3 55.7
(5.4) (5 j) (5.9) (9T) (26) (6.9)
6.5 56.7 56.5 58.1 60.5 55.3 563
(4.6) (9.2) (&9) (11.4) (21) (27)
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Experiment 6
Table 20: Mean pre-treatment scores (standard deviations) for CFF together
with mean changes (standard deviations) from baseline for days 1 and 5 for all 
treatment conditions:
(Eba = ebastine, Trip = triprolidine)
Placebo EbalOmg Eba 20mg Eba 30mg Trip lOmg
D1 HO 28.110
(3.796)
27.615
CT683)
28.110
(3.796)
2T483
(3.615)
27.710
(3.605)
D1 HI -1.055
(1.349)
0.196
(1.221)
-0.173
(1.297)
0.159
(1.458)
0.053
(1.066)
D1 H2 -1.652
(1.413)
-0.515
(0.921)
-0.862
(1.317)
-0.724
(0.792)
-1.830
(1.161)
D1 H4 -1.187
(1.160)
-1.026
(0.829)
-1.137
(1.557)
-0.856
(1.137)
-1.062
(1.692)
D1 H8 -1.978
(0.901)
-1.770
(0.766)
-1.465
(1.778)
-1.676
(1.189)
-1.519
(1.297)
D5 HO -(0.773)
(0.971)
-0.357
(0.867)
-0.307
(1.163)
0.430
(1.023)
0.392
(0.903)
D5 H I -1.168
(1.568)
-0.374
(1.874)
0.092
(0.986)
0357
(1.447)
-0.163
(1.126)
D5H2 -1.373
(1.103)
-0.835
(1.526)
-1.318
(1.177)
-0.405
(1.566)
-1.038
(0.914)
D5 H4 -1.142
(1.075)
-0322
(1.066)
-1.043
(1.132)
-0.615
(1.566)
-0.655
(0.914)
D5 H8 <L688
(0.713)
-1.654
(0.610)
-1.562
(1.753)
-1.348
(1.334)
-1.390
(1.255)
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Table 21: Mean pre-treatment scores (standard deviations) for compensatory
tracldng task -  reaction time (msec) together with mean changes (standard 
deviations) from baseline for days 1 and 5 for all treatment conditions:
(Eba = ebastine, Trip = triprolidine)
Placebo Eba lOmg Eba 20mg Eba 30mg Trip lOmg
D1 HO 374.976
(45.311)
379.658
(49.757)
381.515
(50.676)
381.281
(45.622)
375.689
(40.460)
D1H2 10.286
(13.289)
24.238
(18.627)
12.586
(23.673)
22T66
(24.398)
34.614
(17.114)
D1 H4 18.724
(16.514)
21.731
(41.767)
20.470
(30.574)
32.766
(17.533)
39.719
(25.774)
D1 H8 18.504
(17.854)
37.589
(39.603)
30.203
(37.248)
17.354
(26.515)
57398
(46.783)
D5 HO 10.686
(21.992)
14.513
(23.293)
13.125
(26.739)
11.064
(46.550)
10.950
(27.898)
D5H2 19.414
(20.853)
20.786
(2Z893)
17.890
(39.513)
24.540
(52.433)
34.174
(30.980)
D5 H4 26.180
(26.558)
17.267
(32.256)
2.756
(53.997)
14.568
(27.806)
45.644
(34.004)
D5 H8 26.022
(15.737)
9.411
(24.534)
21.527
(51.607)
19.339
(33.812)
27.045
(30.927)
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Table 22: Mean pre-treatment scores (standard deviations) for compensatory
tracking task -  tracking accuracy (rms) together with mean changes (standard 
deviations) from baseline for days 1 and 5 for all treatment conditions:
(Eba = ebastine, Trip = triprolidine)
Placebo EbalOmg Eba 20mg Eba 30mg Trip lOmg
D1 HO 5.770
(1.618)
6.515
GL573)
5.609
(1.621)
6372
(1.947)
6.028
(1.947)
D1 H2 -0.255
(0.413)
-0.429
(0.648)
0.210
(0.600)
-0.34
(0.356)
0.803
(0.741)
D1 H4 -0.118
(0.530)
-0.010
(1.159)
0.427
(0.800)
0.215
(0.458)
0.800
(1.744)
D1 H8 -0.095
(0.447)
0.304
CL163)
0.027
01123)
0.184
(0.851)
1.318
(4.000)
D5 HO -0.526
(0.396)
-0.800
(1.206)
-0.683
(0.725)
-0.649
(0.701)
-0.683
(0.987)
D5 H2 -0.572
(0.724)
-1.273
(1.214)
-0.662
(1.081)
-0.560
(1.114)
-0.662
(1.081)
D5 H4 -0.361
(0.840)
-1.307
(1.301)
-0.513
(1.258)
-0.349
(1.519)
-0.513
(1.258)
D5 H8 -0.374
(0.600)
-1.012
(1.263)
-0.411
(1.093)
-0.533
(1.066)
-0.411
(1.093)
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Table 23: Mean pre-treatment scores (standard deviations) for short term
memory scanning task (msec) together with mean changes (standard deviations) 
from baseline for days 1 and 5 for all treatment conditions:
(Eba -  ebastine, Trip = triprolidine)
Placebo Eba lOmg Eba 20mg Eba 30mg Trip lOmg
D1 HO 384.670
(60.320)
366.978
(45.933)
376.720
(56.265)
374.740
(63.506)
364.590
(43.252)
D1H2 -7.80
(34.097)
-12.967
(21.168)
^1480
(17.524)
-19.022
(34.896)
21.80
(32.746)
D1 H4 -21.690
(20.392)
5A56
(12.700)
-9.600
(18.740)
-10.40
(37.436)
24.310
(32.480)
D1H8 -26.40
(30.480)
-5.189
(35.796)
-16.80
(14.117)
-8.389
(33.131)
23.410
(48.656)
D5 HO -21.830
(32.787)
-9.533
(31.763)
-14.10
(17.835)
-27.044
(28.970)
-10.070
(16.829)
D5H2 -25.270
(33.632)
1.178
(25.961)
-25.250
(41.454)
-14.789
(45.869)
-2.670
924.913)
D5 H4 -23.440
(48.738)
-9.456
(41.384)
-13.720
(30.254)
-11.789
(69.587)
-4.290
(41.940)
D5 H8 -14.250
(47.077)
-16.189
(30.789)
-17.730
(33.986)
-21.778
45.695)
-0.080
(23.147)
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Table 24: Mean pre-treatment scores (standard deviations) for Line Analogue
Rating Scales for Sedation (mm) together with mean changes (standard deviations) 
from baseline for days 1 and 5 for all treatment conditions:
(Eba = ebastine, Trip = triprolidine)
Placebo EbalOmg Eba 20mg Eba 30mg Trip lOmg
D1 HO 51.433
(3.422)
50.704
(0.853)
50.50
00563)
50.467
(0.40)
50.733
(1.181)
D i m -0.533
(1.956)
-0.445
(1.054)
0.167
(0833)
0.519
(0.918)
&033
01433)
D1H2 2.20
(3.560)
1.630
04.476)
1.70
C2.904)
1.185
02.085)
7.933
(6J35)
D1 H4 2.0
(3.827)
2.926
(3.295)
5.634
(6.165)
5.333
(4.879)
8.0
(7.309)
D1 H8 1.533
(2.227)
1.889
(3.236)
2.967
(3.035)
2.815
(3.225)
5.333
0x871)
D5 HO -0.367
(4.446)
-0.297
(0.576)
-0.10
(0.857)
-0.407
(1.538)
-0.30
(0.433)
D5 H I -0.167
C2.237)
-0.370
(0.429)
0.033
(0.849)
1.371
(4.084)
-0.533
(1.045)
D5H2 2.233
04.669)
0.518
(1.744)
0.233
(1.086)
3.778
(5.482)
230
(4.664)
D5 H4 1.30
(3.542)
1.074
(2.083)
2A33
(4.101)
7.444
00383)
4.767
0T782)
D5 H8 2.967
(4.212)
2.741
(6.415)
1.50
(2.372)
2.926
(4.011)
2.133
0T385)
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Table 25: Mean pre-treatment scores (standard deviations) for Leeds Sleep
Evaluation Questionnaire -  Getting to Sleep (mm) together with mean changes 
(standard deviations) from baseline for all treatment conditions:
(Eba = ebastine, Trip = triprolidine)
Placebo Eba lOmg Eba 20mg Eba 30mg Trip lOmg
D1 HO 50.967
(3.638)
51.333
(2.250)
49.833
94.729)
52.10
(L232)
51.833
(4.113)
D2 HO 1.233
(6.136)
4.333
(5.756)
7.60
(10.875)
12.592
(11.919)
11.10
(10.790)
D6 HO 4.867
(7.137)
8.222
(10.183)
2.0
(6.189)
10.741
(12.637)
/T967
(10.017)
Table 26: Mean pre-treatment scores (standard deviations) for Leeds Sleep
Evaluation Questionnaire -  Quality of Sleep (mm) together with mean changes 
(standard deviations) from baseline for all treatment conditions:
(Eba = ebastine. Trip = triprolidine)
Placebo Eba lOmg Eba 20mg Eba 30mg Trip lOmg
D1 HO 49.550
(3.643)
49.944
(1.877)
49.60
(5.389)
51.050
(3.798)
51.2
(3.551)
D2 HO 1.80
(13.437)
3.50
(11.993)
7.850
(11.354)
15.167
(13.762)
14.250
(12.758)
D6 HO 2.850
(4.172)
9 J0
(11.232)
2.70
(7.467)
5.111
(15.663)
7.50
(12.307)
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Experiment Seven
Table 27: Hamilton Anxiety Rating Scales: Mean values (Hz) and standard
errors (s.e.) for the overall score, psychic and somatic scores for both treatment 
conditions:
Intention to Treat with Last Value Carried Forward
Treatment Visit HAM-A HAM-A
Psychic Somatic
HYDROXYZINE 1 9.90 (0.37) 15.48 (0.60)
5 6.14(0.61) 7.55 (0.85)
LORAZEPAM 1 9.05 (0.37) 15.95 (0.68)
5 7.08 (0.53) 10.87 (0.94)
Table 28: Cognitive Failures Questionnaire: Mean values together with
standard errors (s.e.) with both treatments:
Intention to Treat with Last Value Carried Forward
Treatment Visit Mean s.e
Hydroxyzine 1 51.404 233
2 50.024 2.44
3 45.929 2.60
4 45.833 2.63
5 44.595 2.52
Lorazepam 1 48.744 2.19
2 48.102 2.64
3 46359 234
4 47.026 296
5 46.051 331
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Table 29: Clinical Global Impressions -  Cognitive Function: Mean change from
baseline together with standard errors (s.e.) with both treatments:
Intention to Treat with Last Value Carried Forward
Treatment Visit Mean s.e
Hydroxyzine 2 0.170 0.234
3 0.220 0336
4 0.317 0343
5 0.731 0.251
Lorazepam 2 -0384 0342
3 -0.210 0350
4 -0.256 0359
5 -0333 0.280
Table 30: Clinical Global Impressions -  Quality of Sleep: Mean change from
baseline together with standard errors (s.e.) with both treatments:
Intention to Treat with Last Value Carried Forward
Treatment Visit Mean s.e
Hydroxyzine 2 1.488 0.229
3 1.561 0.229
4 1337 0381
5 1.683 0384
Lorazepam 2 1.513 0.294
3 1.605 0.281
4 1.230 0303
5 1.230 0.317
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Table 31: Critical Flicker Fusion: Mean Values (Hz) together with standard
errors for both treatment conditions:
Intention to Treat with Last Value Carried Forward
Treatment Visit Mean s.e
Hydroxyzine 1 30.285 0.434
2 29.601 0.466
3 29A32 0.511
4 30.198 0.505
5 29388 0.508
Lorazepam 1 30353 0.547
2 30.745 0.550
3 30.682 0.462
4 30.792 0.488
5 30.953 0.494
Table 33: Leeds Sleep Evaluation Questionnaire -  Awakening from Sleep: Mean 
Values together with standard errors (s.e.) for both treatments:
(GTS = Getting to Sleep, QOS = Quality of Sleep, AFS = Awakening from Sleep)
Treatment Visit GTS QOS AFS
Hydroxyzine 2 32.61 (2.50) 34.26 (3.04) 49.81 (2.20)
3 35.73 (1.89) 32.91 (2.66) 45.43 (2.32)
4 34.79 (2.04) 33.61 (2.79) 45.06 (2.14)
5 32.86(2.11) 32.36 (2.85) 42.98 (2.78)
Lorazepam 2 27.16(2.56) 33.93 (2.82) 57.01 (3.67)
3 28.16(2.45) 31.11 (2.88) 53.59(4.19)
4 30.84 (3.01) 36.70 (3.33) 53.85 (4.01)
5 33.28 (3.24) 35.89 (3.48) 53.55 (4.30)
or
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